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Introduction: Two pore domain potassium (K2P) channels are responsible for background currents that 
regulate membrane potential and neuronal excitability. Compounds which alter the activity of these 
channels are predicted to have therapeutic potential in treating CNS disorders. Members of the TREK family 
of K2P channels (TREK1 and TREK2) have been shown to play an active role in neuroprotection, depression 
and pain, whilst TRESK, with high expression in sensory neurons, has a role in nociception. Sipatrigine, a 
neuroprotective agent and a derivative of the anticonvulsant lamotrigine, is a known antagonist of TREK 
channels whilst lamotrigine is thought to primarily inhibit TRESK channels. A new compound, Cen-092-C, has 
also been developed which is structurally similar to lamotrigine. However, its effects on K2P channels are 
unknown. To understand the mechanism of channel inhibition by drugs, the structure of TREK2 was solved 
and was co-crystallised with norfluoxetine. This showed that fenestration sites were important in channel 
and current inhibition. Furthermore, TRESK docking studies showed that F145 and F352 function in a similar 
way to TREK2 fenestration site, as the bulky phenylalanine faces into the pore, and are thought to be 
important for compound binding. The aim of this study is to clarify to differences in the inhibitory effect of 
these compounds on the selected K2P channels and to investigate the mechanism by which these compounds 
inhibit the channels current. 
Methods: Wild-type (WT) and mutated human K2P channels were transiently expressed in tsA-201 cells. 
The currents were measured using whole-cell patch-clamp electrophysiology.  
Results: Sipatrigine was shown to inhibit both TREK1 and TREK2 current. Lamotrigine was also found to 
inhibit TREK1 and to a lesser extent TREK2. Cen-092-C was found to be less effective on TREK1 and TRESK 
current compared to sipatrigine, but similar to lamotrigine results. The sipatrigine inhibitory effect, but not 
lamotrigine, was reduced by mutations on the M4 region at the fenestration site of TREK1 and TREK2 (L286 
and L320). This sensitivity is selective at this site as other mutations in the central cavity showed no change 
in sipatrigine inhibition. Interestingly, the gain-of-function mutation (TREK1 E306A) on the C terminus 
showed a reduced sipatrigine inhibition. The effect of sipatrigine on TREK2 showed an over-recovery of 
current following wash-off of the compound. The wash-off current increase was not seen if the N-terminus 
length is forced into intermediate and short isoform. Sipatrigine inhibition was significantly decreased when 
the N-terminus was truncated. Sipatrigine has been shown to strongly inhibit TRESK. Lamotrigine was seen 
to inhibit TRESK current, however significantly less effective compared to sipatrigine. Furthermore, 
lamotrigine did show state dependent inhibition when TRESK is in the fixed activated state. Cen-092-C was 
also found to inhibit TRESK to a similar degree to lamotrigine, however there was no state dependent 
inhibition on TRESK current. The effects of these antagonists on TRESK has been shown to be abolished by 
mutations on two sites at the central cavity (F145 and F352).  
 
Conclusion: Lamotrigine was found not to be TRESK selective, contrary to other studies. Sipatrigine and 
lamotrigine inhibition works through binding to the channel. The fenestration site in both TREK1 and TREK2 
has been found to be an important binding site of sipatrigine, differing from lamotrigine. This suggests that 
the structurally similar compounds bind to different regions of the TREK channels. Furthermore, the over 
recovery of TREK2 current after sipatrigine wash off is believed to show the compoundげゲ biphasic effect, 
where the underlying enhancement of current is hidden by the action of inhibition. The N-terminus is 
therefore believed to be important in regulating sipatrigine action on TREK2.  
It remains unclear whether the TRESK potential binding sites (F1452 and F352) are important in compound 
binding as the inserted mutation is believed to shift the channel to constant active state. The newly 
developed compound Cen-092-C shows a significantly greater degree of inhibition of TRESK when compared 
to TREK1. Cen-092-C and lamotrigine inhibition of TRESK is not significantly different. Lamotrigine inhibition 
of TRESK current is state dependent whereas sipatrigine and Cen-092-C inhibition of TRESK current is shown 
as state independent. All of this together could lead to a better understanding of how neuroprotective 
agents effect TREK and TRESK channels and could contribute to the design of more efficient ligands.  
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1 General introduction 
Ion channels are pore forming proteins found in the plasma membrane and forms a 
passageway which allows of the flow of ions across the membrane. The human genome 
contains over 200 genes which code the primary (g) subunit that form ion channel and the 
number for ion channel proteins may be even greater because of the formation of 
heteromeric channel subunit arrangements (Alexander, Mathie and Peters 2011). There are 
ion channels that are voltage gated, for example most Na, K, Ca and Cl channels. However, 
there are others that are insensitive to voltage and use secondary messengers and other 
intracellular and /or extracellular mediators to gate the channels. Along with this, 
neurotransmitter activated, ligand-gated ion channels are gated by the binding of 
neurotransmitter which triggers changes in conduction of ions across the plasma membrane 
(Overington, Al-Lazikani and Hopkins 2006)  
Characterising ion channels can be greatly improved by understanding their structure, 
various gating processes and functional states. The mechanism by which ion channels 
interact and recognise modulators is essential in the understanding of how ion channels are 
regulated. Improving our knowledge of ion channel structure will also emphasise any 
differences between other ion channel sequences and overall structures. The potential 
importance of the specific structural differences could contribute to a better understanding of 
the function and sensitivity of the channel (Bagal et al 2013).  
Ion channels are responsible for the flux of ions from one side of the membrane to the other 
which will generate the action potential. The availability of pharmacological tools to target ion 
channels is therefore important for potential therapeutic effects. New therapies for diseases 
could result from new drugs designed to target ion channels (Mathie 2010). There have also 
been recent advances in information about ion channel structure aiding research into ion 
channels function. 
This introduction will focus on the evolution of ion channels and their common structural 
features such as pore structures with a particular focus on K channels. This then leads to 
comparing different ion channels and how structural information about the Kcsa channel led 
to a better understanding of the selectivity filter of K2P channels. This is followed by a review 
of recent ideas of how K2P channels gate, which is an important aspect for this thesis. The 
final section of the introduction will investigate how TREK1, TREK2 and TRESK are 




1.1 The voltage-gated ion channel super-family 
The voltage-gated ion channel protein superfamily is one of the largest families of signal 
transduction proteins and contains over 140 members. The basis of the ion channel families 
is centred on four variations surrounding the common pore-forming structure (Yu et al 2005). 
Sodium channels were the first members of the superfamily to be identified as a protein and 
also the first amino acid sequence to be solved (Catterall 2000; Noda et al 1984). The 
voltage-gated sodium channel is a large, complex which consists of four domains (1TM-
4TM) which forms the common structural motif for the family. Each of the domains contains 
six g-helical transmembrane segments (S1-S6). There is an embedded membrane - 
reentrant loop between helices S5 - S6 which forms the narrow, ion-selective filter at the 
extracellular end of the pore. The intracellular end of the pore is formed by four S6 segments 
(Yu and Catterall 2003). The voltage-gated calcium (Cav) channels are structurally similar to 
that for the Nav channel. The g subunit of Cav channel is similar to sodium channels as it is 
comprised in four homologous domains with six transmembrane segments. The S4 segment 
sense changes in the electric field and is important in channel gating. The transmembrane 
segments S5 and S6 contains a pore loop and determines ion conductance and selectivity 
(Hofmann et al 1994).   
Voltage-gated potassium (Kv) channels were first sequenced after analysis of the Shaker 
mutation in the fruit fly Drosophila (Papazian et al 1987). Kv channels are similar to the 
channels described above as the g subunits is a tetramer which resembles domains found in 
sodium and calcium channels. There are several other families of ion channels which have 
the same structure including; 
• Calcium-activated potassium (KCa) 
• Cyclic nucleotide-gated (CNG) 
• Hyperpolarization-activated cyclic nucleotide-modulated (HCN) 
• Transient receptor potential (TRP) 
 
Recent studies in structural modelling have found that ryanodine receptors 1 (RyR1) hold 
structure similarities to Kcsa channel. The region of similarity has been identified as 
important in gating the Kcsa channel and thus could also be important in gating RyR1. 
Therefore, the ryanodine receptor family could be added into to superfamily as there share 
structure features (Efremov et al 2015).  
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The inwardly rectifying potassium channel (Kir) is the simplest structure compared the 
channels above. The channel is formed from four subunits that consist of only two 
transmembrane segments (TM1 and TM2) which corresponds to the pore forming segments 
of Nav, Cav, and Kv channels (S5 and S6). Two pore potassium channel (K2P) are formed 
from two Kir that are linked together (Yu et al 2005). 
1.2 Evolution of ion channels 
In Kv channels, the subunits are separate proteins and consists of 6TM and forms a tetramer 
of four protein subunits. Kv channels are thought to have evolved by the addition of the 
voltage-sensing region (S1 – S4) from a basic protein structure which consists of two 
transmembrane (2TM) segments that is connected by a pore forming loop (Jiang et al 2003). 
Ligand-gated channels such as calcium-activated potassium channels (KCa), cyclic 
nucleotide-gated (CNG) channels and hyperpolarization-activated cyclic nucleotide-gated 
(HCN) channels are 6TM domain proteins that also assembles into a tetrameric structure 
and holds a pore-forming region which is made up of four highly similar domains 
(Mocydlowski and Latorre 1983). There are also combinations of voltage-gating regions and 
pore forming modulates such as two 2TM pore modulates (K2P), which forms a dimer with 
two subunits (Lesage et al 1996a). However, it must be noted that in Kv channels each 
domain is a separate protein, whereas Nav and Cav channels hold a pore-forming single 
protein which makes up the four domains. This evidence shows strongly that Nav and Cav is 
evolved from Kv channels. It must also be noted that domains I and III in Nav are more 
similar to one another compared to domains II and IV (Strong, Chandy and Gutman 1993). A 
further look at channel expression in lower eukaryotes show that most protozoans use Ca2+ 
as the inward charge carrier. Purely Na+ dependent action potentials are not found until early 
metazoans. Therefore, it is thought that Nav channels evolved as a result of gene duplication 
of ancestral Cav channel, as the four domains of Nav are more similar to the corresponding 
Cav domains than to each other. There is low similarity when compared to Kv channel (Hille 
1984). This would suggest that the four-domain precursor protein leads to the formation of 
Na+ and Ca2+ channels and came about through two round gene duplication of the single-
domain 6TM channel. The initially formation of these channels are believed to have started 
when a single domain of a two-domain protein results in the formation of the four-domain 
channel (Anderson and Greenberg 2001). The evidence would suggest that there is a 
common evolutionary pathway from a 2TM ancestor like the bacterial KcsA or Kir channel 
despite the ion selectivity and gating differences. Many bacteria have 2TM potassium 
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channels similar to Kir. Bacteria also express 6TM voltage-gated potassium channels (Booth, 
Edwards and Miller 2003).  
A)           B) 
 
Figure 1.1: A) Representation of the 143 members in seven ion channel families (adapted 
from Yu et al 2005, Anderson) B) Evolution of the voltage gated ion channel superfamily 
(adapted from Greenberg 2001). 
Evolution of ion channels have led to additional intracellular regulatory domains which are 
used in ligand binding and 4TM domain induced voltage-dependent gating. This allows for 
the ability to assemble information from different sources to control cell physiology and more 
complex processes such as learning, memory and muscle movements. This link to these 
important functions makes them targets for current therapy and could be used in the 









1.3 Ion channel nomenclature 
Ion channel improved resolution of structures has been a great influence on understanding 
the structural basis of how an ion channel functions and it has been shown that many ion 
channels share a similar structure as they are thought to have evolved from a mutual 
ancestor. Cl channels, aquaporins and connexins on the other hand differ from this common 
structure and therefore evolved independently (Alexander, Mathie and Peters 2011). 
1.3.1 Potassium channels 
Potassium channels contribute to the frequency and the shape of the action potential and 
are central regulators of excitability. The different channels are grouped into families 
depending on their structure and function. The three main families grouping (2TM, 4TM and 
6TM) is dependent on the transmembrane (TM) numbers (Alexander, Mathie and Peters 
2011). 
1.3.1.1 The 2TM family 
The 2TM family is characterised as the inward-rectifier K channel family. The family is 
grouped into seven subfamily; KIR1.x – KIR7.x. The g subunit found at the pore can form 
tetramers and heteromeric channels within the subfamilies for example KIR3.2 can bind with 
KIR3.3. These channels are strongly inward-rectifiers with KIR3.x being a G protein-activated 
inward-rectifier and KIR6.x is ATP-sensitive (Snyders 1999).  
Subfamily Channels 
KIR1.x KIR1.1 (ROMK1) 
KIR2.x  KIR2.1- 2.4 (IRK1-4) 
KIR3.x  KIR3.1- 3.4 (GIRK1-4) 
KIR4.x  KIR4.1- 4.1 
KIR5.x  KIR5.1 
KIR6.x  KIR6.1- 6.2 (KATP) 
KIR7.x  KIR7.1 
Table 1.1:  The 2TM potassium ion channel subfamily 
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1.3.1.2 The 6TM family 
The 6TM family contains the voltage-gated Kv subfamilies (Kv1.x-Kv12.x). The Kv subfamily 
can then be divided again into subtypes based on what the channels are related to. Four 
sequence-related potassium channels genes – shaker, shaw, shab and shal- were first 
identified in Drosophila. The homologs genes have been found in humans. This gene 
encodes a member of the potassium channel- voltage-gated, shaker-related subfamily. The 
member this subfamily is made up of 6TM and shows delayed rectification. The members of 
this subfamily will allow for repolarisation of nerve cells following the action potential. The 
channels also play a role in T-cell proliferation and activation (Jiménez-Pérez et al 2016; 
Roberds and Tamkun 1991).   
Subfamily  Type 
Kv1.1-Kv1.8:  Shaker-related 
Kv2.1-2.2:  Shab-related 
Kv3.1-3.4  Shal-related 
Kv4.1-4.3:  Shaw-related 
Kv7.x:  KCNQ 
Kv10.x, Kv11.x, Kv12.x:  EAG which include hERG channel 
KCa 2.x, KCa3.x:  Ca2+ activated SK subfamily   
KCa1.x, KCa4.x, KCa5.x:  Ca2+ -activated Slo subfamily which is 
actually comprised of 7TM 








1.3.1.3 The 4TM family 
The 4TM family is referred to as the two-pore domain (K2P) family as the pore-forming g 
subunit contains two pore domains and is therefore thought to form dimers instead of 
tetramers which are more usually see in potassium channels. This family is grouped into six 
subfamilies based on structure and functional properties (Ketchum et al 1995). 
Subfamily Channels   
TWIK: Tandem of P-
domains in a Weakly 
Inward rectifying K+ 
channel 
K2P1.1 (TWIK1) K2P6.1 (TWIK2) K2P7.1 (KNCK7) 
TREK: TWIK-related 
K+ channel 
K2P2.1 (TREK1) K2P10.1 (TREK2) K2P4.1 (TRAAK) 
TASK: TWIK-related 
acid sensitive K + 
channels 
K2P3.1 (TASK1) K2P9.1 (TASK3) K2P15.1 (TASK5) 
TALK: TWIK-related 
alkaline activated K+ 
channel 
K2P16.1 (TALK1) K2P5.1 (TASK2) K2P17.1 (TASK4) 
THIK: tandem pore 
domain halothane 
inhibited K+ channel 
K2P13.1 (THIK1) K2P12.1 (THIK2)  
TRESK: TWIK-
related spinal cord 
K+ channel 
K2P18.1 (TRESK)   









1.3.1.3.1 Classification of K2P channels  
Table 1.3.1 shows each individual K2P channel, including six subfamilies, and a summary of their key properties.  




Gi-coupled receptors-mediated trafficking to 
the cell membrane. 
Acid pHi 
Protein kinase C 
Dynamic ion selectivity 
Heterodimerization with K2P 




  Slow inactivation  
KCNK7 
K2P7.1 

































Multiple unitary conductances with 
alternative transcription initiation 































Dynamic ion selectivity 














  No measurable current  
TASK2 
K2P5.1 




Reactive oxygen species 
   
TALK2 
K2P17.1 
   
THIK1 
K2P13.1 
PUFA (arachidonic acid) Hypoxia Halothane No change 












Protein kinase C 
PUFA (arachidonic acid) 
Sanshool 
Asymmetrical gating 





Table 1.3.1: Natural and chemical effectors of K2P channels including salient features and interacting partners. PUFA, polyunsaturated fatty acid; 
LP, lysophopholipid; ER, endoplasmic reticulum; COP-I, coat protein 1; AKAP-150, A-kinase anchoring protein 150; Mtap2, microtubule-
associated protein; NO, Nitric oxide (adapted from Feliciangeli et al 2011) 
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1.3.2 Sodium channels 
Sodium channels are voltage gated and have one pore-forming g subunit. Sodium channels 
contain four domains (I-IV) which has six transmembrane segments (S1-S6) and a pore 
forming loop. The S4 is positively charged and therefore acts as the voltage sensor for 
voltage gating. Voltage-gated sodium channels are important in the generation of the action 
potential as when the channels open, this will shift the membrane potential to a more 
positive value and will depolarise the cell. An important feature for these sodium channels is 
the carry out rapid voltage activation and inactivation of the channel. Inactivation of the 
channel involves closing the channel and preventing it from reopening until full recovery, 
which is important for the action potential (Armstrong 1973). The inactivation state has also 
been found to hold some clinically useful benefits as local anaesthetics and antiarrhythmic 
drugs will bind to the channel and stabilise the channel in the inactivated state. The 
subfamilies are characterised by their inactivation rate. 
Subfamily Function 
Nav1.1-Nav1.7 Fast inactivation (between 0.5 ms – 1 ms). 
Nav1.8-Nav1.9:  Slow inactivation (between 6 ms – 16 ms). 
Table 1.4:  The voltage-gated sodium ion channel subfamily and function 
Fast inactivation works as a “ball-and-chain” mechanism where portion of the cytoplasmic 
region blocks the pore by binding to a docking region. During sustained membrane 
depolarization, the channel will further inactivate to a non-conducting state which is referred 
to as slow inactivation. Slow inactivation of the channel involves a conformational change in 
the structure of the sodium channel (Goldin 2003). A functional difference that is used to 
characterise the channels is its sensitivity to tetrodotoxin (TTX) as Nav1.5, and the slow 
inactivated Nav1.8 and Nav1.9 are less responsive to TTX compared to the other channels 
(Sangameswaran L et al 1996).   
Another type of sodium channel is the sodium leak, non-selective channel which has a 
similar structure to the voltage-gated sodium channel family. However, it differs from the 
voltage gated sodium channels as Nav2.1 is unresponsive to voltage and is also insensitive 





1.3.3 Calcium channels 
Calcium (Ca2+) channels are voltage-gated ion channels that are located in the membrane of 
many excitable cells. Ca2+ channels form hetero-oligomeric complexes and contain pore-
forming g1 subunit which offers extracellular binding site(s). A g1 subunit contains of four 
domians (I-IV) with each comprising of six transmembrane segments (S1-S6) and a pore-
forming region between S5 and S6. The S4 segment is positivity charge and is therefore 
thought to be associated with gating. The 10 g1 subunits and characterised into three 
families (Simms and Zamponi 2014). 
Subfamily Function 
Cav1.x L-type: High voltage activated dihydropyrine-sensitive family 
Cav2.x High voltage activated dihydropyridine-insensitive family 
Cav3.x T-type: Low-voltage activated 
Table 1.5:  The voltage-gated calcium ion channel subfamily and function 
1.3.4 Chloride channels 
Chloride channels are anion selective channels which are involved in the regulation of 
excitability of neurons, skeletal, cardiac and smoot muscle cells. They are also involved in 
salt transport, inter- and extracellular acidification, cell cycle regulation and volume 
regulation.  GABAA and glycine receptors are characterised as chloride channels but is 
gated by neurotransmitters. The voltage-sensitive CIC-1 and CIC-2 are found in the plasma 
membrane. CIC-Ka and CIC-Kb channels are also found in the plasma membrane and the 
other members of the CIC family are localised intracellular. Other chloride channels included 
the CFTR which are cAMP regulated found in the epithelial cell membrane and is involved in 
fluid transport. Chloride channels activated by intracellular calcium (CaCC) are expressed in 
excitable and non-excitable cells (Dutzler et al 2002).  
1.3.5 Hyperpolarization Ȃ activated, cyclic nucleotide gated 
(HCN) channels 
The hyperpolarisation-activated, cyclic nucleotide-gated (HCN) are cation channels which 
are both permeable to sodium and potassium. The HCN channel family are comprised of 4 
members (HCN 1-4), which are expressed in the heart and the nervous system. These 
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channels are involved in setting the equilibrium potential of sodium, which shifts the resting 
potential of the whole cell more positive to that of the reversal potential of the potassium 
channel. These channels are activated by hyperpolarisation at -50mV and more negative 
voltages. To activate the channel, the cyclic nucleotides cAMP and cGMP act directly on the 
channel which causes the activation curve to shift to more positive voltages. The members 
are separated by their speed in activated (DiFrancesco 1993).  
1.3.6 Transient receptor potential (TRP) cation channels 
TRP contains six transmembrane domains which are used to form homo- or hetero- 
tetramers to form cation selective channels. TRP channels are widley distributed in different 
tissues and cell types. Activated TRP channels are involved in depolarisation of the cellular 
membrane. This will activate voltage-dependent ion channels, which will change the 
intracellular concentration of calcium. This is important for the function of intracellular 
organelles for example endosomes and lysosomes. The TRP superfamily is classified into 
six subfamilies (Nilius and Owsianik 2011). 








 Table 1.6:  The TRP ion channel subfamily names and what they stand for. 
1.3.7 Other ion channels 
There are many other ion channels for example; the epithelial sodium channels (ENaC) are 
responsible for sodium reabsorption in the distal part of the nephron and the collecting duct 
of the kidney. Cyclic nucleotide-gated (CNG) are responsible for signalling in the primary 
sensory cells of the vertebrate. Aquaporins and aquaglyceroporins are membrane channels 
which allow the permeation of water. Acid-sensing ion channels (ASICs) are members of the 
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sodium channel superfamily and form proton-gated, voltage-insensitive sodium permeable 
channels. CatSper channels are voltage-gated calcium permeant channels and there are 
four members of this family (CatSper 1-4) (Alexander, Mathie and Peters 2011).  
1.4 Membrane potentials 
In cells, there is an electrical potential difference between the intracellular compartment and 
the surrounding external environment. Transported substances in cells will carry a net 
charge. The movement will be influenced by its concentration gradient and the membrane 
potential, the electric potential (voltage) across the membrane. These two forces combined 
is called the electrochemical gradient and will establish the energetically favourable direction 
of charged molecules across the membrane. The electric potential that is seen across most 
membrane is caused by a small imbalance in the concentration of positively and negatively 
charged ions on the two sides of the membranes. This separation of charge between the two 
locations is measured in units of volts. Neurons can conduct, transmit, and receive electric 
signals. This characteristic is a result of specific ion channels in the neuron plasma 
membrane.  Therefore, ion channels are essential for normal functioning of neurons (Lodish 
et al 2000). 
1.4.1 Neuronal Signalling 
The central nervous system (CNS) is composed of different cell types; including many 
different neurons, astrocytes, microglia and oligodendrocytes. Neurons are used to process 
information entering the CNS. Neurons have the ability to communicate information over 
great distances by propagating a transient electrical signal across their axonal membranes 
(Lodish et al 2000). This electrical signal (action potential) will reach the presynaptic 
membrane, connected to the dendrite, and will trigger the release of neurotransmitters 
across the chemical synapses. The action potential will drive the Ca2+ ions influx via voltage-
gated calcium ion channels along the presynaptic membrane. Another mechanism of 
calcium concentration increase is through the release of Ca2+ from intracellular stores 
(Eilers, Plant and Konnerth 1996). The calcium will then bind to synaptotagmin which is 
found on the membrane of the synaptic vesicles. This newly formed protein will bind with 
SNAREs which will induce vesicle fusion with the presynaptic membrane. This will therefore 
trigger the neurotransmitter glutamate in synaptic vesicles to be released and diffuse across 
the synaptic cleft. Glutamate will bind to a specific transmembrane receptor called the N-
methy-D-asparate (NMDA). Neurotransmitters can affect the postsynaptic cell be initiating an 
excitatory postsynaptic potential (EPSP) and therefore influencing the likelihood of the firing 
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of an action potential by depolarizing towards threshold. When the neurotransmitter binds to 
the postsynaptic receptor, this will induce EPSP activity (Purves et al 2001).  
Signalling is necessary for neural function and is regulated by a flow of ions through ion 
channels. Binding of the neurotransmitter triggers changes in the ion permeability of the 
postsynaptic plasma membrane which changes the electric potential of the membrane 
(Lodish et al 2000).   
1.5 The resting membrane potential and the 
estimation of membrane potential 
The concentration of K+ ions is greater intracellularly than extracellularly, whereas it is the 
opposite for Na+ and Cl- ions.  
 
Figure 1.2: The unequal distribution of ions found at the resting membrane potential 
The different ion concentration is sustained by ATP-dependent pumps, mostly notably the 
Na+/K+ pump. The pump transports three Na+ ions out of the cell, and two K+ ions into the 
cell (Barnett and Larkman 2007). 
The plasma membrane also contains open “resting” or “leaky” K2P channels which are ion 
specific. The resting potential is therefore determined by the selective permeability of these 
K2P channels and the movement of K+ ions. This movement of K+ across the membrane 
causes an excess of negative charge to be left behind. If K+ ions were the only movement of 
ions than the resting membrane potential would be the exact value of potassium equilibrium 
(Ek) which is around -90mV. A key determinant of the membrane resting potential has been 
linked to K2P channels. The increased potassium permeability imparted by leak K+ currents 
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through K2P channel causes an increase K+ conductance and stabilizes cells at the 
hyperpolarised resting membrane potential (RMP) (MacKenzie, Franks and Brickley 2015). 
The Nernst equation calculates the potential for a single permeable ion. 継沈墜津  噺  迎劇権繋   In 岶件剣券岼剣岶件剣券岼件  
Figure 1.3: Nernst equation. Eion: equilibrium potential, R: universal gas constant, T: 
temperature (K), z: charge of the ion, F: Faraday constant, (ion)o: the extracellular ion 
concentration, (ion)i: the intracellular ion concentration (Copper 2012).    
However, in reality, the resting membrane potential is less than EK (between -50mV and -
80mV) as Na+ ions contribute to the value. The main source for setting the resting 
membrane potential is K+ so the EK is closer to the resting potential in comparison to ENa 
(+65mV) (Purves, Augustine, Fitzpatrick, et al 2001). ECl has a similar potential to EK 
however there are only a few Cl- channels open and therefore could not contribute to the 
resting membrane potential in a significant way (Lodish et al 2000).  
The Goldman-Hodgkin-Katz equation is used to estimate the membrane potential using the 
net flow of all the ions across the membrane. It is the same concept as the Nernst equation 
as it takes into account the charges of the ion. However, it also looks at the relative 
permeability of the membrane of each of the different ion channels (Copper 2012) 
 
Figure 1.4: Goldman-Hodgkin-Katz equation.  Vm: membrane potential, R: gas constant, T: 
temperature (K), F: Faraday constant, (ion)in: the intracellular ion concentration, (ion)out: the 
extracellular ion concentration, Pion: ion permeability (Copper 2012). 
1.5.1 The action potential 
The action potential begins with the opening of voltage-gated Na+ channels. This movement 
of high external Na+ ions diffuses down the concentration gradient into the neuron. The 
external Na+ ions will also diffuse down the electrochemical gradient as the Na+ ions are 
attracted to the negative internal charge of the neuron. The Na+ ions carry a net positive 
electrical charge and will allow the neuron the approach ENa (the peak of action potential) 
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while leaving an excess of negative ions outside the membrane face. The movement is 
known as depolarization. If depolarization reaches threshold it will lead to an action potential. 
The shift of charge is represented as a spike on an action potential trace (Barnett and 
Larkman 2007).  
As the membrane voltage increases, most gates in the voltage-sensitive Na+ channels will 
open. However, this increase will also close the channels inactivation gate at a slower rate. 
Therefore, when membrane voltage is raised suddenly, the Na+ channels open initially but 
due to the slower inactivation gate will close. This will lower the membranes permeability to 
Na+ which will drive the membrane voltage towards the negative voltage. The net movement 
of Na+ ions into the neuron will cease also because the concentration gradient is balanced 
by ENa found inside the neuron.  
The newly developed positive voltage of the neuron will cause voltage sensitive K+ channels 
to open. This efflux of K+ ions will drive the membrane voltage towards EK. as the membrane 
permeability changes between Na+ to K+ ions and repolarisation of the neuron will take 
place. The outward movement of K+ begins the progression toward resting membrane 
potential (Lodish,et al 2000). 
The next stage is hyperpolarisation as the neurons slowly recover from the overshoot of the 
resting potential. The membrane becomes excessively negative and undershoots the resting 
potential (-70mV) (Barnettand and Larkman 2007). The K+ channels remain open because 
of the influx of calcium during the action potential (Copper 2012). The K+ channels do not 
inactivate and thus the K+ ion movement is ceased by the closure of the activation gate. This 
closure of the gate however is slow and means the channel remains open for a longer phase 
and results in the described overshoot which generates this after-hyperpolarisation step 
(Barnett and Larkman 2007). 
Each action potential is then followed by a refractory period which involves two stages; an 
absolute refractory period which cannot evoke an action potential and the relative refractory 
period which can induce an action potential but requires a very strong stimulus. The absolute 
refractory period is caused by the inactivation of the Na+ channels and the channel cannot 
be opened again (Copper 2012). When the Na+ channels reach back to its resting state and 
several voltage-gated K+ channels remain open, it makes it very difficult to stimulate a new 
action potential. This is known as relative refractory period. There are a number of class 1B 
antiarrhythmics for example lidocaine and phenytoin which are known to block sodium 
voltage-gated channels which may underly the therapeutic potential as it decreases 
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excitability of abnormally firing cells. In addition to this, these compounds will accelerate 
cellular repolarization by increasing potassium efflux and also decrease the duration of the 
action potential and the refractory period (Catterall 1987). Lidocaine is also a local anesthetic 
which is used in neuropathic pain conditions but also in acute and chronic pain (Golzari et al 
2014; Kosharskyy et al 2013). When all the voltage gated K+ channels are closed and the 
“leaky” K2P channels are all open, the membrane potential begins to stabile and return to the 
resting membrane potential, below the firing threshold. Therefore, K2P channels are 
important in influencing the level of stimulation needed to initiate the action potential and 
regulates the shape, frequency, and magnitude of each spike (Plant 2012). Subsequent 
action potentials can now be fired. When an action potential is fired, its signal is carried 
along the axon until it reaches the axon terminal. This signal is continued to the next neuron 
via neurotransmission (Copper 2012).  
1.6 The pore structure of Kcsa 
The structure of Kcsa was the first structure that revealed the pore structure of a K+ channel. 
The three-dimensional structure of Kcsa showed a two trans-membrane (2TM) bacterial 
potassium channel. The channel shows a conical shape where four subunits surround the 
central ion pathway. The M1 and M2 segments are arranged around the pore. The pore is 
characterized by four short loops which contain the signature sequence of the K+ channel.  
The intracellular side of the channel is comprised of four inner helices that would pack 
against each other to form the helix bundle crossing. Thus, the Kcsa is thought to have been 
solved in the closed configuration (Doyle et al 1998). In the inwardly-rectifying potassium 
channel, which is analogous with Kcsa, the TM2 segment after each pore loop will make up 
the intracellular portion of the ion cavity pathway. These potassium channels are formed as 
tetramers with one pore loop in each subunit however K2P channels consists of two pore 
loops in a single subunit. Therefore, four pore loops from two subunits comprises K2P 
channels, which is how the name two-pore domain potassium channel was assigned. M1 
and M3 are the outer helices of the P domain 1 and 2 and M2 and M4 are the inner helices 
of P domain 1 and 2 (Kollewe et al 2009). The pore structure of Kcsa is also shared with the 
cyclic nucleotide-regulated channel (MlotiK), voltage-gated Na+ channel from Arcobacter 




Figure 1.5: Ribbon representation of the Kcsa K+ channel (1BL8) with four subunits coloured 
differently. The channel is oriented with the extracellular solution on top.  
 
1.7 The selectivity filter in potassium channels 
Potassium channels are characterized by a common selectivity filter. The sequence of the K 
channel selectivity filter is a salient feature of K2P channel which indicates identical properties 
of the channels. The highly conserved K+ channel signature sequence is XXTTXGXG is 
important in the diffusion of potassium ions.  
Potassium ions are hydrated in the central cavity and then dehydrated at the selectivity filter. 
The K+ ions are then rehydrated in the extracellular entryway of the channel. The binding 
sites for ions inside the selectivity filter are comprised of eight oxygen atoms in the 
extracellular entry of Kcsa K+ channel. These sites, when not bond to potassium ion, are 
occupied by water molecules. In the K+ selectivity filter, four binding sites of oxygen atoms 
are seen and therefore the sequence of binding goes between two configurations; where K+ 
bind at position 1 and 3 (K+-water-K+-water) and position 2 and 4 (water-K+-water-K+).  
There is also a concentration-dependent path where a third ion enters the selectivity filter 
and another ion exits from the other end. Conformational change in the channel is caused by 
different concentrations of ions. The main differences come down to changes in the shape of 
the selectivity filter with the remainder of the channel unchanged. In the low-potassium 
structure it is seen that G77 faces into the pore and could therefore block the pathway after 
the alpha carbon twists the residue. The twisting also gives the filter an hourglass shape. 
This low concentration of potassium ions causes the channel to become non-conducting as 
the selectivity filter is pinched shut. In high concentration of potassium ion, the channel is ion 
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conducting as the residue G77 is identified as providing two binding sites for two K+ ions. 
(Zhou and MacKinnon 2003). The channel is only conducting once the filter is straight, which 
is seen in high K+ structure. The high conductance of potassium ions and binding to the 
selectivity filter are examined by electrostatic repulsions between the ions. Two ions in the 
filter would stop the cavity from collapsing and would also repulse one of the ions out of the 
channel. This will cause tension in this two ion conformation and will lead to a decrease in 
affinity for K+ ions (MacKinnon 2004).   
The ion-dependent conformation change is believed to switch in accordance to a timescale 
of gating (milliseconds) rather than ion conduction (nanoseconds). It should also be noted 
that the activation gate is important in identifying the ion concentration as the activation gate 
is found in between the selectivity filter and the cytoplasm. The position allows the activation 
gate to open the filter to sense the concentration of potassium ions (Zhou et al 2001).  
1.7.1 Ion permeability of potassium and sodium channels 
In molecular dynamic simulations of the bacterial potassium channel (Kcsa), differences 
between the interactions of the selectivity filter and the ions potassium and sodium are 
shown. It was identified that K+ ions and water molecules bind within the filter and 
translocate between adjacent sites on a nanosecond timescale, while in contrast Na+ ions 
are bound in a more fixed matter to their sites within the filter. The ions also differ in how 
they like to bind in the channel. K+ ions are held within a cage of eight oxygen atoms 
contained in the filter while on the other hand, Na+ ions bind with the ring of four oxygen 
atoms (Shrivastava et al 2002). Regarding the sodium channel permeability, there are 
important conditions that improve Na+ channels selectivity of Na+ ions over K+ ions. The 
pore preferring Na+ ions provides three instead of four protein ligands to coordinate the ion. 
The hydration of Na+ ions is also less important and the Na+ ions favour the pore to be 
relatively rigid, constricted, and solvent exposed. It was also revealed that factors that favour 
Na+ ions over K+ ions in Na+ channels will cause K+ channels to prefer Na+ ions over K+ ions 
(Dudev and Lim 2010).   
New crystal structure of the prokaryotic sodium channel from Magnetococcus marinus 
(NavMs) shows the pore only containing sodium ions. This structure was able to identify the 
binding sites of the three Na+ ions in the centre in the selectivity filter. The selectivity filter of 
sodium channels contains a highly conserved glutamate region which therefore allows 
hydrated sodium ions to pass through the pore, unlike K+ channels. Potassium ions are 
prevented from passing through the pore as the K+ ions would need to be desolvated to fit 
through the NavMs selectivity filter. The crystal structure also showed that NavM channel 
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has a much wider pore compared to K channels, which allows space for intervening water 
molecules (Naylor et al 2016). 
 
Figure 1.6: The ion binding in sodium and potassium channels. Left: sodium ions in the 
selectivity filter of the NavMs channels. Right: potassium ions in the selectivity filter of Kcsa 
channel (adapted from Naylor et al 2016). 
All this evidence suggests that there are distinctions between sodium and potassium 
permeability in the respective ion channels. However, some ion channels have shown 
changes in ion channels selectivity. Evidence emerged that showed that the ion selectivity of 
TWIK1 changes to conduction of sodium at acidic pH and when the extracellular potassium 
is lowered (Chatelain et al 2012). Sodium ion selectivity in TREK1 will become TWIK1-like if 
a mutation is made at the selectivity filter (I267T) that is homogenous to TWIK1. However, 
BL-1249 will restore the K+ ion permeability as it’s believed to stabilize the selectivity filter 
(Decher et al 2017). 
1.8 Two pore domain potassium channels (K2P) 
1.8.1 Discovery of K2P channels 
The first member of the K2P family to be discovered was TOK1 and was cloned from 
Saccharomyces cerevisiae. An important characteristic that was identified was that the 
channel contained two P domains or pore domain. The signature P domain (XXTTXGXG), 
as previously described, was used to identify in S.Cerevisiae genome and was subsequently 
translated to the amino acid sequence. The family was therefore predicted to have two pore 
like domains that consist of these eight residues. This was the first example of an outwardly 
rectifying potassium ion channel to be involved in the resting membrane potential (Ketchum 
et al 1995; Lesage et al 1996b). Subsequent studies showed however that K2P channels 
cloned from Drosophila melanogaster predicted a four transmembrane segment and was 
therefore referred to as TWIK- (Tandem of P domains in Weakly Inward Rectifying K+) 
related channels channel (Goldstein et al 1996, Lesage et al 1996a). The human genome 
contains at least 70 genes that code for potassium ion channels. The unique two pore/ four 
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transmembrane features have helped in identifying fifteen genes that encode the K2P 
channels (Goldstein et al 2005). 
1.9 Gating of K2P channels 
1.9.1 C-type inactivation in K2P channels  
Voltage-gated potassium (Kv) channels contain an outer pore gate that produces “C-type” 
inactivation. The conformation changes seen at the gating of K2P channels shows a 
resemblance to the external pore C-type inactivation of Kv channels (Cohen, Ben-Abu and 
Zilberberg 2009). The evidence of this similarity is seen when comparing Kv channels and 
the two pore KCNKØ channels to their effects to zinc and tetraethylammonium (TEA). 
In voltage gated Shaker-delta K+ channel, the C-type gate is controlled at position T449. A 
cysteine mutation at this location allows for inhibition by zinc and cadmium at a relatively 
small concentration compared to WT. The ions bind weakly when the channel is in an open 
state and slows the movement of the channel into the inactivation state. However, there is 
higher binding affinity when the channel starts in the inactivation state (T449C), which shows 
that there is a structural change in the external mouth of the pore during inactivation gating 
(Yellen et al 1994). Zinc is a potent inhibitor of KCNKØ channels and extracellular histidine 
29 is required for zinc block. It would therefore appear that this interaction requires structural 
changes in the external mouth of the pore similar to that of the C-type inactivation gate 
(Zilberberg, Ilan and Goldstein 2001). Choi, Aldrich and Yellen (1991) showed that external 
tetraethylammonium (TEA) blocks the slow inactivation of the C-type gate in Kv channels. In 
relation to this, KCNKØ channels current is also blocked by TEA reducing the single channel 
conductance.  
More similarities are seen as both K2P channels and Kv channels show C-type inactivation 
gating in the presence of external permeant ions. In Shaker-delta potassium ion channel, a 
reversibly slowed closure of the inactivation gate was seen in high external potassium 
solution (López-Barneo et al 1993). This is a similar response to that of KCNKØ channels 
which showed that in high external potassium there is a high probability of an open state 
leading to an increase in current (Zilberberg, Ilan and Goldstein 2001).  
As mentioned above, the importance of T449 in Shaker potassium channel has been 
connected to the C-type activation gate. The analogous site in K2P channel is found in the 
first P loop T112. The mutation of this site (T112Y) allows for stability in the closed state of 
the channel and alters the C-type gate, as a faster inhibition speed from zinc is seen 
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(Zilberberg, Ilan and Goldstein 2001). In the attempt to discover more about the inactivation 
gate, the negatively charged glutamate 418 in Shaker channels was identified. This residue, 
found in most VGK and KCNK subunits, is believed to be involved in the interaction between 
the S4 movement and the pore in slow inactivation.  To examine the role of E418, the 
Shaker channel was compared to the known structure KcsA. This structure suggested 
potential binding between G452 and V451 in S6 with E418 in S5.  Therefore, cysteine 
mutations were carried out on these sites and E418C was seen to hold disulphide bonds to 
G452C and V451C. This indicated that the channel was stabilised in the inactivated state. 
These results suggested that E418 forms hydrogen bonds with the external end of S6 which 
holds the gate fixed in the open conformation. However, when these bonds are broken after 
rotations in the channel, it leads to closed inactivation state (Larsson and Elinder 2000). 
Zilberberg, Ilan and Goldstein (2001) carried out similar experiments on E28 and T115 K2P 
channels, which are analogous to the Shaker sites E418 and G452. Cysteine mutations 
showed that disulphide bonds could be formed and that these bonds could be broken in a 
similar fashion to that of the Shaker channel. All this evidence taking together confirms that 
there is indeed a functional upper gate found near the selective filter in K2P channels and 
that the transition between open and closed is associated with conformational changes in 
the extracellular side of the pore (Cohen, Ben-Abu and Zilberberg 2009). 
Kv channels have a well-defined method in controlling its opened and closed conformation 
involving both an upper inactivation gate and a lower activation gate. It was found that the 
state of the activation gate is connected to the state of the inactivation gate and vice versa. 
This cross-talk communication is negatively coupled as the opening of one causes the 
closure of the other. This negative cross-talk is believed to be involved in controlling the 
activity of the action potential (Panyi, and Deutsch 2006). With K2P channels containing one 
similar gate, it was then thought that K2P channel could have a similar lower gate. 
1.9.2 Is there a functional activation gate in K2P channels?  
Voltage-gated potassium channels holds a well-defined activation gate. This gate is formed 
by a four-helix bundle which is located at the intracellular side of the pore on the sixth 
transmembrane segment (S6) (Tombola et al 2006). When investigating the role of this gate 
in K2P channels it was important to note that voltage gating at this time was poorly 
understood in K2P channels. A study with quaternary ammonium (QA) showed that there is 
no gating at the helix bundle crossing. QA has the ability to bind to TREK1 channel pore 
when it is positioned in its closed and open state. There is also a similar binding affinity in 
both states. Thus, the bundle is constantly open and is not directly involved in blocking the 
ion conductance (Piechotta et al 2011).  It is also believed that K2P channels are open over a 
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wide range of membrane voltage and therefore it was theorised that the mechanism is 
different to that of Kv channels (Renigunta et al 2015).  However, a recent study has shown 
how K2P channels operate as a voltage-dependent channel without a conventional voltage-
sensor site.  
It was found that excluding TWIK1, K2P channels are dependent on the movement of ions in 
the channel and creating an electrochemical potential difference. Physiological activation by 
lipids, membrane stretch and intracellular acidification can switch from voltage dependence 
to leak mode. It is believed that voltage dependence is caused by three to four ions moving 
into the selectivity filter. When the channel is in the “ion depleted” state, the channel contains 
none or one ion in the selectivity filter at negative potentials. Upon depolarisation, there will 
be a flux of ions into the pore to fully occupy the selectivity filter and allow for the outward 
rectification of K+ ions (Schewe et al 2016).  
It was originally hypothesised that the inner bundle crossing is important in activation of 
voltage gating in TASK3 channels (Ashmole et al 2009). The voltage gate activation is weak 
compared to the Schewe et al (2016) study. Mutating these channels at the pore lining in 
TM2 and TM4 however can enhance the activity of the voltage gate. The mutations did not 
affect extracellular acidification inhibition which is known to occur at the selectivity filter, thus 
suggesting two separate gates (Ashmole et al 2009; Niemeyer et al 2016). Further support 
was seen in Ben-Abu et al (2009) which showed that in Shaker Kv channels in the closed 
state are intrinsically more stable than the open state. Whereas K2P channels have a higher 
open probability compared to the closed state. The difference in preferential states is 
believed to be directly caused by the activation gate site. In Kv channels the activation gate 
region is lined with hydrophobic residues termed the “hydrophobic seal” whereas the 
corresponding activation gate region found in K2P channels consists of several glycine 
residues. Mutating these hydrophobic residues with glycine in Kv channels would stabilise 
the open state and mutating the glycine residues with hydrophobic residues in K2P channels 
showed a non-conducting state (Ben-Abu et al 2009).  
Ben-Abu et al (2009) also wanted to show the presence of the lower activation gate in K2P 
channels and so developed a Kv-K2P chimera channel that contained the first pore domain of 
K2P and the voltage sensor end of the Kv channel. This would demonstrate that K2P channel 
could close in response to change in voltage by adding the functioning voltage sensor found 
in the Kv channel. This chimera channel showed its ability to close in a voltage-dependent 
manner in milliseconds, which is a characteristic of the lower activation gate movements. It 
must also be noted that the new tetrameric structure of the chimera could influence the 
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movement of TM2 that could not be seen in the native dimeric structure (Niemeyer et al 
2016). 
Further evidence seen in a molecular dynamic simulation study on TWIK1 crystal structure 
showed an interesting mechanism separate from the C-type gating. It was found that the 
pore lining below the selectivity filter is highly hydrophobic which creates a dewetting area. 
This region may form an energy barrier which blocks the ion passage with residues L146 
and L261 forming the “hydrophobic cuff”. This therefore suggests a hydrophobic gating 
mechanism for regulating TWIK1 and account for the low functional activity (Aryal, Sansom 
and Tucker 2015). 
1.9.3 Importance of C-terminus for gating 
The carboxyl terminal domain of TREK1 is essential for regulatory properties (Honoré 2007). 
However, mutations at the C-type gate causes a change in activation response linked to the 
C-terminal of TREK1. Mutagenesis scanning discovered the highly conserved W275S 
residue on the N-terminal portion of the M4 transmembrane segment of TREK1. This site is 
also close to the selective filter and the upper C-type gate. The mutation substantially 
blunted activity by regulatory modulators, such as temperature, which act on the C-terminus. 
These results therefore supported the idea that these sites close to the selectivity filter are 
used in regulation even if the action is on the C-terminus. This also shows that the mutation 
uncouples the sensors used by each stimulus from its gating mechanics. It was seen that the 
mutation abolished any inhibition of TREK1 through extracellular acidosis. An increase in 
extracellular potassium concentration would antagonise the inhibition of TREK1 current by 
external acidosis. However, the mutation TREK1 W275S showed a diminished response and 
was seen to have failed sensitivity to potassium concentration. Another mutation, F276L, 
discovered in this study did not show the change in response which shows that residue 
W275 is important in the gating mechanism. As can be seen there are modulators that act 
on the C-terminal but cause a reaction from the C-type gate. (Bagriantsev et al 2011). 
Therefore, how did the signals from the C-terminal effect the C-type gate and open the 
selective filter?  
It was hypothesised that there was clear cross-talk between the lower gate and the upper 
gate found at the selectivity filter. An important site on TREK1 for this new gating mechanism 
was identified as G137. The mutation, G137I would halt any inhibition through acidosis and 
was seen to stabilise the C-type gate. Indeed, both W275S and G137I showed a reduced 
effect of membrane potential on the channel which may be linked to their close proximity to 
one another (Bagriantsev, Clark and Minor 2012). 
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A)                                                           B) 
                  
Figure 1.7: TREK1 and C-terminus gating. A) shows important residue sites in relation to 
cross talk gating and C-terminus gating.  B) TREK1 channel, based on TRAAK model, 
showing the location of W275 and G137 (adapted from Bagriantsev et al 2012). 
To further investigate cross-talk through M4 transduction, M4-Ct region was uncoupled from 
the intracellular domains which were achieved by mutating I262-G293-D294 to glycine or 
alanine. The mutation using glycine adds flexibility and alanine removes sidechain 
interactions. These mutations did in fact eliminate the C-terminus function and kept the 
channels extracellular acidosis sensitivity. More importantly, both mutations were insensitive 
to changes in membrane potential whereas the WT did alter. The lack of response is caused 
by uncoupling of the C tail from the bilayer and not from the C-type gate. Activation caused 
by increase in temperature is abolished by the triple mutations and therefore is also believed 
that this stimulus relies on the C terminus binding to the pore as the pore domain has 
temperature sensors. This shows that a signal moves from the C-terminal through the M4 
segment to communicate to the extracellular C-type gate (Maingret et al 2000). 
 
Figure 1.8: Model of coupling gates: Shows the activation and inactive state based on the 
binding of C terminus and the membrane bilayer (adapted from Bagriantsev et al 2012). 
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All this evidence together would strongly suggest that K2P channels do not have a functional 
bundle crossing gate or functional activation gate, but that this lower gate is open and is 
insensitive to stimulation. It is in fact the upper C-type gate found near the selective filter that 
is the primary gate. This also correlates to the finding from Ben-Abu et al (2009), which 
reported movement made by the lower gate would affect the state of the C-type gate at the 
selectivity filter. More recently, evidence supporting a continually open activation gate was 
found as solved crystal structure of K2P channels were developed.  
1.9.4 K2P channel gating structure 
The first proposed gating system of K2P channels has been extrapolated from 
crystallographic three-dimensional structures of two bacterial channels, KcsA (Doyle et al 
1998) and MthK (Jiang et al 2002). In closed conformation, it is seen that the pore inner 
helices are straight and point outwards. This will allow a helix bundle to form at the 
intercellular region of the pore. In the opened conformation, the inner helices will bend at a 
‘glycine hinge’, which causes the cytoplasmic region of the pore to open (Cohen, Ben-Abu 
and Zilberberg 2009).  
However, after the crystal structure for TRAAK and TWIK1 were defined, considerable 
differences were observed (Brohawn 2015). One of the most interesting differences between 
the old prospective K2P model and the new crystal structures of TRAAK and TWIK1 is that 
the inner helical gate is indeed constantly open. It is seen that when P1 domain of TRAAK is 
most constricted, it is similar to the most open conformation of MthK (~12 Å). The P1 domain 
is less open than when it is most restricted (~10 Å), however this is more expressive than 
the open conformation of Kv channels (Brohawn, Del Mármol and MacKinnon 2012). The 
TWIK1 cavity is also measured at similar values to that of open state channels (~11 Å) (Fig 
1.9) (Miller and Long 2012).  Another K2P channel structure, TREK2 has also be visualised 
as a crystal structure with norfluoxetine. This channel also has a continually open 
cytoplasmic gate even in a closed state (Dong et al 2015). 
All the structural information together supports the idea that K2P does not gate at the lower 




Figure 1.9: Structure of K2P TWIK1 channel (3UKM) with an open inner gate. Subunit A is 
coloured and Subunit B is grey. TM1 is labelled in blue. TM2 is orange. TM3 is labelled pink 
and TM4 is labelled red. C helix coloured in light pink. 
1.10 TREK channels 
1.10.1 TREK tissue distribution and diversity  
TREK1 is widely distributed in the CNS with expression at its highest in the striatal tissue, 
spinal cord and other areas in the brain for example cortex, hippocampus, hypothalamus, 
amygdala and the olfactory. To a lesser extent, it is also found in the GI tract (Medhurst et al 
2001). TREK2 has similar distribution with less expression found in the brain; however, 
TREK2 was also seen in peripheral tissues like kidney and pancreas (Bang et al 2000; 
Medhurst et al 2001). TREK channels are known to form several different isoforms. TREK1 
produces two isoforms and TREK2 form three isoforms through alternative translation 
initiation. K2P channels are naturally widely expressed in areas which overlap each other 
channels so it has been widely thought that TREK channels form more heterodimer bonds 
than previously considered (Honoré 2008).   
Heterodimerization is also an important part of channel diversity without increasing the 
number of genes. Combinations of different properties of the bound channels can change  
the channel’s sensitivity to pharmacological agents. It was once believed that TWIK1, a non-
functional channel, can become functional after achieving heterodimer binding with TREK1 
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(Mi Hwang et al 2014). However, after repeat experiments it was found that no interaction 
was found between the two channels. It was in fact established that all ATI isoforms of 
TREK1 and TREK2 can form a heterodimer bond with each other and with the TRAAK 
channel. TREK1 has a high binding affinity to itself and TREK2; however, it does not bind as 
efficiently to TRAAK. Heterodimerisation have seen changes in drug sensitivity for these 
channels. A TREK1 and TRAAK activator ML67, has seen intermediate degree of activation 
when interacting with the heterodimer TREK1/TRAAK. Changes in sensitivity was also seen 
in fluoxetine, which is a known TREK1 inhibitor and has no effect on TRAAK. The 
heterodimer TREK1/TRAAK has a lesser degree of fluoxetine inhibition when compared to 
TREK1 WT. Therefore, for compounds that are less specific, heterodimerisation has a 
moderate effect on their action however more targeted compounds could have an increase 
in their spectrum of effect with heterodimerisation (Levitz et al 2016). 
1.10.2 Regulation of TREK channels 
1.10.2.1 Mechanical stimulation and polyunsaturated fatty acids 
activation 
TREK1 was the first identified K2P channel to be regulated by mechanical stress. It was 
indicated that the shape of the membrane has a direct effect on channel functions. In an 
inside out patch clamp approach, negative pressure shows a significant effect on opening of 
TREK1 and TREK2 channels when compared to positive pressure. Therefore, specific 
changes in cell shape where convex curvature of the membrane allows for the opening of 
the channel (Patel et al 1998; Bang, Kim and Kim 2000). The mechano sensitivity of TREK1 
was found in both cell attached and inside out recordings. TREK1 contains a charged region 
between D294 and E309 that, when truncated, showed a marked resistance to stretch. 
Therefore, the C-terminus in TREK1 is believed to be important in mechanoactivation (Patel 
et al 1998; Maingret et al 1999). The importance of the cytoskeletal network has also been 
investigated as methods which disrupts actin cytoskeleton (cytochalasin D for example) 
activates the channel which suggests the cytoskeleton acts as an inhibitory agent of 
mechanoactivation (Lauritzen et al 2005).  
TREK channels are also reversibly opened by polyunsaturated fatty acids (PUFAs) for 
example arachidonic acid (AA). In fact, TRAAK (another K2P channel) is an acronym for 
TWIK-related arachidonic acid-stimulated K+ channel. PUFAs part in activation is similar to 
that of stretch and mechanoactivation in TREK channels, as the C terminus has been shown 
to play a role (Patel et al 1998). Anionic amphipaths (negatively charged) can insert into the 
membrane leaflet and this creates a convex curved membrane. It is the opposite when 
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discussing cationic amphipaths (positively charged) where is membrane formed in a 
concave shape and caused the channel to close (Martinac, Adler and Kung 1990). 
Stretch activation and mechanosensitivity is also believed to be affected by conformational 
changes of the channel and influence gating of the channel. Force which causes membrane 
tension will change the shape of TM4 and TM2-TM3 which creates a flatter membrane 
surface. An increase in stretch sensitivity can be seen in TREK1 I267T which suggests that 
the selectivity filter is important mechano activation. High tension at the membrane will 
cause the channel to open as the energy caused by the movement of the channel from 
closed to open will deform the lipid bilayer. In addition, PUFAs are believed to promote 
activation of TREK channels in the lipid bilayer even in low tension by lowering the lipid 
deformity barrier as PUFAs decrease the bilayer bending modulus. TREK1 I267T shows a 
significant decrease in AA sensitivity which suggests a link between stretch and lipid- 
activation (Decher et al. 2017). 
1.10.2.2 Evidence of voltage dependency of TREK1 
K2P channels have traditionally been thought of as “leak” channels and therefore voltage 
independent. The channels exhibit an outwardly rectifying current which is was believed to 
be caused by the difference in concentration of K+ ions across the membrane which is 
predicted by the Goldman-Hodgkin-Katz (GHK) equation. This equation predicts that the flow 
of ions will increase across the membrane from the side with a higher concentration of K+ 
ions and that there is no voltage dependent gating (Goldstein et al 2001). This equation also 
assumes that permeating ions do not interact with each other however in the case of K2P 
channels multiple ions are known to enter the pore simultaneously and their movement will 
affect each other. TREK1 displays a strong outward current in response to voltage steps 
instead of a linear current predicted by the GHK equation. This prominent outward rectifying 
current shows that the channel adheres to voltage-dependent activation gating (Schewe et al 
2016). To discover where the voltage gating occurs on the channel, deletional and chimeric 
analysis on TREK1 where carried out and the C terminal domain thought to regulate the 
voltage- dependent gating. Phosphorylation by protein kinase A of S333 in the C terminal 
was proposed as the voltage regulation site. However, dephosphorylation mutation on this 
site (S333A) did not show any difference from TREK1 WT and is not thought to be involved 
in voltage gating (Maingret et al 2002). 
A more recent study has shown that voltage-dependent gating site is located within the 
selectivity filter, similar to Kv channels. It found that the threonine within the K+ signature 
motif (TIGFG) is responsible to voltage-dependent gating. These threonine sites are highly 
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conserved in all K2P channels and therefore is important in the voltage-dependent gating 
mechanism within the K2P family. Mutations on TREK1 (T142C and T251C) exhibited a linear 
current-voltage relationship caused by a loss of K+ binding on the S1 and S4 in the channel 
pore. Therefore, ion binding is central to voltage gating. When the pore is ion-depleted 
(containing one and zero ions) the channel enters a conformation similar the C-type 
inactivation observed in Kcsa channels. Upon depolarization, three-four ions enter the filter 
via the electrochemical K+ gradient and enters an active, conductive state. TRAAK channels 
however still show limited voltage-independent activation as stimulation by AA converts the 
channel to the classical leak conformation at higher concentrations. Moreover, the voltage-
gating mutated TRAAK (T212C) abolishes the activation by AA which shows the importance 
of the primary gate at the selective filter. Subsequently these channels have been proposed 
to be described as “ion-flux-gated” channels instead of “leak” (Schewe et al 2016). 
1.10.2.3 Regulation by pH 
Internal acidification is known to cause a shift in atmospheric pressure which cause positive 
pressure onto the membrane and ultimately sensitives that channel to stretch activation. 
E306 in TREK1 and E333 in TREK2 were identified as a proton sensor using alanine 
scanning mutagenesis. This site also falls into the charged cluster region which is critically 
for mechano-gating. Protonation of this site and removing the negative charge converts the 
channel from a mechano-gated channel to an open, leak channel. E306 in the presence of a 
low pH will reduce binding to the cytoskeleton and allows stretch activation to occur. It is also 
interesting to note that E306A locks the channel into the activated conformation and is a 
gain-of-function mutation (Honoré et al 2002). 
TREK1 WT is strongly inhibited by high extracellular pH. TREK2 is also sensitive to 
extracellular pH however it differs from TREK1 as it is strongly activated by acidification. 
Alanine screening mutagenesis was carried out and resulted in finding that if TREK1 H126 
and its counterpart TREK2 H151 is mutated, it causes to channel to lose its regulation. It 
was therefore concluded that these are proton sensors and that they play a key component 
in extracellular acidification control. These two histidines however act in opposite ways when 
comparing TREK1 and TREK2. TREK1 H126 is flanked by negatively charged residues and 
therefore protonated side chains will be attracted to the region. The bonds formed between 
the side chains and the histidine site will cause the selective filter to collapse. On the other 
hand, TREK2 H151 is partnered next to basic residues and therefore no attraction takes 
place when the protonation occurs. It is most likely to repulse side chains and therefore open 
the channel (Sandoz et al 2009). 
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The heterodimerisation of TREK1/TREK2 showed a unique change in pH sensitivity as 
extracellular acidification and alkalization resulted in activation of the channel. The pH 
sensors of the individual channels are still functional in the heterodimer however as mutation 
of one channel’s pH sensors will lead to the other channel in the dimer to operate as if it was 
in a homodimer. Unlike TREK1 and TREK2, TRAAK is activated by internal alkalinisation. 
However, TREK1/TRAAK show a weak increase in activity when in the presence of an 
increased or decreased intracellular pH. This shows that separate pH regulators found in 
TREK1, TREK2 and TRAAK individually sense the intracellular pH and are active in 
heterodimers. These changes in pH from physiological values will increase hyperpolarising 
outward potassium current which could help prevent damaging hyperexcitation and lead to 
neuroprotection of neurons (Levitz et al. 2016).   
1.10.2.4 Phospholipid regulation of TREK channels 
The neurotransmitter glutamate activates group 1 metabotropic glutamate receptors (1 
mGluRs). This activation will lead to depolarisation of the cell membrane and an increase in 
cell firing and neuronal excitability. Group 1 mGluRs are primarily coupled to G糎q protein 
(Czirjak and Enyedi 2002).  Activation of G糎q stimulates the enzyme phospholipase C (PLC) 
which then leads to the hydrolysis of PIP2 into the secondary messenger DAG and inositol 
trisphosphate (IP3). IP3 will activate the release of calcium from intracellular stores and DAG 
stimulates the activation of protein kinase C. Neither IP3 nor intracellular calcium has any 
effect on the conductance of the TREK channel. However, a depletion of PIP2 will cause 
inhibition of TREK, as PIP2 is thought to be used to maintain normal activity. PIP2 regulates 
this pathway as it can lead to an increase in activity after cationic molecule inhibition 
(Chemin et al. 2003; Kang et al 2006). It has also been hypothesised that following PLC 
activation, direct inhibition of TREK occurs via diacylglycerol (DAG) independently of protein 
kinase C (PKC). However experimental studies showed that DAG produces minimal 
inhibition of current when directly applied (Lopes et al 2005).  
 
Figure 1.10: TREK inhibition activated by G閤q and mediated by PKC or a depletion of PIP2 
(adapted from Chemin et al 2003; Kang et al 2006; Mathie 2007). 
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Along with inhibition via G糎q activation, there is a second hypothesis that inhibition of TREK 
can be activated by G糎s protein. Activation of G糎s leads to an elevation of the concentration 
of cyclic adenosine monophosphate (cAMP). TREK channels are phosphorylated by cAMP 
which converts the channels behaviour from a leak conductance channel to a channel with a 
much lower open probability. This also lead to the hypothesis that if an increase in cAMP 
causes a decrease in TREK current, a decrease in cAMP caused by G糎i will lead to an 
increase TREK current (Patel et al 1998; Lesage et al 2000).  
 
Figure 1.11: Regulation of TREK via the fluctuation of cAMP concentration (adapted from 
Mathie 2007; Murbartián et al 2005: Patel et al 1998). 
There are two phosphorylation sites which have been identified for PKA- and PKC- mediated 
inhibition on TREK1 channel, S333 and S300. It was found that with alanine mutations, the 
channels inhibition would be abolished. Through these mutation studies it was also 
determined that phosphorylation of TREK1 at site S333 by PKA predisposes the channel for 
consequent phosphorylation by PKC at S300. Thus, there is a link between these serine 
sites on the C terminus for both the G糎q and G糎s inhibition cascade (Murbartián et al 2005). 
1.10.2.5 Lysophospholipids 
In contrast to phospholipids, extracellular lysophospholipids activate TREK. This stimulatory 
effect is dependent on the length of the carbonyl chain and the presence of a large polar 
head group. The conical shape of lysophospholipids is believed to cause the activity of the 
channel. Intracellular lysophospholipids on the other hand, are seen to inhibit TREK because 
of its concave shape (Patel, Lazdunski and Honoré 2001). 
TREK1 is also strongly activated by lysophosphatidic acid (LPA). This activation is seen 
when applied to the intracellular side of the channel. LPA is thought to convert the voltage, 





1.10.2.6 General anaesthesia 
Both TREK1 and TREK2 are opened by xenon, nitrous, chloroform, diethyl ether, halothane 
and isoflurane (Patel et al 1999; Gruss et al 2004). It is also seen that in TREK1 knockout 
mice, there is a decreased sensitivity in these types of anaesthesia. Anaesthesia, 
interestingly, has no effect on TRAAK. Deletion of the carboxyl terminus eliminates the 
activation of TREK current via anaesthesia’s and therefore is a critical region of the channel 
(Patel et al 1999). Therefore, when extensive mutagenesis was studied this region was of 
particular interest. Mutations of TASK3 L241A and L242A saw a reduction in activation and 
was predicted to interrupt hydrophobic side chain interactions. However, it could not be ruled 
out that the mutation interfere with channel gating (Bertaccini et al 2014). Furthermore, an 
alanine mutation on the C terminus site E306A showed to almost abolish the effect of 
anaesthetics (xenon, nitrous oxide and cyclopropane) on TREK1 current again showing the 
importance of the C- terminus in anaesthetic sensitivity (Gruss et al 2004).  
1.10.2.7 Thermosensitivity 
Thermal nociceptors are localised in the dorsal root ganglion which also expresses TREK 
channels. When these thermal nociceptors detect noxious heat, the neurons will begin to 
fire. TREK channels are activated gradually over a broad temperature spectrum. The rate of 
increase in activation is at its highest between 22 and 42°C (Maingret et al 2000). It w as 
believed that the C-type gate was important in temperature sensing as mutation of G137I 
near the selectivity filter abolishes any response to heat. This function however is dependent 
on a C-terminal as mutations added between M4 and Ct will cause the channel to become 
insensitive to heat. The absence of this communication had a profound effect on heat 
sensitivity with no effect on the functional C-type gate. Indeed, the Ct domain is the structural 
element needed for heat sensing which then leads to the opening of the heat-insensitive C-
type gate via an allosteric mechanism (Bagriantsev, Clark and Minor 2012). 
1.10.3 TREK as potential target for treatments 
1.10.3.1 TREK links to pain 
Chronic pain is associated with the activity of nociceptive neurons that will transmit stimuli 
from the periphery to the central nervous system (CNS). This works as the signal, which is 
causing the pain, is sensed by ion channel and receptors found on nociceptor peripheral 
terminal. The signal is then transmitted to the CNS through dorsal root ganglion (DRG) 
neurons. The opening of K+ channels will cause current hyperpolarization across the plasma 
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membrane as the efflux of potassium ions will limit neuronal excitability. Therefore, it is 
thought that TREK channels could be novel targets for treatment in pain (Tsantoulas and 
McMahon 2014).   
TREK1 is highly expressed in small and medium DRG sensory neurons and are also co-
localised with the transient receptor potential cation channel subfamily V member 1 (TRPV1) 
channels. These channels are capsaicin-activated nonselective ion channel which are 
known to recognise the sensation of pain (nociception) and noxious heat (>42 °C). The 
sensitivity of TRPV1 in response to these noxious stimuli is thus important for the latency 
and intensity of pain (Caterina et al 2000). When tissue damage occurs, inflammatory 
mediators for example prostaglandins and bradykinin are released. The inflammatory agents 
will activate the phospholipase C pathway leading to phosphorylation of TRPV1. Overall, the 
inflammatory mediators release will increase the sensitivity to hyperalgesia with non-painful 
stimuli (Katanosaka et al 2008). Mice lacking TRPV1 does not abolish pain sensitivity in 
general but lacks sensitivity to noxious temperatures (Caterina et al 2000). It is therefore 
proposed that TRPV1 antagonist is an analgesic agent. However, it is also known that the 
TRPV1 agonist capsaicin can also be used in pain relief. It was seen that application of a 
low-dose or single application at a high dose, shows relief from painful neuropathic 
conditions. The TRPV1 agonist is thought to desensitise the receptor and the neurons. 
Indeed, it is still argued that TRPV1 receptor agonist and antagonist may provide 
complementary treatments for analgesia (Derry et al 2009; Knotkova, Pappagallo and 
Szallasi 2008) TREK1 is known to be modulated by heat. TREK1 increase in activity 
contributes to the peripheral C-fibre heat nociception at the range of between noxious 
warmth and painful heat. TREK1 knockout results in hypersensitivity to heat at this range. 
The change in sensitivity to pain occurs in the noxious heat region between non-painful and 
painful stimulation. These results show that TREK1 channels are associated with the lower 
threshold of thermal pain and results in allodynia. Further mice experiments showed that 
TREK1 -/- are more sensitive to mechanical stimuli and showed when in inflammation 
conditions (injection of intraplantar with carrageenan to produce inflammation) there was an 
increase in thermal and mechanical hyperalgesia (Alloui et al 2006). TREK2 channels are 
important to determine between moderate heat perceptions as TREK2-/- observe non-
harmful heat, near 40°C, as aversive. This observation is seen in cold perception also 
between non-painful low temperatures and aversive cold (Pereira et al 2014). It was 
therefore suggested that TREK activators could have analgesic effect.  
It is also believed that morphine has direct action on TREK1 channels. Morphine, acting on 
mu opioid receptors, enhances TREK1 current and has significantly less effect of an 
analgesic effect when depleted. The deletion of TREK1 channel however has no effect on 
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the three main side effects; constipation, respiratory depression and dependence. It is 
therefore concluded that the side effects and the analgesic effect do not involve the same 
mechanism and that activation of TREK1, downstream from mu opioid receptors, could be a 
possible target for pain relief (Devilliers et al 2013). However, activation of TREK1 channels 
for analgesia can also have adverse effects including depression (Heurteaux et al 2006). 
1.10.3.2 TREK links to depression 
Depression is a mental disorder with symptoms that include depressed mood, 
worthlessness, and suicidal ideation. Serotonin (5-HT) is a neurotransmitter involved in the 
transmission of nerve impulses and has been linked to depression. The neurons of the 
dorsal raphe nuclei (DRN) are the principal source of 5-HT release in the brain (Ressler and 
Nemeroff 2000). 5-HT is transported into vesicles in the serotonergic neuron towards the 
presynaptic membrane into the synaptic cleft. Once here, 5-HT will diffuse across the 
synapse and bind to postsynaptic serotonin receptors transmitting the signal which will 
change the electrical state of the cell. However, the serotonin transporter (SERT) on the 
presynaptic neuron will recycle 5-HT at the synaptic cleft, thereby regulating the signal. 
Furthermore, presynaptic serotonin 1A (5-HT1A) is an autoreceptor and upon stimulation, the 
autoreceptor will inhibit the firing of 5-HT neuron. This will ultimately result in less serotonin 
levels (Newman-Tancredi 2011; Ressler and Nemeroff 2000) TREK channels have long 
been known to be a homolog of the Aplysia S-type channel. The Aplysia S-type channel is 
highly controlled by serotonin and this is the same as TREK1, therefore it is important to 
note its relationship to TREK1 and depression (Siegelbaum 1982). TREK1 is also highly 
expressed in regions of the brain that are important in cognitive attributes of depression 
(prefrontal cortex and the hippocampus) (Tally et al 2001). In TREK1 -/- mice there is an 
increase in the activity of 5-HT transmission which is realized as increased firing of 5-HT 
neuron from DRN. In fact, the firing rate of 5-HT in TREK1 -/- mice is two-fold larger than 
TREK1 +/+. It could therefore be said that TREK-/- leads to a longer depolarisation rate and 
overall an increased firing rate in neurons. However, this antidepressant like property is not 
established in all K2P channels. TRAAK-/- showed no depression resistant phenotype. Thus, it 
is not as simple as a change in the efflux of potassium, but it is a specific characteristic to 
the TREK1 channel. This specific factor could be linked to TREK1 inhibition through G 
protein-coupled receptors which does not affect TRAAK. A G protein-coupled receptor that is 
important in depression is 5-HT1A. This receptor mediates inhibitory neurotransmission and 
are also a part of a serotonin negative feedback loop. The presynaptic 5-HT1A receptors are 
used as autoreceptors which triggers the serotonin feedback loop. This will lead to a 
reduction in neuronal activation and serotonin release leaving fewer serotonin molecules in 
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the synapse (Heurteaux et al 2006). 5-HT1A receptors are known to inhibit cAMP which is 
known to enhance TREK1 current causing hyperpolarisation of the neuron. This will cause 
an overall decrease in neuron firing rate and serotonin excretion. This shows that this 
abolishing TREK1 activity could be an important factor in disrupting the negative feedback 
loop which can alleviate depression (Gordon and Hen 2006). 
It has been shown that TREK-/- mice show resistance to “depression-like” symptoms. In fact, 
the TREK-/- mice showed behaviour which was similar to that seen in TREK1+/+ mice treated 
with the anti-depressant fluoxetine with no further effect on their behaviour. The resistance to 
‘depression-like’ symptoms was tested using four distant models of antidepressant activity. 
The first was the Porsolt forced swim test (FST) which is based on the rodents’ immobility 
time when placed in an inescapable tank of water. The immobility time in the wildtype mice 
were found to be twice as long compared to the TREK1-/- mice (178 ± 2 s and 87 ± 8 s). The 
second test was the tail suspension test (TST) which again showed a shorter immobility time 
compared to the wildtype. In the conditioned suppression of motility test (CSMT) measures 
the conditioned suppression of motility when placed in an area which had previously set an 
electric shock through the foot. This showed a 44% reduction in conditioned suppression in 
TREK1-/- compared with the TREK1+/+ mice. The fourth and final test is linked to chronic 
antidepressant use leading to stopping learned helplessness. It was found that the wild-type 
mice became helpless, as these mice showed increased escape latencies after exposure to 
shock compared to non-shocked control mice. TREK1-/- however showed significantly short 
escape latencies after training in the inescapable shock environment compared to the 
TREK1+/+ mice. There was also no significant difference between shocked TREK1-/- and 
untrained control TREK1-/-. These results were interpreted as the TREK1-/- mice being less 
susceptible to induced ‘depression-like’ phenotype states (Heurteaux et al 2006).  
1.10.3.3 TREK links to neuroprotection 
Astrocytes are specialized glial cells which are known to play a functional role in ischemic 
neuronal death. It has been demonstrated that also maintain ionic homeostasis involving 
glutamate uptake. It is also thought that K2P channels including TREK1 is involved in 
astrocytic passive conductance and contribute to the negative membrane potential (Chu et al 
2010). The lipid and mechano-gated TREK1 channel is connected to conditions such as 
ischemia and epilepsy. TREK channels are known to be activated by PUFAs (poly 
unsaturated fatty acids) for example arachidonic acid and lysophospholipids (LPLs). These 
are both potent neuroprotective agents which protects against ischemia and seizures (Wu et 
al 2013). It has been seen in mice models that TREK1 -/- display an increased sensitivity to 
both ischaemia and epilepsy when compared the WT mice. In TREK1 KO mice, there was a 
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lack of neuroprotection when PUFA was applied when compared to WT mice via seizure 
scores and mortality rate. TREK1 channels are therefore believed to protect neurons from 
ischemia induced excitotoxicity. However, it must be noted that TRAAK-/- mice showed no 
change in ischemia sensitivity showing that neuroprotection linked to TREK1 activity is a 
specific effect and is not due to any K+ channel action (Heurteaux et al 2004). When 
ischemia occurs in the brain, arachidonic acid (AA) is released and the intracellular pH will 
become more acidic leading to neuronal swelling. The acidic intracellular pH will increase 
TREK current and lead to hyperpolarisation. This will subsequently reduce activation of 
presynaptic Ca2+ channels and inhibit glutamate release at a presynaptic level and lower 
excitability of the neurons. At the postsynaptic level, hyperpolarisation will assist in Mg2+ 
blocking NMDA (N-methyl-D-aspartate) glutamate receptors causing a shift towards more 
negative potentials. This will limit Ca2+ release and therefore lower glutamate release and 
excitability of neurons (Franks and Honoré 2004). Therefore, a potential mechanism of 
neuroprotection is TREK1 activation. TREK1 is also found to be activated by volatile 
anaesthetics such as sevoflurane and that preconditioning cells with sevoflurane causes 
neuroprotection by increasing the expression of TREK1 channels. This preconditioning is 
believed to protect neurons from ischaemic injury. This may be caused by reduction in the 
inhibitory effect on the glutamate release which leads to a reduction in the excitatory neuron 
transmission leading to a possible mechanism of neuroprotection (Tong et al 2014). TREK2 
channels have also been found to be up-regulated and that this activity will help maintain the 
membrane potential of astrocytes and will lower extracellular glutamate release during 
ischemia (Kucheryavykh et al 2009).  
1.11 TRESK channel 
1.11.1 TRESK tissue distribution 
Human TRESK channel was identified in the human genome database and was originality 
only thought to be found in the spinal cord, hence the acronym TWIK-related spinal cord K+ 
channel (TRESK) (Sano et al 2003). However further expression was detected primarily in 
the nervous system. Localisation of TRESK has been found using RT-PCR to determine the 
distribution of TRESK in mouse tissue where results showed expression in dorsal root 
ganglion (DRG) neurons (Kang and Kim 2006) the cerebrum, cerebellum, brainstem 
(Czirják, Tóth and Enyedi 2004) and in the sympathetic and parasympathetic ganglia 
(Cadaveira-Mosquera et al 2012). The channel was then subsequently found in human brain 
with a particularly high expression rate in the DRG and the trigeminal ganglion (Liu, C., et al. 
2004). Through these experiments, they have also found expression of mouse TRESK in 
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non-nervous tissues such as testis (Czirják, Tóth and Enyedi 2004), spleen, thymus and 
heart (Kang and Kim 2006). The presence of TRESK was also identified using 
immunostaining which also identified a high expression rate in the dorsal root ganglion which 
is important to note as this region is thought to be involved in nociceptive trafficking and pain 
perception (Yoo et al 2009). It was thought by Kang, Mariash and Kim (2004) that a 
previously uncharacterised mouse ortholog of TRESK was discovered, an isoform called 
mTRESK-2. mTRESK-2 showed a 65% similarity with hTRESK. However further 
investigation identified the mouse genome and human database each only contains a single 
TRESK gene, which share a 92% similarity sequence identity. This indicates variable 
TRESK subunits between the two species (Keshavaprasad et al 2005). 
1.11.2 Regulation of TRESK 
1.11.2.1 Calcium signalling regulation 
Gq-coupled receptor stimulation leads to an increase in TRESK activation. This increase is 
not a direct effect from the Gq-coupled receptor but is thought to be from an elevation of 
cytoplasmic calcium. It can be seen in experiments that after activation from calcium the 
TRESK channel remained in an activate state long after the calcium concentration had 
normalised. This would suggest that the calcium activation is in fact an indirect effect. This is 
confirmed in single-channel currents experiments, when calcium is applied to intracellular 
side and fails to effect TRESK current (Enyedi and Czirják 2014). The calcium ion does not 
bind to the channel protein, which can be seen in the classical Ca2+ -activated K+ channels.  
To look further into what is causing the activation, a specific inhibitor of the protein 
phosphatase calcineurin called cyclosporine A (CsA) was studied with an ionomycin induced 
enhancement of TRESK. It was seen that even in low concentrations of the compound, the 
enhancement was completely eliminated. This lead to the strong suggestion that calcineurin 
is involved in activation of TRESK channel. TRESK channel is the only K2P channel that is 
regulated by calcineurin. The study went even further and applied another calcineurin 
inhibitor FK506. This again showed an abolished enhancement of current. A rigid active 
calcineurin (CnA 1-441) was developed and coexpressed with TRESK along with the 
regulatory B subunit of calcineurin. CnA 1-441 lacks any C-terminal and therefore lacks any 
inhibitory properties. It resulted in the triple expression causing higher basal currents than 
TRESK alone and calcium signal by ionomycin. This indicates that active calcineurin allows 
TRESK to enter its activated state, and cannot be further stimulated by calcium (Czirják, 
Tóth and Enyedi 2004).  
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1.11.2.2 Calcineurin binding partner 
The enzyme/substrate relationship between TRESK and calcineurin has been identified; 
however there have been further binding partners and interactions which take place that are 
important in the activation of TRESK via calcineurin. Calcineurin has been seen to interact 
with TRESK via NFAT-like docking site (Czirják and Enyedi 2006). The non-catalytic surface 
of calcineurin is necessary for the binding of this enzyme to the Nuclear Factor of Activated 
T cells (NFAT) (Li et al 2007). The interaction was first identified in mouse TRESK with the 
amino acid sequence PQIVID, found in the N-terminal side of the intracellular loop. 
Mutations of the PQIVID motif (PQIVIA, PQIVAD and PQAVAD) were shown to decrease 
any calcium-dependent activation using a microinjection of the VIVIT peptide. This peptide is 
designed to eliminate the calcineurin-PQIVID site interaction which prevents any TRESK 
activation in the mouse model. The human ortholog sequence was identified as PQIIIS and 
acts identically to mouse TRESK in regard to calcium signalling (Czirják and Enyedi 2006). 
A further interacting site for calcineurin-TRESK activation has been identified in the human 
TRESK loop close to the serine cluster called LQLP. It was revealed that combined 
inactivating mutation of PQIIIS and LQLP (PQAAAS and AQAP) abolished the calcium-
dependent regulation of TRESK channel. The AQAP mutation on its own was also shown to 
slow down its sensitivity to high calcium, reducing the rate of activation. Binding experiments 
that replaced PQIIIS amino acid sequence with a high calcineurin binding affinity sequence 
PVIVIT, determined whether LQLP was an auxiliary binding site or a major determinant of 
the calcium sensitivity of TRESK regulation. The loss of function mutation (AQAP) was co-
expressed with the gain of function motif PVIVIT. This resulted in the conclusion that the two 
sites are not functionally equal and that the gain-of-function action could not compensate for 
the loss of function brought about by the AQAP mutation. There is also suggestion that the 
binding of calcineurin to TRESK is observed in two consecutive steps as the binding of 
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Figure 1.12: Representation of human TRESK activation. A) Calcineurin binds the PQIIIS 
motif independently from cytoplasmic calcium. B) LQLP binds to calcineurin under calcium 
signalling and causes the serine residues to reside closer to calcineurin (adapted from 
Czirják and Enyedi 2014). 
As seen in the diagram above calcineurin is attached to PQIIIS at rest. As the cytoplasmic 
calcium level increase, calcineurin anchors to the LQLP motif and subsequently it is 
positioned near the regulatory serine cluster. It could be said that PQIIIS is used for 
calcineurin availability and LQLP brings the adjacent serine residue into the proximity of the 
activated phosphatase calcineurin (Czirják and Enyedi 2014). 
1.11.2.3 Regulation through 14-3-3 proteins  
14-3-3 proteins are highly conserved regulatory proteins and has been implicated in a 
number of cellular processes. It has also been show to associate with many ion channels. In 
the K2P family, it has been recognised that all isoforms of 14-3-3 protein interacts with the C-
terminus of the TASK subfamily. This binding is central for membrane targeting of the 
channel (Rajan et al 2002). 
The 14-3-3 protein binds to the RSNSCPE motif and was firstly identified in mouse TRESK 
and subsequently in the human TRESK in the intracellular loop region (Czirják, Vuity and 
Enyedi 2008). Protein kinase A enzyme is thought to be the auxiliary channel inhibitor as it 
phosphorylates the S252 which will lead to the recruitment of 14-3-3 protein (Czirják and 
Enyedi 2010). The phosphorylation of the S252 in this sequence is required for the 
interaction to occur (Enyedi, Braun, and Czirják 2012). Indeed, it has also been shown that 
14-3-3 protein was responsible for halting the return to the currents previous resting state 
after calcineurin-medicated activation. It was originally believed that association of 14-3-3 
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protein to the newly phosphorylated S252 residue in TRESK would interfere with re-
phosphorylation of the regulatory S264 residue and would hinder current recovery (Czirják, 
Vuity and Enyedi 2008). However new evidence shows a more complex mechanism, which 
involves different forms of inhibitory phosphorylation, connected to 14-3-3 protein. 
1.11.2.4 Inhibition pathway of TRESK  
There are two pathways that inhibit TRESK activation. The first involves phosphorylation of 
S252 by protein kinase A which then leads to the consequent union of the 14-3-3 protein to 
the serine residue. When the single site S252 was in a functional state (TRESK-S264E) it 
was observed that the basal activity was heightened in the absence of 14-3-3 protein. 
Therefore, it was concluded that the binding of 14-3-3 to S252 would enhance the inhibitory 
effect.  The second pathway implicates the inhibition of TRESK by phosphorylation of the 
serine cluster. However surprisingly, this action is obstructed by 14-3-3 protein (Czirják and 
Enyedi 2010).  
MARK, microtubule affinity-regulating kinase, is believed to have a regulatory effect on 
TRESK as it has been identified as a binding partner of the intracellular loop of TRESK. 
MARK1, MARK2 and MARK3 accelerate the return of the TRESK resting state following 
calcium-dependent activation. However, 14-3-3 protein inhibits the kinases phosphorylation 
of the serine cluster. MARK2 has previously demonstrated a negative response to 14-3-3 
protein and was therefore identified as a potential new TRESK-inhibitory kinase. 14-3-3 
protein plays a role in the involvement of MARK2 and the recovery of basal kinetics in 
TRESK. The quantity of 14-3-3 in the cytoplasm has been reported to affect the recovery of 
basal recovery. However, MARK kinases did increase activity in a reduced amount of 14-3-3 
protein and overexpression of 14-3-3, but does not abolish the result of MARK on TRESK. It 
was also shown that even in the removal of 14-3-3 binding to MARK using a double mutation 
(S400A/T539A); it did not deter the action of MARK on TRESK. Therefore, it can be 
concluded that MARK is not completely influenced by 14-3-3 protein and is vital in TRESK 
regulation. The target for MARK2 was investigated and showed that even if S252 TRESK 
was mutated, the current would return to its resting state. This would indicate that the S252 




Figure 1.13: Representation of human TRESK regulation A) TRESK channel is constitutively 
phosphorylated under resting conditions. Phosphorylation occurs at S252 and leads to 14-3-
3 protein binding to this serine site. This phosphorylation and protein binding leads to an 
inhibitory effect. B) Through calcium signalling, LQLP will bind to calcineurin and the 
calcineurin phosphatase will become activated and will lead to dephosphorylation. This also 
causes a detachment of 14-3-3 protein from the channel. C) The channel will then slowly 
phosphorylate and will return to its basal state. PKA and MARK kinases are involved in this 
process. The pathway is extended in the presence of 14-3-3 (adapted from Enyedi and 
Czirják 2014). 
 
1.11.2.5 Activation by protein kinase C 
Further activation pathways were investigated using mouse TRESK channel. It was found 
that the PKC activator phorbol 12-myristate-13-acetate (PMA) did not affect mouse TRESK 
and PKC did not influence the return to this original resting state after activation. However 
consequent human TRESK studies showed PMA contributed to activation of the channel. 
Mutations of potential PKC phosphorylation sites were identified (none of which are found in 
mouse sequence) but it did not affect the PMA-induced increase of current. This would 
suggest that the PKC activation is an indirect effect and is not mediated through direct 
binding to the human TRESK channel. However, the possibility of other PKC-




1.11.2.6 TRESK pharmacological characteristics 
Like other K2P channels, TRESK is inhibited by high concentration of extracellular Ba2+, 
quinine and quinidine. Ba2+ is thought to bind to the channel at the plasma membrane as 
inhibition is seen at negative membrane potential. Quinine and quinidine accomplishes 
inhibition by blocking the channel. However, the channel also shows differential properties 
from that for the other K2P channel as it is unaffected by classic K2P blockers for example 4-
aminopyridine, apamin, CsCl and ATP-sensitive K+ clockers tolazamide and glipizide 
(Enyedi and Czirják 2014).  
Both mouse and human TRESK channels are also sensitive to several different 
anaesthetics. Isoflurane, halothane, sevoflurane and desflurane are all volatile anaesthetics 
that increase the TRESK current three-fold (Liu et al 2004). In vivo experiments show that 
TRESK knockout mice were less sensitive to isoflurane but show the sensitivity to 
desflurane, halothane and sevoflurane was unchanged (Chae et al 2010). This difference in 
sensitivity would suggest that TRESK is substituted by other anaesthetic-sensitive channels 
or TRESK is not the major target of the anaesthetic effect (Enyedi, Braun and Czirják. 2012). 
It was also found that the mortality rate increased in the KO mice compared to the WT (Chae 
et al 2010). This could suggest that TRESK is required for survival under these conditions; 
however, this process is not fully understood (Enyedi, Braun and Czirják 2012). There is a 
uniquely longer loop segment found in TRESK which differs from other members of the K2P 
family. This loop connects the second and third transmembrane together. It is thought that it 
is this region that makes TRESK more sensitive to volatile anaesthetics than other K2P 
channels, however more studies are needed in this region. Local anaesthetics are found to 
inhibit TRESK but at concentrations larger than those compared to the other K2P channels. 
The target site for local anaesthetics is believed to be intracellularly or on the membrane. IV 
anaesthetics did not enhance TRESK channels at any significant level. Furthermore, the 
nonimmobilizer compound 1,2-dichlorohexafluorocyclobutane had no effect on TRESK (Liu 
et al 2004).   
1.11.2.7 Difference between TRESK species 
There are certain characteristics of TRESK channels that exhibited species-specific 
variations. Human TRESK channels are found to be weakly sensitive or insensitive to 
extracellular pH whereas mouse TRESK is strongly regulated by extracellular pH. As the pH 
reaches pH 6, there is a drop in current. While an alkalinisation of pH increases the current 
in mouse TRESK. The homologous histidine in mouse TRESK (His-132) is responsible for 
the proton sensor activity and is only conserved in mouse TRESK. This residue is found 
45 
 
directly downstream from the selectivity filter sequence (GYG). This site has also been seen 
to be significant for pH sensitivity in TASK-1 and TASK-3. It can be seen however that a 
mutation of the human TRESK analogue from a tyrosine to a histidine (Y121H) is sufficient 
for the channel to become pH dependent. A replacement of the mouse TRESK histidine to 
an asparagine will eliminate any pH sensitivity (H132N) (Dobler et al 2007).  
Another species-specific variation for TRESK is zinc inhibition. Mouse TRESK is inhibited by 
zinc whereas human TRESK is resistant. The histidine residue mentioned for pH sensitivity 
has proved to be responsible for zinc binding (Czirják and Enyedi 2006). 
1.11.3 TRESK involvement in pathological processes 
1.11.3.1 Pain pathway  
As previously discussed, TRESK is highly expressed in DRG neurons. Following nerve 
injury, DRG is the source of increased nociceptive signals and because of the increase in 
neuronal excitability. It is also an important messenger to transport this pain signal from the 
periphery system to the central nervous system. Sensory neurons during hyperexcitability 
will prompt the enhancement of depolarisation and assists in reaching the action potential 
threshold. Hyperexcitability is also characterised by its decrease in nerve impulses and 
repetitive firing during extended depolarising stimuli.  
Changes in the expression of ion channels have been seen to influence the action potential 
by increasing the amount of open TRESK channels and decreasing the action potential 
threshold. Chronic nerve damage and inflammation will down regulate the expression of 
TRESK and it is therefore believed to be linked with pain (Tulleuda et al 2011). 
An important insight into the regulation and function of TRESK was discovered through the 
ENU-derived mouse knockout. It was seen that if a missense mutation was used, the 
channel will completely lose function. TRESK is believed to decrease membrane excitability, 
seeing as the loss-of-function TRESK mutation (G339R) increases DRG excitability (Dobler 
et al 2007). Down regulation of TRESK in neuropathic pain models also induces 
hyperexcitability and blocking or silencing the channel via pharmacological means results in 
the activation of sensory neurons and nociceptive fibres that begins the algesic effect 
(Tulleuda et al 2011). This affect can be seen in through calcineurin-inhibitor induced pain 
syndrome (CIPS). CIPS is described by severe pain after calcineurin inhibitor, has been 




In rats, it has been found that chronic nerve damage and inflammation will alter the 
expression level of TRESK mRNA. Over-expression of TRESK has been seen to inhibit the 
DRG-released capsaicin mediated substance P, which is used in the transmission of 
nociceptive impulses at the spinal cord level. TRESK over – expression also alleviates 
mechanical allodynia caused by nerve injury. The results therefore indicate that over-
expression of TRESK and therefore an increase in channel activity diminishes the sensitivity 
of neurons to harmful stimuli (Guo and Cao 2014). Taking all these results together suggests 
that a TRESK-specific activator may display analgesic effects as ultimately this will lead to a 
significant decrease in the excitability of DRG neurons. 
1.11.3.2 Migraine with aura 
Migraine is a highly prevalent condition and has been described as one of the top 20 causes 
of disabling chronic disorders among adults of all ages. The aura is associated with cortical 
spreading depression (CSD), which causes neuronal depolarisation that spreads to the 
cortical regions of the brain. Migraine is caused by hyperexcitation of neurons (Enyedi and 
Czirják 2014). This hyperexcitation activates CSD signals over the brain, which acts directly 
onto nerves in the trigeminal ganglion to release pro-inflammatory peptides (capsaicin 
mediated substance P for example) in the meninges. The meninges will start to inflame and 
promote the activation of trigeminal nerves and will lead to a painful throbbing headache 
(Lafrenière et al 2010). Under calcineurin inhibitor immunosuppressant treatment, patients 
began to develop headache symptoms. It was stated that 74 organ transplant patients 
received calcineurin inhibitors and that 38% of the patients developed migraines within three 
years of the organ transplantation. This showed indirect evidence that through the 
inactivation of calcineurin and therefore the inhibition of TRESK, lead to an increase in the 
frequency of migraine headaches (Ferrari et al 2005). 
To delve deeper into the relationship between migraine and pain linked to TRESK, the 
KCNK18 gene was sequenced in a multigenerational family who suffered with migraines. It 
was discovered that a mutant KCNK18 gene was found in members of the family that were 
affected with typical migraine headaches. The mutant gene contains an F139WfaX24 
frameshift mutation which causes a 2-bp deletion at position 414-415 at the C-terminal and 
truncation of the protein at position 162 in the second transmembrane segment. This 
mutation caused the channel to be non-functional and that the gene was inherited in a 
dominant fashion and causes a dominant-negative suppression of WT channel function 
(Lafrenière et al 2010). This F139WfaX24 mutation has also been found in a different, 
unrelated migraine sufferer which reinforces the conclusion that the dominant-negative 
mutation is directly linked with this type of rare migraine (Enyedi, Braun and Czirják 2012). In 
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additional screening for KCNK18 mutation discovered another missense variant C110R. 
C110R showed a loss-of-function similar to that of the TRESK framework mutation as it was 
able to reduce activity from co-expressed TRESK WT channels. However, the mutation was 
found to have no correlation with migraine suffers and showed that a single non-functional 
mutation is not enough to develop migraine (Andres-Enguix et al 2012). This screening also 
showed an interesting site S231 in relation to migraine. The original study showed that 
TRESK S231P had no effect on TRESK activity. However, this site was identified in a female 
patient in Poland suffering with migraine with aura. Therefore, this site may contribute to 
migraine with typical aura (Domitrz et al 2015). 
Millan-Guerrero et al (2008) discussed the role of TRESK coupling with the histamine H1 
receptor as histamine activates TRESK channels. It has been suggested that TRESK is 
involved in “dampening” the activation of a cellular action involved in inflammation as 
histamine is known to be released in response to inflammation. The findings of this paper 
say that migraine symptoms decreased by ~50% when patients used subcutaneous 
histamine as a treatment for migraine.  
Migraines are known to be linked to inflammation of the meninges and therefore the role of 
TRESK is deemed to be regulating the excitability of neurons during inflammation. It is 
therefore thought that the TRESK framework mutation causes an increase in excitability of 
trigeminal nociceptive pathway which ultimately allows for a higher predisposition to migraine 
headaches (Lafrenière and Rouleau 2011). It is not however believed that the dominant-
negative mutation is directly responsible for the aura symptoms as the mutation does not 
induce CSD. The WT TRESK channel stabilises the normal neuronal activity by preventing 
the activation of neurons that trigger CSD. The dominant-negative mutation may delete this 
protective mechanism and cause the aura symptoms. These results would indicate that 
upregulating TRESK activity using a channel specific agonist could be a potential treatment 
for migraine suffers (Enyedi, Braun and Czirják 2012). 
1.12 Sipatrigine and its derivative lamotrigine 
Sipatrigine (BW 619C89) is a compound derived from the antiepileptic agent lamotrigine, 
which has a substituted pyrimidine into the structure. The change in chemical structure was 
developed to improve the neuroprotective effect seen with lamotrigine (Leach et al 1993). In 
vivo lamotrigine has been found to be a less potent neuroprotectant compared to sipatrigine, 




Figure 1.14: Structure of sipatrigine and lamotrigine 
Both compounds were originally described as “glutamate release inhibitors”. In vitro 
experiments showed that sipatrigine inhibited glutamate release from brain slices which was 
found to be an animal model for neuroprotection and cerebral ischemia (Leach et al 1993). 
However, sipatrigine is not believed to have a direct effect on glutamate receptors as this 
compound has a weak affinity for excitatory amino acid binding sites. There was also no 
effect on glutamate release when measuring excitatory potentials in the presence of 
sipatrigine (100 µM) in rat hippocampal brain slices. Lamotrigine was also identified to 
protect against ischaemic damage and this is completely independent of direct glutamate 
action (Garthwaite et al 1999).   
1.12.1 Sipatrigine inhibition of ion channels 
Sipatrigine has been shown to act in a reversible manner to inhibit voltage-gated Na+ 
current. The compound was shown to be a dose and voltage-dependent inhibitor of native 
Na+ and type 11A Na+ channels. The inhibitor is believed to work on these channels by 
stabilising the inactivated states of the channels. Therefore, this inhibition is believed to 
prevent membrane depolarization which is an effective strategy against neuroprotection 
(Garthwaite et al 1999). However, sipatrigine is not channel specific as it is equally effective 
as a calcium channel inhibitor. Sipatrigine was seen to inhibit human P and /N-type Ca2+ and 
was likely to provide cerebral protective effect. Ca2+ channels are important for release of 
glutamate from presynaptic terminals and inhibition could therefore decrease excitability of 
neurons (Garthwaite et al 1999; McNaughton et al 1997). Furthermore, low-voltage-activated 
T-type Ca2+ channels mediated by channels with g11 subunits have also been found to be 
inhibited by sipatrigine. In fact, sipatrigine was more effective on T-type Ca2+ than type- 11 
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Na+ channels or N-type Ca2+ channels. Therefore T-type Ca2+ channels are believed to 
contribute to the neuroprotective and anticonvulsant effect (McNaughton et al 2000).  
The action of sipatrigine on Ca2+ and Na+ channels do show several shared features, as 
inhibition of both channels are reversible and enhanced antagonism of the channels is seen 
when the membrane is depolarized. It can therefore be suggested that sipatrigine binds 
more strongly when the channels are in the inactivated state. Furthermore, inhibition of 
voltage-gated K+ by sipatrigine in hippocampal neurons have been observed. The inhibition 
of outward K+ currents in the presence of 10 µM sipatrigine was ~ 30% at a holding potential 
of -90 or -60 mV. Sipatrigine did however show a greater affinity to inactivated Na+ whilst 
inhibition of inactivated K+ current was voltage-independent. This would indicate a selectivity 
to Na+ channels over K+ at less negative potentials (Xie and Garthwaite 1996; (McNaughton 
et al 1997). 
1.12.1.1 Sipatrigine effect of K2P channels 
The action of sipatrigine is believed to have a broader effect on K2P channels compared to 
lamotrigine. TASK1 current showed to be inhibited by sipatrigine (10 µM) by ~ 37%. A 
member of the TREK family, TRAAK, produced sipatrigine inhibition of ~ 45% at a 
concentration of 10 µM. Sipatrigine was characterised as an effective inhibitor of TREK1 
channels with a 75% decrease in current using 10µM of sipatrigine (Meadows et al 2001). 
TREK1 inhibition by sipatrigine has been associated with an antidepressant effect as its 
believed to be disrupting the serotonin feedback (Tsai 2008). Sipatrigine inhibition of K2P 
channels is thought to be involved in neuroprotection as chronic depolarisation block of 
glutamate release. It was also noted that the inhibition of TREK1 by sipatrigine and the 
subsequent wash off saw an over recovery of current not seen in the related TRAAK 
(Meadows et al 2001).  Up until this work, no experiments have been carried out on TRESK.  
Little is known of how the different channels are regulated by sipatrigine and lamotrigine and 
insight into this could lead to new information about the structure and gating of the channels.  
1.12.2 Lamotrigine inhibition of ion channels 
Lamotrigine has similar pharmacology to sipatrigine; however, it is deemed less potent in 
comparison (Hainsworth et al 2000). The ability of lamotrigine to modulate neuronal activity 
has made it useful in treating epilepsy and bipolar disorder. Lamotrigine is known to inhibit 
presynaptic voltage Na+ channels which blocks glutamate release and decrease neuron 
excitation. However, the affinity of sipatrigine to inactivated Na+ is four times higher than 
lamotrigine. This leads to lamotrigine being less effective in neuroprotection compared to 
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sipatrigine (Xie and Garthwaite 1996). Regarding Ca2+ channels, lamotrigine is known to 
inhibit both N- and P-type Ca2+ channels which would play a role in decreasing the Ca2+ 
dependent excitability of neurons. The difference however between lamotrigine and 
sipatrigine is that lamotrigine has no effect on T-type Ca2+ currents (Hainsworth et al 2000). 
1.12.2.1 Effect of lamotrigine on K2P channels 
The actions of lamotrigine have been characterised with TRESK channel and was shown as 
a potent inhibitor. It was found that for mouse TRESK, lamotrigine (30 µM) inhibited the 
current by ~50% followed by recovery of current with wash-out in an inside-out patch 
configuration. Therefore, it is believed that the inhibition is both a direct action on the 
channel and also involves intracellular mechanism (Kang et al 2008). These experiments 
also established that lamotrigine had little to no effect on all members of the TREK family 
(Kang et al 2008; Meadows et al 2001). This believed selectivity of lamotrigine on TRESK 
has been used in studies to show inhibition in cultured TG neurons. It was therefore 
concluded that lamotrigine primarily acts on TRESK channel (Liu et al 2013). 
1.13 Cen-092-C  
Cen-092-C, a newly developed compound, antagonises Na+ channels with an IC50 of       
29.5 µM in rat model (unpublished data, Leach). Cen-092-C is derived from lamotrigine and 
has a similar structure to sipatrigine. The difference between Cen-092-C and lamotrigine is 
the replacement of fluorine to chloride in different position. 
 
Figure 1.15: Chemical structure of sipatrigine, lamotrigine and Cen-092-C 
Cen-092-C was used in a multiple sclerosis study in an EAE (experimental autoimmune 
encephalomyelitis) model and showed to nullify any clinical EAE symptoms when compared 
to untreated models (unpublished data, Leach). As this is a new compound, its testing has 
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been limited and has not been used on K2P channels. Therefore, because of its close relation 
to lamotrigine, it would be interesting to find if the same degree of inhibition occurs on each 
K2P channel. 
1.14 Aims and objectives of thesis 
The aim of this research is to investigate the effect and mechanism of action of sipatrigine 
and lamotrigine on TREK1 (chapter 3), TRESK (chapter 4) and TREK2 (chapter 5). 
Furthermore, the effect of the related compound Cen-092-C was also investigated on 
TREK1 and TRESK (chapter 6). This was all carried out using site directed point mutations 
and whole cell patch clamp electrophysiology. 
Chapter 3 involves clarifying the effect of sipatrigine and lamotrigine on TREK1. A potential 
binding site of the compound at the fenestration site (L286) was examined. Furthermore, 
important binding sites for activators at the central cavity was also investigated. The effect of 
sipatrigine on the gain-of-function mutated TREK1 was also investigated to further examine 
the importance of the fenestration sites in sipatrigine binding.  
In chapter 4, TRESK current inhibition by sipatrigine and lamotrigine were identified and the 
identified potential binding sites in the central cavity (F145 and F352) were mutated to 
investigate if these sites were important in compound binding. State dependent inhibition of 
TRESK was also studied in all selected compounds to further investigate how these 
inhibitory compounds act on the channels. TRESK activation has been linked to analgesia, 
therefore novel agonists of TRESK were also tested.  
Chapter 5 investigates the degree of lamotrigine and sipatrigine inhibition on TREK2. Similar 
to chapter 3, the fenestration site was investigated for sipatrigine binding. Moreover, TREK2 
isoforms were created through alternative translation initiation to further investigate 
sipatrigine effects on TREK2 current.  
Chapter 6 investigates the novel compound Cen-092-C effect on TREK1 and TRESK 
channels. Cen-092-C binding on TRESK was investigated by mutation at potential binding 
target found at the central cavity sites (F145 and F352). Furthermore, the effect the 
compounds has when the channel is in different phosphorylation state was also examined, 
to further investigate to full action of this novel compound. This chapter’s aim is to explore 

























2.1 Preparation of poly-D-lysine (PDL) plates 
For electrophysiology experiments, Nunclon 4-well dishes (ThermFisher Scientific) were 
prepared in advance. The cover slips (13mm circular, VWR) were first washed in a petri dish 
of distilled water to remove any glass debris. The cover slips were then removed individually 
using forceps and allowed to dry. The cover slips were then added to a petri dish of ethanol. 
When completely dried, the coverslips were transferred into four well plates. In a 
microbiological safety cabinet, 300 µl of PDL (0.1mg/ml) was dropped onto each cover slip 
to ensure good cell adhesion. The plates were allowed to dry for 20-30 minutes. Any leftover 
PDL was removed with a pasteur pastette and allowed to dry completely. The plates were 
then transferred to a UV hood for sterilisation for 1-2 hours. The plates were stored at -20°C  
2.2 Cell culture 
The tsA 201, modified human embryonic kidney (HEK) cell line was chosen to transfection 
and electrophysiology because of its quick, manageable reproduction and maintenance, high 
efficiency of transfection when expressing protein of interest, and the small cell size suitable 
for voltage-clamp experiments.  
This cell line was cultured in media containing Dulbecco’s modified Eagle’s medium (88%), 
with Earl Salts, heat-inactivated foetal bovine serum (10%), NEAA (1%), 2 mM L-Glutamine, 
and penicillin-streptomycin (1%).  The cells were kept in two different sized flasks, 75cm2 
and 25cm2. These cultured flasks were incubated at 37°C tissue culture incubator with 5% 
CO2 and 95% air. Cells were sub-cultured every 2-3 days if using 25cm2 flask and every 4-5 
days if using 75cm2 flask. Cells should be 70-80% confluent at this stage. The cells were 
detached using Trypsin-EDTA (0.25%). When the cells are adhered to the smaller 25cm2, 
1.5ml of Trypsin-EDTA is used. The larger flasks (75cm2) use 3ml of Trypsin-EDTA cell 
dissociation solution. The flasks were agitated gently and the left in the incubator for 3-5 
minutes. The cells were removed from incubator and placed back in the fume hood. The 
cells were agitated again to ensure the cells have been dispersed from the bottom of the 
flask. Added 5ml of fresh media to the flask and pipetted up and down to ensure no clumping 
of cells and to remove any further cells from the bottom of the flask. Transferred 5ml of stock 
solution to a 15ml falcon tube. The falcon tube was placed into a centrifuge and spun at 
room temperature at 800rpm for 3 minutes. The supernatant was then poured out and the 
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cells were then re-suspended in 5ml fresh media and diluted for passage into a new flask. 
For cell passage, 20ml of fresh media is added to 75cm2 flask and then 0.5ml of stock cell 
solution. If cell passage uses 25cm2 flask, 5ml fresh media was added and then 0.5ml of 
stock cell solution. For electrophysiology experiments, 8.5ml of fresh solution was added to a 
falcon tube, followed by 0.5ml cell stock solution. Transfer 0.5ml of resuspended cells into 
each well of the plate. Cells prefer to grow between two surfaces, which can cause you to 
get a lot of cells growing on the bottom of the coverslip, rather than the top. Leave in 
incubator and allow cells to grow over night.  
2.3 Calcium phosphate transfection 
Calcium phosphate transfection is a popular method for introducing foreign DNA plasmid into 
cells. tsA 201 cells can be transiently transfected using the calcium-phosphate method. The 
HEPES-buffered saline solution containing negativity charged phosphate ions will combine 
with the positivity charged calcium chloride solution containing the DNA. This combination 
will form a fine precipitate and will bind to the DNA on its surface. The suspension of the 
precipitate is then added to the cells to be transfected. The DNA-calcium phosphate 
precipitate is then internalised by the cells through endocytosis. Transfection begins 24 
hours after the cells were plated. The tsA 201 cells are transfected with a plasmid encoding 
the cDNA of WT or mutated K2P channel and cDNA of green fluorescent protein (GFP). GFP 
is used as a reporter of expression and is exhibited in the cytosol of the cells that has been 
transfected. GFP will then omit a bright green fluorescence under UV light at a wavelength of 
395 nm, which can be seen under the fluorescent microscope (Nikon Eclipse TS100). It is 
then easy to know which cells have been successfully transfected.  
Two solutions are needed for this method of transfection. Tube A consists of 0.5 µg of the 
channel of interest, 0.5 µM GFP, 22.5 µl CaCl2 and deionised water to reach the total 
volume of 100 µl. Tube B consists of 100 µl phosphate-free Buffer (HEPES) and 1.8 µl 
phosphate buffer. Tube B is then added to Tube A dropwise and left for 5-20 minutes to form 
a CaPO4/DNA precipitate. The newly formed precipitate is mixed gently and 50 µl is pipetted 
into each of the 4- well plate. The cells are then washed 4-8 hours later twice with 1 ml PBS 
and then 50 µl of media is added to each well plate. The plate is then left in an incubator for 






Point mutations were introduced by site-directed mutagenesis into K2P channel clones using 
the Quikchange II site-directed mutagenesis kit (Agilent). The mutagenic oligonucleotide 
primers are all designed individually for the desired mutation. When creating the mutagenic 
primers there are parameters that need to be meet. The mutagenic primers must contain the 
desired mutation site and anneal must match the opposite strand of the plasmid. The 
primers should be between 25-45 bases in length with the mutation site sitting in the middle 
of the primer with ~ 10-15 bases on either side of the desired mutation site. Anything over 
that length could lead to the formation of a secondary structure. The primer should also 
contain 40%-60% glycine and cysteine (GC) content and end on either a C or G base. The 
two newly synthesised complimentary oligonucleotides containing the desired mutation is 
now ready to be prepared for thermal cycling reaction.  
To prepare the LB agar plates, add 35g pre-mixed LB agar powder to 1L ddH20 and mix. 
Autoclave the liquid and when this is completed, remove from autoclave and allow to cool. 
Add 500 µl of 50mg/ml antibiotic ampicillin into 1L of LB agar. Next pour the liquid into a 
polystyrene petri dish (100mm x 15 mm) on a sterile bench and near a Bunsen burner for 
sterilisation. Cover with lid and allow the solution to solidify and cool which takes around 30-
60 minutes. Label plates with antibiotic and date and allow sit in plastic bags with an 
absorbent material at 4°C to reduce condensation.   
To prepare synthesis of the mutant strand it is important that all solutions are kept on ice and 
are as cold as possible at all times. To prepare a control reaction, add 5 µl of 10x reaction 
buffer, 2 µl of control plasmid and 1.25 µl of each control primer into a PCR tube. Next, add 
1 µl of dNTP mix and 39.5 µl of double-distilled water (ddH20). Finally add 1 µl of PfuTurbo 
DNA polymerase. To prepare the sample reaction in a PCR tube, add 5 µl of 10x reaction 
buffer, 1 µl of the sample dsDNA template. Following this add 1.25 µl of each oligonucleotide 
primers, 1 µl of dnTP mix, 3 µl of QuikSolution reagent to improve linear amplification. The 
solution final volume should be reach 50 µl by adding ddH20. Then add the final solution of 1 






The number of cycles and temperature settings depends on what type of mutation is 
needed, which is described in Table 2.1.  
Type of mutation desired Number of cycles 
Point mutations 12 
Single amino acid changes 16 
Multiple amino acid deletions or insertions 18 
 Table 2.1: Number of cycles needed of each type of mutation 
Following temperature cycling, the reaction should be placed in ice for 2 minutes so that the 
reaction reaches a temperature of ≤ 37 °C. 
Add the restriction enzyme, Dpn I to the reaction tube. When the enzyme is added, gently 
mix the solution through pipetting up and down. Spin the solution down and incubate at room 
temperature for an hour.  
The next stage is transformation of XL1-Blue cells. The cells are gently thawed out on ice. 
For each reaction, aliquot 40 µl of the supercompetent cells into a pre-chilled 14ml BD 
Falcon polypropylene round-bottom tube. Transfer 3 µl of Dpn I-treated DNA from each 
reaction to separate aliquots of the supercompetent cells. Swirl the transformation reactions 
to gently mix the solutions and incubate the reactions on for 30 minutes. The transformation 
reactions should then be heat pulsed for 45 seconds at 42°C and then placed on ice for  2 
minutes. Add 350 µl of preheated NZY+ broth and incubate the transformation reaction at 
37°C for an hour with shaking at 225-250 rpm. Plate 5 µl of trans formation solution onto a 
LB-ampicillin agar plate and spread. The plate can then be incubated at 37°C for >16 hou rs. 
This process was carried out by Emma Veale.  
2.5 Electrophysiology experiments 
2.5.1 Voltage clamp technique 
The road to modern day voltage patch clamping started with Cole (1949) and, Hodgkin and 
Huxley (1952) and their experiments using giant squid axon in their study of ionic 
conductance. Hodgkin and Huxley used a two-electrode voltage clamp where the membrane 
voltage was controlled via a feedback amplifier and the current was measured to analyse ion 
channel activities. However, the disadvantage of this technique is that it could only be used 
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on larger cells (>20µm) and could not be used in tissue cells (Sontheimer and Ransom 
2002). 
Neher and Sakmann (1976) went on the develop patch clamp method further by using 
relatively large-tip pipette which did not penetrate the cell but formed a seal. This seal was 
stronger than the membrane, thus pulling the pipette away from the cell would cause the 
membrane the rupture around the patch but keep the seal intact. This introduced single 
channel recordings from the membrane patch to come into contact with defined media 
(Hamill et al 1981). 
The voltage clamp method is useful in two different ways. Firstly, it separates the membrane 
ionic current from the capacitive current. Secondly, the membrane voltage is controlled. 
Therefore, the currents being recorded are measured under uniform conditions and 
experience the same voltage (Halliwell et al 1994). 
Patch clamping is a form of voltage clamp, as it uses a feedback amplifier to set the 
membrane potential (Vm) of the cell to the command voltage (Vcomm). The clamping amplifer 
passes current to control Vm. Vm is measured by the voltage follower. The feedback 
amplifier is a differential amplifier that compares the difference between the two voltage 
inputs, Vm and Vcomm and makes it equal to the output (Vo).  
Vo = Vcomm ȂVm 
The amplifier contains a feedback resistor (Rf), with a known value, which allows the flow of 
a feedback current (If) to make the Vm equal to Vcomm. 
 
Figure 2.1: The patch clamp differential amplifier works to ensure the pipette voltage equals 
the command voltage  
The feedback resistance is located between the output and the negative input. This is 
important as Ohm’s law states that a current will flow through this resistance proportional to 
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the voltage difference between the two ends of the resistance, thus the current flow is a 
result of the difference between the Vo and Vm. The causes Vm to always be at Vcomm.  
This will allow for the calculation of the ionic current, which is equal to the amount of current 
which passed through the pipette to sustain Vm = Vcomm. As stated previously, the Rf will 
cause Vm to equal Vcomm  
Ip = (Vcomm – Vo) / Rfeedback 
Now that we have the Vcomm and Rf, we can now conclude the Ip , pipette current, by 
measuring Vo. Therefore, the feedback amplifier function as a current (Ip)-to-voltage (Vo) 
converter. It is assumed in these equations that Vm is equal to Vp, pipette voltage (Halliwell 
et al 1994). 
Vo = - IpRf + Vcomm  
2.5.2 Electrical Properties of the Cell Membrane 
The phospholipid barrier acts as a barrier to ions and, in contrast, the intra and extracellular 
media act as effective conductors of ions due to its dilute saline solutions. Therefore, the 
membrane has a conductor-insulator-conductor sequence which makes an excellent 
capacitor. However, the insulation is not perfect as the membrane contains numerous ion 
channels which will lead to some leaks.  
The membrane potential (Em) is the potential difference between the inside and the outside 
of the cell. This movement of ions across the membrane is expressed in current. There are 
two factors that determine the size of the flow of ions: driving force and membrane 
resistance. The driving force is defined as the difference between the equilibrium potential 
and the membrane potential. The greater the distance between the two potentials; the higher 
the net flow of a particular ion. Thus, current is proportional to driving force (volts). The 





Input resistance (Rinput) will determine the change in membrane voltage (〉V) in response to 
current (I). Rinput depends on the size of the cell, the membrane resistance and the density of 
opened channels. 志惨 噺 薩 三餐仔使四嗣 
As stated before a membrane is a capacitor. A capacitor has the ability to store electrical 
charge. The membrane exerts an electromagnetic field on both sides on the bilayer. This will 
allow charged particles to gather at the membrane. The amount of charge stored at the 
membrane can be calculated. 晒 噺  撮仕 察 
Figure 2.2: Q is the charge stored, Em is the potential difference and C is the membrane 
capacitance (in farad). 
 
This equation shows that the capacitance is the measure of the membranes ability to store 
charge at any potential. This capacitance needs to be charged to alter the voltage and this 
current pass is not instantaneous and therefore imparts a delay. Membrane capacitance is 
also linked to physical dimensions of the membrane, as the bigger the membrane the larger 
accumulation of charge. The membrane thickness is uniform however the capacitance is 
proportional to the circumference of the cell membrane.  
 
For that reason, the capacitance is a good estimation of the membrane surface area 
(Molleman 2003). The membrane time constant also determines the rate of change in 
membrane potential. The time constant is proportional to the input resistance and the 
capacitances 滋 噺 三察 






Figure 2.3: Simplified Voltage clamp circuit. E = V command, VT: True membrane potential, Rs: 
serial resistant, Ra: access resistant, Vo: amplifier output (Halliwell et al 1994).  
2.5.3 Series resistance and capacitance compensation 
During whole cell patch clamping, there are resistance in series with the membrane and the 
electrode. The series resistance (Rs) is the sum of the pipette (electrode) resistance (Rp) 
and access resistance (Ra) which is located between the end of the electrode and the 
interior of the cell. There are problems that can result from the Rs. The first is that the 
membrane potential measured and controlled at Vp and the voltage at the membrane may 
be different due to current flowing across the Rs. This will lead to a voltage drop. The second 
problem caused by Rs is its interaction with the membrane capacitance. The resistance and 
the capacitance are linearly proportional to the time constant (RC). A rapid step change in 
the Vcomm will change the Vm. However, there will be a delay by a few millisecond by Rs 
caused by a strong low–pass filtering effect which will increase the time constant. Therefore, 
the voltage step will not be immediately changed at the membrane (Sontheimer and Ransom 
2002). The size of the series resistance error is IxRs, this can be significant in large current 
measurements. If it is significant, Rs compensation can be actualised through adding voltage 
signal depending on the membrane current and to the Vcomm (Halliwell et al 1994).  
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Capacitance compensation can be important as rapid voltage changes are used to record 
the behaviour of the ion channels. As the membrane potential is changing, a transient 
capacitance current is produced. This transient current needs to be suppressed as the 
current will become too large to pass through the resistor. The system would become 
saturated and the step voltage change would be prolonged. In most voltage clamp 
experiments, the voltage change is in the form of a square step. This voltage step will cause 
a rapid spike of capacity current before the rate of voltage change (dV/dt) is zero at which 
the voltage step is at a steady state and the current can be recorded. It must also be noted 
that the electrode wall acts as an insulator between two conductors (the bath solution and 
the electrode solution). To compensate this saturation, the approximate current is passed 
through the amplifer input (Yamane 2007).  
2.5.4 Pipettes and internal solution 
Patch clamping technique uses two electrodes: the pipette electrode and the bath electrode. 
Both are made from silver chloride. Silver chloride electrode is a silver wire or pellet which 
has been immersed in bleach of 10-15 minutes which results in cloriding of the silver wire. 
This will allow the wire to become a reversible electrode. To establish the membrane 
potential, a redox reaction takes place between the metals and the salt solutions. In 
experimental situations, if the metal-liquid junction potentials are not equal, it will cause 
offset current which could be incorrectly cancelled out. It is therefore important to use 
identical material with similar surface area so that you will get matching but opposite solid-
liquid potentials on both sides and it can cancel each other out. Other problem can occur is 
electrode polarisation. This can occur when ions accumulate near electrodes that have direct 
current (DC) potential difference. Cations move to the negative electrode and anions move 
towards the positive electrode. This will lead to delays in potential changes and increases 
resistance. Electrode polarisation is subject to material, and silver chloride is the weakest 
polarisation material (Molleman 2003). 
Patch pipettes (or electrodes) are made from thick-walled glass capillaries which are heated 
until molten and stretched into shape. This is a two-stage process carried out by a vertical 
puller (Narishige). The first stage is the heated coil is set at 76 degrees. The glass capillaries 
are thinned in the middle at this heat. The second stage consists of the glass capillaries 
being re-centred to the thinnest point and in respect to the heated coil. The coil is set at 60 
degrees. This results in the capillaries breaking at the thinnest part, which will fashion two 
pipettes. The pipette tip should be 1-2 µM wide with a resistance measuring between 3 -6 
MΩ for whole-cell patch clamping. The second stage temperature can be adjusted if the 
resistance is not in this range (Halliwell et al 1994). This is seen as relatively blunt tip in 
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comparison to other patch clamp techniques however the blunt tip is needed to achieve and 
sustain a stable electrode-membrane seal (Sontheimer and Ransom 2002). Patch pipette 
were filled with standard (high EGTA) internal solution. Internal solution contains 150mM 
KCl, 3mM MgCl2, 5mM EGTA and 10mM HEPES and was then adjusted to pH7.4 using 
KOH. This internal solution contains electrolytes and other concentration solutions that are 
similar to the cytoplasm.  
2.5.5 The whole cell configuration and current recording 
The whole cell patch clamp technique is used to study the properties of a small patch of the 
membrane. Current was recorded from cells clearly expressing WT or mutant K2P channels. 
Patch pipette were filled with internal solution and mounted to the pipette holder. The pipette 
holder is controlled by its manipulator which allows to experimenter to move the pipette in 3D 
movements. The pipette is lowered into the bath solution. A square pulse is used to measure 
the resistance of the pipette. If the resistance is between the parameters, the pipette can be 
lower towards the target cell. To start the formation for a high resistance seal (Giga-ohm) by 
first applying light contact on a tiny area, or patch, of cell membrane. A small amount of 
negative pressure is applied using a 5ml syringe connected to the pipette holder. The length 
of time taken to form this seal varies however it should take around 30 seconds. When the 
giga-ohm seal forms, the displayed resistance of the electrode seen as the square current 
will disappear. It is an all-or nothing process. The giga-ohm seal should remain intact after 
the pressure is released. A tight seal is important as it prevents the leakage of current and 
diffusion of small molecules. At this stage in experiment has entered the cell-attached 
configuration.  
After this, higher but shorter negative pressure then follows to break the patch of the cell 
membrane giving a ‘whole cell’. The pressure must break the patch between the pipette tip 
and the cytoplasm without disrupting the seal at the pipette edge and the membrane.  Now 
at the whole cell configuration, the interior of the pipette and the cytoplasm are in contact 
and this allows for the recording of the exchange of ions and drug molecules. The 
Membrane Test in Clampfitx 10.2 produces a definable voltage pulse which can then be 
used to read a range of measurements. This included: Membrane capacitance (Cm), Access 
resistance (Ra), Membrane resistance (Rm) and Total resistance (Rt). The current is filtered 




Figure 2.4: Formation of whole cell patch clamp. A) the patch pipette is placed on the 
transfected cell which is indicated by a small increase in the pipette resistance.  B) cell-
attached was achieved using negative pressure to form a giga-ohm seal. C) quick 
application of negative pressure would break the membrane patch and form the whole cell 
mode (Li 2008). 
2.5.6 Electric circuit 
The pipette holder (Warner Instruments) is attached to the amplifier stage head. The pipette 
holder contains a AgCl wire which is connected to the stage head. This allows for an internal 
solution filled pipette to become in contact with the wire and therefore the rest of the circuit. 
A ground pipette, also AgCl, is placed in the bath to close the circuit.  
The circuit is connected to a digitiser interface (Digidata 1440A) which is used to visualise 
the cellular electrical signals onto the computer. A specific stimulation was entered on the 
computer and converted into an electrical current by the interface to be sent to the pipette 
inside the electrode. This electrical signal was then converted into a digital signal for the 
computer. The circuit is also connected to the amplifier (Axopatch 200B) which filters and 
converts the current the voltage coming from the electrode in the external bath by a low pass 
filter set at 2kHz.  
Other important features to the rig set-up are the microscope with the epi-fluoresence 
attachment (Nikon Eclipse TS100) which are used to identify transfected cells under UV light 
at a wavelength of 395 nm. A vibration isolation table (TMC, Micro-g lab table) is used to 
keep a minimal mechanical interference. A faraday cage (Scientifica) was used to eliminate 
any electrical noise or hum from the environment. A piezo-electric manipulator (Scientifica) 
was used to manuever the pipette and patch the cell. The computer software (Clampx 10.2) 






Voltage-clamp recordings were made using the whole cell recording techniques. A step-
ramp protocol was used in the recording. The cells were held at a holding potential of -60 
millivolt (mV). The cells were then hyperpolarised from -60mV to -80mV for 100ms and then 
held at -40mV for 500ms. This concludes the step part of the protocol. The cells are then 
held at -120mV for 100ms before beginning the ramp to +20mV which lasts for 500ms. After 
the ramp, the cells are held at -80mV for 100ms before resuming to -60mV holding potential. 
The protocol lasts for 1.5 seconds, including sampling at the holding potential. The protocol 
was repeated every 5 seconds (sweep) with constant super-fusion of external bath solution. 
As the voltage changes the current is measured and plotted. Currents were low pass filtered 
at 2kHz and digitized at 5kHz using a Digidata 1440A. 
 
Figure 2.5: Voltage protocol used to study K2P channels. The cursors show where the currents were 
measured from (-80mV and -40mV). 
K2P channels are activated at wide ranges of voltages. This allows us to measure at -80 mV, 
close to K+ equilibrium (~ -90 mV), and at -40 mV. This step produces a driving force for 
current to flow through the conductive channel. The -40mV step is designed to ensure that 
there is no contamination from endogenous Kv channels found in tsA 201 cells. The current 
amplitude is measured by subtracting the current at -80 mV from the current at -40 mV. If the 
current at the holding potential is below 0 pA, it is seen as a leaky current. Also, if the current 
at -80 mV is below -200pA is it deemed a leak current. These recordings are then excluded.  
The protocol ramp also allows assessment of the quality of the recording. If the ramp is seen 
as linear during a change in current it could suggest a leak current.  
2.5.8 Data Analysis 
Current obtained was analysed using pClamp 10.2 software (Molecular Devices). Any further 
analysis and statistical tests were performed using Excel (Microsoft) and GraphPad Prism 
(GraphPad Software). Data are expressed as mean ± standard error of the mean. Unpaired 
Welch’s t-tests were used as to assume unequal variances and when there were unequal 
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sample sizes. It must be noted however that testing for variance can lead to Type 1 error 
and has therefore been advised to use the unequal variance without preliminary tests 
(Ruxton, G. D. 2006).  The two-tailed Welch’s t-test was used to test both directions of the 
relationship. The one-tailed Welch’s t-test was used if the question is the difference is 
significantly greater or less, it cannot test for both. One-way ANOVA tests were used when 
more than two data sets were analysed. The Dunnett’s method was used in ANOVA where 
every mean is compared to the control mean. The Tukey test is a post-hoc ANOVA test 
which shows the overall significance of the whole data set (Rowe 2016).  
2.5.9 Drug application 
Extracellular solution (1litre) was made up of 145mM NaCl, 2.5mM KCl, 3mM MgCl2, 1mM 
CaCl2 and 10mM HEPES and was then titrated to pH 7.4 with NaOH. Stock solutions of 
compounds were made using DMSO or ethanol and stored in the required environment. 
Drug solutions were made fresh every day performing electrophysiology. Drug solutions 
were made at the intended concentration for the electrophysiology experiments via dilutions 
from a stock solution into the extracellular solution. Recordings were carried out with the 
cells superfused with the drug free extracellular solution, and then drug solution accordingly. 
The drug solution was then washed off by control to evaluate the reversibility of its effect. All 
compounds were applied from the extracellular side of the membrane by bath perfusion. 
Complete exchange of bath solution occurred within 100-120s. All data were collected at 
room temperature (19-22°C).  
2.6 Limitations 
The compound stock solutions were made up in 100% DMSO or ethanol to a final 
concentration of 10 mM. The stock solutions were then diluted down in external solution to 
the respective concentrations described. However, control DMSO and ethanol were not 
used, and this may be a limitation in the experiments.     
2.7 Structure visualisation    
2.7.1 Channel mutation creation  
All channels need a PDB (Protein Data Bank) file to carry out mutations. These PDB files 
can be opened using PyMol software. PyMol creates a three-dimensional model structure of 
the ion channel. Modeller 9.12 software was used in mutating PDB channel files as needed. 
Python 2.3 (software language) was installed and Modeller was installed under the Python 
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directory. The mutate model script was created by the laboratory of Andrej Sali 
(www.salilab.org). This script is activated through Modeller to be used to mutate the selected 
channel. The script takes the selected PDB file and mutates a single residue of the channel. 
The new mutated ion channel is saved as a PDB file and can therefore be opened in PyMol. 
If multiple residues need to be mutated, the script is run multiple times and this creates 
multiple PDB files each time. It must be noted however that the script only works on one 



























Regulation of TREK1 channels 





3.1 Complex neurobiological systems mediate pain 
Pain is a system caused by diseases of the brain, spinal cord and nerves in the nervous 
system. Pain has proved to be a complex challenge which has been approached by various 
medicines. The most common drugs used to manage pain are opioid and non-opioid 
analgesics. Unfortunately, a wide range of medicines for pain are inadequate or can cause 
adverse drug reactions (ADRs) and addiction (National Research Council (US) Committee 
2009). 
 
3.2 Somatosensory neurons and nociceptors 
The somatosensory systems process information of several somatic sensations for example 
temperature and touch. The somata of the sensory neurons are found in the dorsal root 
ganglia (DRG). The DRG is located between the dorsal root and the spinal nerve. It is 
understood that after injury, these neurons will increase nociceptive signalling through the 
generation of neuronal excitability. DRG neurons diverge from the axon into the peripheral 
and central afferent fibers. Nociceptors are neurons containing peripheral fibers that are 
stimulated by noxious sensory inputs. The largest group of nociceptors which diffuses pain 
are unmyelinated C-fibers. These C-fibers conduct slowly and respond to noxious stimuli 
and carry electrical impulses along the peripheral axon of the nociceptor into the CNS. There 
are also ion channels called transient receptor potential vanilloid (TRPV1) on nociceptor 
terminals that act as molecular transducers to depolarize these neurons. TRPV1 are known 
targets for inflammatory pain relief by antagonists and agonists (National Research Council 
(US) Committee 2009). 
 
3.3 TREK1 is a novel pain target 
Neuropathic pain is caused by a dysfunction of DRG and it is a difficult type of pain to treat. 
It is known that after injury to afferent neurons, ion channels will produce a greater generator 
potential which leads to an increased probability of action potential. Injury also leads to a 
decrease in threshold of sodium channels to initiate the spike in the action potential. All this 
together develops into DRG hyperexcitation. The symptoms of neuropathic pain include 
hypersensitivity to mechanical and thermal stimuli which is then addressed by nociceptors in 
the somatosensory system (Campbell and Meyer 2006). TREK channels are present on 
sensory neurons including DRG neurons and are co-localised with TRPV1. However, there 
is little information about the expression and role of TREK1 and TREK2 in neuropathic pain. 
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Using markers for the highly expressed IB4 and TREK channels it was found that there was 
coexpression in the DRG in neuropathic pain mouse model. When investigating expression 
of TREK1 it was identified that the channel was up-regulated and activated in the 
neuropathic pain mouse model. It is thought that this over expression is linked to TRPV1 
activity and its contribution the neuropathic pain management. Therefore, it suggests that 
TREK1 downregulation could play an important role in neuropathic pain management (Han 
et al 2016). Intuitively one would predict that activators of K2P channels would be useful in 
pain as they will dampen excitability of DRG neurons by hyperpolarising the membrane. 
However, there is an argument that K2P channel blockers are also effective because 
depolarisation will inactivate voltage-gated Na channels and block AP firing (see discussion 
and, for example, Meadow et al 2001, Mathie 2010). 
  
3.4 K2P lateral fenestrations 
Fenestrations were first characterised in voltage-gated sodium channels. It was seen that 
lipids could enter the four lateral openings and would occlude the cavity and block ion 
conductance (Payandeh et al 2011). The revelation of K2P structures through a series of 
crystallisation and electrophysiology studies have provided a good insight into the gating 
function of the channels. So far K2P channels which have been crystallised have been shown 
to hold lateral openings at the M2 helix and the M4 helix. These so-called openings or 
“fenestrations” allow a connection between the transmembrane pore and the membrane lipid 
bilayer (Brohawn, Campbell and MacKinnon 2013). In TWIK1 channels it was found that acyl 
chain lipids from the bilayer leaflet were able to enter the upper fenestration however it was 
not long enough to enter the pore. It is therefore not believed to block the inner pore. It is a 
similar situation with the lower fenestration as again lipid tails are found at the entrance but 
they are not long enough the block the pore cavity (Aryal et al 2015). TRAAK channels differ 
from TWIK1 as it was revealed that acyl chain lipids may protrude into the cavity. (Brohawn, 
Campbell, and MacKinnon 2014). Moreover, TREK2 co-crystallised channel with 
norfluoxetine identified the same intramembrane-side fenestrations below the selectivity 
filter. It is unclear whether TREK channels also allow acyl chain lipid into the cavity. If alkyl 
chains do enter the pore through the lateral fenestrations, it might impact the conductance 






3.5 Fenestration gating  
The lateral fenestrations seen in K2P channels are a result of conformational changes at the 
M2 and M4 helices alongside bending of the highly conserved glycine hinges. Therefore, it is 
believed that K2P channels enter into two different conformations. 
The “up state” shows an upward movement which results in kinking of the M4 helix at the 
glycine hinge. This upward movement also bends the glycine hinges at M2. This movement 
opens the cavity and closes the fenestrations. This allows for full occupation of ions into the 
selectivity filter. And it therefore believed to be conductive. 
The “down state” holds the M4 down wards and pushed the glycine hinges towards the 
cytoplasm. This movement creates the fenestration between the M4 and M2. Thus, the 
cavity is in contact with the lipid membrane. This results in no ions observed in the pore 
cavity and the channel is therefore non-conductive (Brohawn et al 2015; Dong et al 2015)   
TREK1 and TREK2 has already been discussed as containing the structurally important 
fenestrations seen in both TWIK1 and TRAAK. TREK2 co-crystallised with norfluoxetine 
shows the “down state” and “up state” which represents the non-conductive and conductive 
states, respectably. The fenestrations are only present in the down state as the openings are 
blocked in the up state by the new positioning of the F316 and L320 residues. It is also 
important to note that the co-crystallised structure of TREK2 with the state-dependent drug 
norfluoxetine is in the down configuration. The binding is believed to be dependent on site 
L320 as mutation of this site reduces the inhibition which can only occur if the fenestrations 
are present (Dong et al 2015).  
3.6 Aim of this chapter 
The aim of this chapter is to clarify the difference between lamotrigine and sipatrigine and its 
inhibition of TREK1. To investigate the mechanism of how the channel is regulated, whole-








3.7 Sipatrigine inhibits TREK1 channels 
Currents through wild-type (WT) human TREK channels transiently expressed in tsA-201 
cells were measured using whole-cell patch-clamp electrophysiology. The currents were 
measured in the presence and absence of sipatrigine (100 µM) which significantly reduced 
the TREK1 current (87 ± 2%, mean ± S.E.M., n = 19). Current inhibition was reversed by 70 
± 11% (n = 17) when washing the cells with a drug free external solution. The following 
shows a representation of general TREK1 WT currents (see Fig 3.1).  
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Figure 3.1: Sipatrigine (100 µM) inhibition of WT TREK1 channels. (A) Time-course plot of 
sipatrigine effect on TREK1. Points show current in the presence and absence of sipatrigine. 
(B) Trace of current at different voltages controlled by the protocol. Each trace is an average 
of five consecutive traces in the presence and absence of sipatrigine. (C) Current-voltage 
relationship of TREK1 obtained from the ramp voltage changes in the presence and absence 
of sipatrigine. (D) Average reversal potential of TREK1 current, in control and in the 
presence of sipatrigine (n = 19). Paired Student t-tests was used. 
The reversal potential of TREK1 current was measured to investigate the effect of sipatrigine 
on TREK1 ion selectivity. The TREK1 reversal potential changed to -69 ± 1 mV when 
sipatrigine was in the presence of the channel, compared to -85 ± 1 mV before the drug was 
applied (n = 19) (see Fig 3.1 C-D).  
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3.7.1 TREK1 inhibition by sipatrigine is concentration 
dependent 
Experiments were carried out to investigate how different sipatrigine concentrations may 
affect TREK1 channels. Sipatrigine was applied to TREK1 channels at concentrations of 30 
µM, 10 µM, 3 µM and also at 100 µM which has already been discussed. Sipatrigine (30 µM) 
concentration inhibited current by 56 ± 5% (n = 13), while the 10 µM concentration of 
sipatrigine produced 40 ± 5% (n = 10). The lowest concentration (3 µM) inhibited the channel 
by only 27 ± 4% (n = 8). The fitted curve showed that sipatrigine inhibited TREK1 channels 
with an IC50 = 15.94 µM. 95% Confidence intervals (12.49 – 20.34 µM). The Hill slope was 
0.82 with the 95% Confidence interval between 0.6 – 1 (see Fig 3.2). However, as can be 
seen the dose response curve does not measure 100% inhibition and more concentrations 
could be used to measure this (see Fig 3.2).  
 



























3.7.2 Sipatrigine inhibition of E306A TREK1 channels 
The residue E306 is located between the TM4 and the intracellular C terminus which is a key 
location for gating regulation. It was found that mutation of this site to an alanine will mimic 
the effects of protonation and will lock the channel into a permanently open state (Honoré et 
al 2002). The mutated site E306A showed a significant increase in resting current density 
(137 ± 26 pA/pF, n = 9) compared to TREK1 WT (87± 7 pA/pF, n = 25), shown in Fig 3.3.  

























Figure 3.3: Current density (pA/pF) of TREK1 WT ( n = 25) compared to the gain-of-function 
mutated TREK1 E306A (n = 9). Unpaired one-tailed Welch’s t-tests was used.  
It was also found that sipatrigine (100µM) did produce an inhibitory effect of 64 ± 4%, n = 7 
on TREK1 E306A current. This is significantly less than TREK1 WT inhibition (87 ± 1%, n = 
19).   
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Figure 3.4: Sipatrigine (100 µM) has a significantly effect on TREK1 E306A. A) Time-course 
of sipatrigine (100 µM) effect of TREK1 E306A in the presence and absence of sipatrigine. 
B) Inhibition of WT ( n = 19) and mutated TREK1 E306A (n = 7) with sipatrigine (100µM). 










The reversal potential of TREK1 E306A current was investigated and was shown that no 
significant change was seen in the presence of sipatrigine. 
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Figure 3.5: A) Trace of current at different voltages controlled by the protocol. Each trace is 
an average of five consecutives traces in the presence and absence of lamotrigine. B) 
Average reversal potential of TREK1 E306A current, in control and in the presence of 
sipatrigine (n = 7). Paired Student t-tests was used.   
The results here show that sipatrigine has a decreased degree of inhibition for the channel 
with the gain of function mutation E306A. This would suggest that sipatrigine inhibition may 












3.8 Lamotrigine inhibition of TREK1  
TREK1 (WT) channels were transiently transfected in tsA-201 cells and currents were again 
measured using whole-cell patch-clamp electrophysiology. All currents were measured in the 
presence and absence of lamotrigine (100 µM) showed current inhibition of 30 ± 6% (n = 6). 
The following shows a representation of general TREK1 WT currents (see Fig 3.5).    
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Figure 3.6: Lamotrigine (100 µM) inhibition of WT TREK1 channels. (A) Time-course plot of 
lamotrigine effect on TREK1. Points show current in the presence and absence of lamotrigine. 
(B) Trace of current at different voltages controlled by the protocol. Each trace is an average 
of five consecutive traces in the presence and absence of lamotrigine. (C) Current-voltage 
relationship of TREK1 obtained from the ramp voltage changes in the presence and absence 
of lamotrigine. (D) Average reversal potential of TREK1 current, in control and in the presence 
of lamotrigine (n = 6). Paired Student t-test was used.   
The results show that lamotrigine does indeed inhibit TREK1 channels, in contrast to results 
obtained for the same WT channel which were expressed in HEK293 at a concentration of 10 
µM (Meadows et al 2001). The reversal potential showed little to no change shifting to -83 ± 2 




3.9 Sipatrigine mechanism of action on TREK1 current   
3.9.1 TREK2 docking to predict binding site(s) 
The co-crystallised structure of TREK2 with norfluoxetine showed important binding sites. 
This study showed that the residue leucine at position 320 holds importance in the binding 
and inhibition of norfluoxetine. This residue is located in the fenestration site when the 
channel is in the up state. Norfluoxetine is known to only bind when TREK2 is in the closed 
conformation and therefore when the channel is in the down state. The fenestration site 
L320 is used as a binding site for norfluoxetine as the channel shifts to expose the residue. 
Therefore, I investigated if the same site is important in sipatrigine inhibition. 
3.9.2 TREK1 mutation at predicted sipatrigine binding site 
To investigate the effect of sipatrigine on TREK1, the TREK2 L320 homologues site was 
identified on TREK1. The homologues site was TREK1 L289 (see Figure 3.5).     
            A) 
                                                                           320 
TREK2 K P L V W F W I L V G L A Y F A A V L S M I 
                                                                           289 
 TREK1 K P V V W F W I L V G L A Y F A A V L S M I 
 
          B) 
 
Figure 3.7: A) sequence highlighting TREK2 and TREK1 residue important of inhibition (yellow). 




After identifying the homogenous site, a mutated TREK1 was produced and electrophysiology 
could be carried out. 
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Figure 3.8: A) Current density (pA/pF) of TREK1 WT (n = 25) compared to the mutated 
TREK1 L289A (n = 9). B) TREK1 WT (n = 19) inhibition compared to TREK1 L289A (n = 9) 
with sipatrigine and lamotrigine at a concentration of 100 µM. Unpaired two-tailed Welch’s t-
test was used.   
The current density (pA/pF) of TREK1 WT (87 ± 7 pA/pF, n = 25) was significantly greater 
compared to the mutated TREK1 L289A (34 ± 5 pA/pF, n =9). The results show that 
sipatrigine inhibition was decreased when the channel was mutated. The mutated channel 
showed an inhibition of 56 ± 7% (n=9), compared to the WT at 87 ± 2% (n=19). However, 
lamotrigine sensitivity did not change when the channel was mutated (31 ± 9%, n=6) 
compared to the WT (30 ± 6%, n=6).  
3.9.3 Sipatrigine interaction with double mutations in the 
central cavity of TREK1   
There have been two positions on the K2P pore which have been identified as important in 
the activation of these channels. It was found that mutation of one of these sites on TRAAK 
results in the abolished activation by arachidonic acid (AA) and phosphoinositides (PIP2). It 
was also seen that a single mutation would shift the K2P channel from a voltage gated 
channel to a linear leak channel. The equivalent amino acids in TREK1 were identified (T142 
and T251) as the important residue for AA and PIP2 activation (Schewe et al 2016). 
Furthermore, these sites showed to be important in Ba2+ inhibition as mutations reduced the 
blockade of TREK1 current (Ma et al 2011). These residues were mutated from a threonine 
to an alanine (see Fig 3.7 A-B). These mutated TREK1 channels were used with sipatrigine 







   A)            B)   
 
                           C) 
























Figure 3.9: A) TREK1 structure highlighting mutated residues T142A (red) and T251A (blue). 
B) View of TREK1 structure highlighting the mutated residues at the pore. C) Current density 
of TREK1 WT (n = 8) and the mutations T142A (n = 10), T251A (n = 7) and double mutation 
(n = 7). One-way ANOVA applying post hoc Dunnett’s test was used. 
   
It was also made clear that the current density of the double mutation was significantly 
smaller (16 ± 3 pA/pF, n = 7) compared to TREK1 WT (60 ± 14 pA/pF, n = 8). The current 
density of the single mutation T142A was 54 ± 8 pA/pF (n = 10) and T251A was 75 ± 23 
pA/pF (n = 7). The single mutations were not significantly different to TREK1 WT. The 
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Figure 3.10: A) TREK1 T142A in the presence and absence of sipatrigine (100µM). B) Trace 
of TREK1 T142A current at different voltages controlled by the protocol. Each trace is an 
average of five consecutive traces in the presence and absence of sipatrigine. C) TREK1 
T251A in the presence and absence of sipatrigine (100µM). D) Trace of TREK1 T251A 
current at different voltages controlled by the protocol. Each trace is an average of five 
consecutive traces in the presence and absence of sipatrigine. 
TREK1 WT current inhibition by sipatrigine was 80 ± 5% (n = 11), which is similar to TREK1 
T142A (67 ± 5%, n = 8) and TREK1 T251A (81 ± 4%, n = 8) (see Fig 3.10). The only 
significant difference was seen between TREK1 WT and the double mutated channel 
TREK1 T142A, T251A (45 ± 6%, n = 6). However, as the current is significantly lower 
compared to the WT and single mutations, it does become more difficult to measure the 
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Figure 3.11: A) TREK1 T142A, T251A in the presence and absence of sipatrigine (100µM). B) 
TREK1 WT (n = 11) sipatrigine inhibition is similar to TREK1 T142A (n = 8) and TREK1 
T251A (n = 8). Significant difference was seen between TREK1 WT and TREK1 T142A, 
T251A (n = 6). One-way ANOVA applying post hoc Dunnett’s test was used. 
    
 
3.9.4 25 mM K+ solution effect on TREK1 with sipatrigine 
The low basal current of the double TREK1 mutation (T142A, T251A) made measuring the 
degree of inhibition by sipatrigine difficult. Therefore, an increased KCL external solution 
from 2.5 mM K+ to 25 mM K+ was used. This increase in extracellular potassium 
concentration will cause the potassium gradient to decrease across the membrane. This 
shifts the reversal membrane potential for potassium to more positive voltages (around -
40mV, see Fig 3.10). To investigate the resting basal current and sipatrigine inhibition, a 
different external potassium concentration was used. The current was measured in 2.5 mM 
K+ solution and then at 25 mM K+ solution. Sipatrigine (100 µM) was made in 25mM K+ 
solution. The effect and sipatrigine was then washed off using 25 mM K+ solution and then 
the normal 2.5 mM K+ was then added. The following shows a representation of general 
TREK1 T142A, T251A currents (see Fig 3.11). 
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Figure 3.12: A) TREK1 WT current increase is due to the change in external potassium 
concentration and current inhibition was caused by sipatrigine(Sip) (100 µM). B) TREK1 
T145A, T251A current increase is due to the change in external potassium concentration 
and current inhibition was caused by sipatrigine (Sip) (100 µM). C) TREK1 WT reversal 
potential shifts to the more positive -40 mV. TREK1 WT current was decreased in 25 mM K+ 
and sipatrigine. D) TREK1 T142A, T251A reversal potential shifts to the more positive -40 
mV. TREK1 T142A, T251A current was slightly decreased in 25 mM K+ and sipatrigine, 
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Figure 3.13: Current density (pA/pF) of TREK1 WT (n = 6) in 2.5mM K + solution compared to 
the same cell in 25mM K +solution. Current density (pA/pF) of TREK1 T142A, T251A (n = 6) 
in 2.5mM K + solution compared to the same cell in 25mM K +solution. Paired Student t-test 
was used.     
TREK1 WT and mutated channels were characterised and it was found that there was an 
increase in current. However it was found not to be significantly different between TREK1 
WT in 2.5 mM K+ external solution (43 ± 5 pA/pF, n = 6) and 25 mM K+ solution (60 ± 12 
pA/pF, n = 6). There was significant difference between the TREK1 T142A, T251A in 2.5 
mM K+ solution (20 ± 3 pA/pF, n = 6) and 25 mM K+ solution (45 ± 9 pA/pF, n = 6).  
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Figure 3.14: A) The inhibitory effect of sipatrigine (100 µM) in 25 mM K+ external solution on 
TREK1 WT (n = 6) compared to TREK1 T142A, T251A (n = 6). B) Inhibition of TREK1 WT (n 
= 11) current and TREK1 T142A, T251A (n = 6) in sipatrigine (100 µM) in 2.5 mM K+ 
external solution versus 25 mM K+ external solution. Unpaired two-tailed Welch’s t-test was 
used for 2.5 mM K+ solution. Unpaired one-tailed Welch’s t-test was used for 25 mM K+ 
solution.    
Sipatrigine in 25 mM K+ solution produced inhibition of TREK1 current (79 ± 6%, n = 6). The 
double mutated TREK1 T142A, T251A current showed a significantly reduced degree of 
inhibition of sipatrigine (100 µM) in 25 mM K+ solution compared to the WT (51 ± 5%, n = 6), 
see Fig 3.11 A. The increase in the resting current also showed to have no change in the 
degree of sipatrigine inhibition when compared to the normal 2.5 mM extracellular solution 
(Fig 3.11 B). This shows that the degree of inhibition seen in 2.5 mM external and sipatrigine 










Regulation of TRESK channels 












4.1 Physiological role of TRESK and pain 
The DRG are very important in transmitting nociception as it relays the pain signal to the 
nervous central system. DRG contains the cell bodies of primary afferent neurons which is 
used for transmitting sensory information from the periphery to the central nervous system. It 
has been proven that hyperexcitability and increased discharge of DRG signals plays a role 
in pain models. As TRESK channels are known to be expressed on the DRG neurons and 
modulate the resting background current, the channel could be involved in the discussed 
electrical conduction in neuropathic pain (Tulleuda et al 2011). 
In chronic pain, the condition is regulated by altering the nociceptive function. Stimulation 
from inflammatory mediators released in tissue produced by injury act on GPCRs. GPCR, 
expressed on DRG, activate intracellular signalling systems such as Ggq which evokes the 
release of cytoplasmic calcium stores. This elevation of intracellular calcium promotes the 
release of neurotransmitters at the presynaptic terminal and thereby activating calcineurin, 
which is known to increase TRESK activity (Ji and Woolf 2001). There is further evidence of 
this as lysophosphatidic acid (LPA), an inflammatory mediator, signalling influences 
neurological disorders such as neuropathic pain. It is known that during tissue damage, LPA 
is released from activated platelets or microglia. This release will alter the activity of ion 
channels and influence the excitability of neurons.  In heterologous systems, LPA will 
strongly activate TRESK through Ggq-coupled receptors. This activation of TRESK is 
believed to down regulate depolarisation of DRG neurons and thereby attenuates 
nociception. This is contrary to LPA action on TREK1, as it has an inhibitory effect which 
evokes excitation for nociceptors (Kollert et al 2015).    
The natural analgesic hydroxy-g-sanshool (sanshool) is known to excite a subset of 
capsaicin-sensitive sensory neurons and inhibites TRESK channels. Sanshool is responsible 
for the tingling or numbing sensations associated with Szechaun peppers (Bautista et al 
2008). Another compound Aristolochic acid (AristA) also occurs naturally and has been used 
in traditional medicine to relieve pain. This compound is unique however as it selectively 
inhibits TRESK while activating TREK1 and TREK2 (Veale and Mathie 2016). It remains 
unclear how the inhibition of TRESK current results in the analgesic effect seen by these 
compounds. One thought is that the tingling and numbing effect by the natural compounds 
will desensitise the excited neurons which results in pain relief, similar to that seen with the 
nociceptive agent capsaicin. It is also important to consider what we know about TRESK and 
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the pain linked the migraine. As previously discussed, the mutated gene which encodes for 
TRESK leads to a non-functional TRESK indicating that enhancement of TRESK current is 
important in treating migraines (Lafrenière et al 2010). Taking all this information together 
could be useful in understanding the exact role of TRESK and its therapeutic potential to 
target pain.  
4.2 Regulatory pathways involving phosphorylation 
Calcium-dependent activation of TRESK targets calcineurin and the docking motif PQIIIS. 
The serine residues (S252 and S264) have been identified as important sites for 
phosphorylation/dephosphorylation dependent regulation. Serine 264 is found in the 
intracellular loop and is the target for MARK kinases phosphorylation. Serine 252 is also 
found in the intracellular loop and is phosphorylated by PKA. Substitution of these residues 
to alanine changes the channel to the dephosphorylated state, as the serine residues now 
cannot be phosphorylated. This shift is seen with high basal current and a reduced response 
to the calcium signal which suggest the channels are in this active configuration. Mutating 
the same serine residue to a negative charged glutamic acid is also thought to mimic 
permanent phosphorylated state which shows to have a low basal current and also reduced 
response to calcium. (Czirják and Enyedi 2010).   
4.3 Central cavity is important for blocker binding   
Two key mouse TRESK residues, F156 and F364, were found to be involved in binding 
blockers of K+ channels, such as propafenone and lidocaine, and resulting in current 
inhibition. This evidence is based on homology modelling and molecular docking 
simulations. These phenylalanine residues are conserved in human TRESK channels as 
F145 and F352. Both residues face into the central cavity and form a narrow pore for ion 
conduction. It is therefore likely that these residues interact with TRESK blockers. It is 
believed that inhibitors of TRESK form ヾ-ヾ stacking interactions with the phenylalanine 
residues. It was demonstrated in the mouse model of TRESK that the aromatic rings of the 
blockers will form ヾ-ヾ interactions at the two phenylalanine sites (Kim et al 2013). Alanine 
mutations on both sites would diminish inhibition of TRESK blockers quinine, propafenone, 
and lidocaine. Therefore, the two phenylalanine residues have been proposed as important 
in forming the narrow gate region and for binding for these inhibitors (Bruneret al 2014). 
Therefore, I used the same mutations to see if the same residues are involved in another 
compound’s inhibition.  
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4.4 Aim of the chapter 
I investigated the effect of sipatrigine and lamotrigine on TRESK. This study will aim to 
understand the mechanism by which the drugs act on the channel using direct mutagenesis 
and electrophysiology recording. Additionally, I aim to investigate the action of novel 

















4.5 Sipatrigine inhibition of TRESK 
TRESK (WT) channels were transiently expressed in tsA-201 cells and currents were 
measured using whole-cell patch-clamp electrophysiology. The current was measured in the 
presence of sipatrigine (100 µM) and it was found to significantly reduce TRESK current (73 
± 3%, n = 17). Current inhibition was recovered by 51 ± 6% (n = 13) after wash-off with a 
drug free external solution. The reversal potential of TRESK current in external solution was         
-75 ± 2 mV (n = 16), however there is a shift to a more positive -64 ± 3 mV (n = 16) in 
sipatrigine (100 µM). The following shows a representation of general TRESK currents (see 
Fig 4.1).   
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Figure 4.1: Sipatrigine (100 µM) inhibition of TRESK WT channels. (A) The effect on TRESK 
current in the presence and absence of sipatrigine. (B) Trace of current at different voltages 
controlled by the protocol. Each trace is an average of five consecutive traces in the 
presence and absence of sipatrigine. (C) Current-voltage relationship of TRESK obtained 
from the ramp voltage changes in the presence and absence of sipatrigine. (D) Average 
reversal potential of TRESK current (n = 16). Paired Student t-test was used.     
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4.5.1 TRESK inhibition by sipatrigine is concentration 
dependent 
Sipatrigine was applied to TRESK channels at concentrations of 3 µM, 10 µM, 30 µM and 
100 µM, which has already been discussed. Sipatrigine (30 µM) concentration inhibited the 
channel by 46 ± 3% (n = 19), while the 10 µM concentration of sipatrigine produced 24 ± 4 % 
(n=11). Sipatrigine (3 µM) concentration only inhibited TRESK channels by 11 ± 3% (n = 8). 
TRESK inhibition by sipatrigine showed that sipatrigine an IC50 = 36.57 µM. The 95% 
Confidence intervals was between (30.68 – 43.61 µM). The Hill slope was 0.91 with the 95% 
Confidence interval between 0.7 – 1 (see Fig 4.2). It must be noted however that this dose 
response curve does not measure 100% inhibition and that more concentrations could be 
used to measure this.  




























4.6 Lamotrigine inhibition of TRESK 
TRESK (WT) channels were transiently transfected in tsA-201 cells and currents were again 
measured using whole-cell patch-clamp electrophysiology. TRESK current was measured in 
the presence of lamotrigine (100 µM) showed current inhibition of 35 ± 4%, n = 8. The 
reversal potential of TRESK current in external solution was -78 ± 2 mV (n = 8), however 
there is a shift to a more positive -73 ± 2 mV (n = 8) in sipatrigine (100 µM). The following 
shows a representation of general TRESK currents (see Fig 4.3).     
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Figure 4.3: Lamotrigine (100 µM) inhibition of WT TRESK channels. (A) Effect of lamotrigine 
on TRESK. Time-course plot show current in the presence and absence of lamotrigine. (B) 
TRESK current at different voltages controlled by the protocol. Each trace is an average of 
five consecutive traces in the presence and absence of lamotrigine. (C) Current-voltage 
relationship of TRESK obtained from the ramp voltage changes in the presence and 
absence of lamotrigine. (D) The reversal potential of current in the presence of lamotrigine 





4.7 Sipatrigine and lamotrigine mechanism of action 
on TRESK current   
4.7.1 F156A/ F364A mutation reduces pharmacological 
inhibition on TRESK 
Sipatrigine (100 µM) was applied on TRESK F145A/F352A to investigate its effect on the 
TRESK mutant. Sipatrigine (100 µM) was found to have little or no effect on TRESK 
F145A/F352A (10 ± 2, n = 9). The results show a significant difference in sipatrigine (100 
µM) inhibition between the WT TRESK and the FF mutated TRESK which suggests that this 
location is important in sipatrigine inhibitory effect. The following shows a representation of 
general TRESK F156A/ F364A currents (see Fig 4.4).   
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Figure 4.4: Sipatrigine (100 µM) inhibition of TRESK FF channels. (A) Current density (pA/pF) 
of TRESK WT (n = 28) versus TRESK double mutation (n = 10). B) Comparison between 
TRESK WT (n = 17). and TRESK FF (n = 9) current inhibition in the presence of sipatrigine 
(100 µM). C) TRESK current at different voltages controlled by the protocol. Each trace is an 
average of five consecutive traces in the presence and absence of sipatrigine. D) The effect 
on TRESK in the presence and absence of sipatrigine. Unpaired two-tailed Welch’s t-test 





Lamotrigine (100 µM) was applied on TRESK F145A/F352A (5 ± 2%, n = 11) which saw little 
or no effect compared to TRESK (35 ± 4%, n = 8). The results show a significant difference 
in lamotrigine (100 µM) between the WT TRESK and the FF mutated TRESK which again 
shows that these residues are important for blockers.  
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Figure 4.5: Lamotrigine (100 µM) inhibition of TRESK FF channels. (A) Comparison between 
TRESK WT (n = 8) and TRESK FF (n = 11) current inhibition in the presence of lamotrigine 
(100 µM). Unpaired two-tailed Welch’s t-test was used. (B) The effect on TRESK FF in the 
presence and absence of lamotrigine (100 µM). (C) TRESK current at different voltages 
controlled by the protocol. Each trace is an average of five consecutive traces in the 
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Figure 4.6: The effect that the double FF mutation has on the inhibitory action of sipatrigine 
and lamotrigine. The inhibitory effect of sipatrigine on TRESK WT (n = 16) versus TRESK 
F145A, F352A (n = 9). The inhibitory effect of lamotrigine on TRESK WT (n = 8) versus 
TRESK F145A, F352A (n = 11). Unpaired two-tailed Welch’s t-test was used.   
4.7.2 Is TRESK inhibition state dependent? 
It come as no surprise that the S252A, S264A mutated channel had a significantly larger 
current density (95 ± 9 pA/pF, n = 14) than the WT (64 ± 5 pA/pF, n = 28) as that mutation 
mimics the forced open dephosphorylated state. The phosphorylated S252E, S264E (80 ± 
12 pA/pF, n= 15) had a similar current density to WT. Mutation of the bulky residues (F142 
and F352) in the M2 and M4 inner pore regions of the channel showed a significantly greater 
current density compared to WT (134 ± 17 pA/pF, n=13).       

























Figure 4.7:  Current density (pA/pF) of TRESK WT (n = 28) compared to dephosphorylated (n 
= 14) and phosphorylated state (n = 15) of the channel. One-way ANOVA applying post hoc 
Dunnett’s test was used. 
 
To investigate whether the phosphorylation state of the TRESK channel affects the degree 
of inhibition of certain compounds, electrophysiology recording were used to measure 
inhibition.  
The sipatrigine inhibition of TRESK WT current was 75 ± 2% (n = 16). The inhibition of the 
two forced states were similar to TRESK WT with the degree of inhibition of 70 ± 4% (n = 6) 
for the TRESK AA channel and 79 ± 2% (n = 6) for TRESK EE (see Fig 4.8-A).  
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Lamotrigine (100 µM) showed a significant difference in inhibition between WT (35 ± 4%, n = 
8) and TRESK AA (57 ±3%, n = 9). There was no significant with TRESK EE inhibition (49 ± 
6%, n = 7) and TRESK WT lamotrigine inhibition (see Fig 4.8-B).  
A)                       B) 




































Figure 4.8: A) Sipatrigine (100 µM) inhibition of TRESK WT (n = 16), TRESK AA (n = 6) and 
TRESK EE current (n = 6). B) Lamotrigine (100 µM) inhibition of TRESK WT (n = 8), TRESK 
AA (n = 9) and TRESK EE current (n = 7). The inhibitory effect of lamotrigine on TRESK WT 
versus TRESK AA. One- way ANOVA applying post hoc Dunnett’s test was used.  
 
4.8 Potential activators of TRESK  
Downregulation of TRESK is known to induce hyperexcitability that results in activation of 
sensory neurons and nociceptive fibres. This causes a pro-algesic effect. (Guo and Cao 
2014). Migraine is also caused by hyperexcitation of neurons. Therefore, a TRESK-specific 
activator may display analgesic effects and could be a potential treatment for migraine 
patients as ultimately this will lead to a significant decrease in the excitability of DRG 
neurons (Enyedi, Braun, and Czirják 2012). Two novel compounds (PD0307243 and 
PD0322388) were suggested to be activators of TRESK channels on the basis of data from 
high throughput screening carried out at Pfizer Neusentis. The effects of these two 
compounds were investigated using whole-cell patch-clamp electrophysiology.  
 
4.8.1 PD0307243 and PD0322388 had no effect on TRESK 
current 
PD0307243 (100 µM) was applied to TRESK WT and TRESK F145A/F352A to investigate if 
it enhances the current of TRESK. PD0307243 was found to have little or no effect on 
TRESK WT (-2 ± 4%, n = 8) or TRESK F145A/F352A (-2 ± 3%, n = 7) (see Fig 4.9 A-B). 
PD0322388 (100 µM) was also applied to TRESK WT and TRESK F145A/F352A to see if 
the compound has effect on current enhancement. Little enhancement of TRESK WT current 
was measured after the presence of PD0322388 (7 ± 8%, n =6). TRESK F145A/F352A 
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showed little current activation also at 4 ± 2 (n = 5) (see Fig 4.9 C-D). The results show that 
the potential TRESK activator compounds has no direct action on TRESK channel. The 
following shows a representation of general TRESK currents (see Fig 4.9).   
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Figure 4.9: A) TRESK WT in the presence of the potential activator PD0307243. B) 
Comparison of PD0307243 enhanced current in TRESK WT (n = 8) and TRESK FF mutation 
channel (n = 7). C) TRESK WT in the presence of the other potential activator PD0322388. 
D)  Comparison of PD0322388 enhanced current between TRESK WT (n = 6) and TRESK 
FF mutation (n = 5). Unpaired two-tailed Welch’s t-test was used.   
4.8.2 Potential TRESK current enhancers do not work via the 
calcineurin pathway 
TRESK channels are known to be indirectly activated by calcium through the 
calcineurin/NFAT signalling pathway. Potential activators of TRESK could affect this 
pathway however the internal solution contains EGTA. EGTA is a chelating agent that 
buffers calcium. This is used in whole cell patch as rupture of the cell’s membrane will 
release Ca2+ from intracellular store and damage the seal. To see if the potential activators 
of TRESK work indirectly, low EGTA internal solution (0.1 mM, compared to 5 mM) was 
used. This will allow calcineurin pathway upon cellular calcium uptake.  
Electrophysiology recordings with electrode solution now containing low EGTA where carried 
out in the presence of PD0307243 and PD0322388, respectively. PD0307243 (100 µM) 
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showed little activation (1 ± 5%, n = 8) and TRESK FF also showed no activation (-9 ± 3, n = 
5) (see Fig 4.10 A-B). PD0322388 showed similar results with TRESK WT showing -1 ± 4% 
(n = 7) and TRESK FF mutation with 3.1 ± 5% activation (n = 3) (see Fig 4.10 C-D). The 
following shows a representation of general TRESK currents (see Fig 4.10).   
A)      B) 
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Figure 4.10: A) TRESK WT in the presence of low EGTA internal solution and potential 
activator PD0307243. B) Comparison between TRESK WT (n = 8) and TRESK FF enhanced 
current (n = 5) when in the presence of PD0307243 and in low EGTA internal solution. C) 
TRESK WT in the presence of low EGTA internal solution and the other potential activator 
PD0322388. D) Comparison between TRESK WT (n = 7) and TRESK FF (n = 3) enhanced 
current when in PD0322388 and in low EGTA internal solution. Unpaired two-tailed Welch’s 















 Regulation of TREK2 channels 














5.1 TREK2 linked to pain 
TREK2 is closely related to TREK1 with their sequence being 78% similar however the 
expression level of TREK2 in DRG neurons is low in comparison. The importance of TREK2 
however has been identified in its contribution to the resting K+ current. TREK2 is the most 
active conductive channel at 37°C in DRG neurons (69%), compared to TRESK (16%), 
TREK1 (12%) and TRAAK (3%) (Kang and Kim 2006). This high rate in current conductance 
could be important in spontaneous pain as TREK2 is selectivity expressed in selectin B4 
binding (IB4+) C-fiber nociceptors in small DRG neurons. In neuropathic pain models in rats, 
the spontaneous firing rate are connected to the membrane potential which is highly defined 
by TREK2. It was also seen that rats with a greater amount of spontaneous foot lifting 
measured a lower amount of TREK2 activity. This shows that TREK2 may limit spontaneous 
pain in vivo (Acosta et al 2014). It is therefore not surprising that the neuroprotective agent 
baicalein and wogonin active TREK2 current, which is thought to supress neuronal 
excitability of DRG neurons (Kim et al 2010). It has been reported however that anti-
depressants with analgesic effects inhibit TREK2 channels including amitriptyline, 
citalopram, escitalopram, and fluoxetine. This study however could not determine the 
relationship between the analgesic inhibitions to pain. It was noted that activation of 
inhibitory interneurons caused by depolarization of the resting potential could lead to 
treatment to pain, however there are no accounts of TREK2 expression on inhibitory 
interneurons (Park et al 2016).    
5.2 Variation of the channel structure  
For manufacturing protein, the information in DNA is transferred to a messenger RNA 
(mRNA) by transcription. The DNA is used as a template for complementary base pairing 
and an enzyme called RNA polymerase transcribes primary transcript mRNA (pre-mRNA) 
molecule into the mature mRNA. The mature mRNA molecules must leave the nucleus and 
travel to the ribosomes. This resulting mRNA is a single-stranded gene, which will be 
translated into a protein molecule. The translation of mRNA begins when the small subunit of 
the ribosome and a transfer RNA (tRNA) molecule assemble on the mRNA transcript. Each 
tRNA contains a set of three nucleotides called an anticodon. The anticodon tRNA will bind 
to the specific AUG start codon of the mRNA transcript. The tRNA molecule also carried by a 
methionine, the amino acid that the tRNA binds to. The ribosome will move along the mRNA 
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in the 5’–to-3’ direction. Termination will occur when the stop codons are recognized by 
proteins (Flinta et al 1986).    
When it comes to diversity of ion channels to alter channel function and neuronal excitability, 
alternative translation initiation (ATI) plays a key role. ATI has also been shown to further 
increase the molecular and functional complexity of K+ channels. ATI is thought to occur on 
eukaryotic mRNA that contains a weak Kozak sequence which is skipped by the scanning 
ribosome and translation is initiated at a different start codon (Thomas et al 2008). The 
optimal sequence for translation transpires when the start codon is flanked by strong Kozak 
consensus sequence. The third nucleotide base (-3) before the start codon must be an 
alanine or guanine and the fourth nucleotide base (+4) after the start codon must be a 
guanine (Simkin et al 2008). 
-3           +4  -3             +4 
GCCATGG or ACCATGG 
Figure 5.1: Kozak scanning model for optimum translation where A is position one and ATG is 
the start codon (Simkin, Cavanaugh and Kim 2008). 
The ATI produces an isoform of TREK1 where the first 56 amino acids, found at the N-
terminal, are truncated because of the “leaky” scanning. This shorter isoform yields smaller 
currents when compared to the full-length gene and the shorter isoform loses its selective 
permeability to potassium as the reversal potential shows an increase in permeability to 
sodium. It has been noted that the shorter isoform is involved with depolarisation in rat 
hippocampal neurons (Thomas et al 2008).  
There are three TREK2 isoforms that can form: The “full length” protein is established when 
the first start codon is translated. The first start codon is a weak Kozak sequence as it 
flanked only by adequate sequence for translation. The full-length protein is created by 
mutating the second (M60) and third (M72) initiation sites to an isoleucine. This will force the 
first start codon to be translated even though it is weak site. The second protein that can 
arise is “intermediate length” as the first start codon is skipped and translation begins at the 
second codon site. The second site for initiation has a strong consensus sequence and 
therefore is routinely translated from methionine. The channel was truncated (1-56〉) and the 
third translation site is mutated (M72I). This will force translation is begin at M60. The third 
isoform is “short length” and is formed when both the first and second start codons are 
skipped. The third methionine is flanked by an “adequate” consensus sequence. This site is 
believed not to be a popular initiation site for translation due to the previous strong 
consensus sequence. The formation of the short ATI was created by truncation of the N-
terminus (1-63〉) which caused translation to begin at M72.The forced long form TREK2 
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isoform creates the small and large conductance channel while, the two shorter isoforms 
produces the large conductance channel only. TREK2 isoforms differs from the TREK1 
isoform as the reversal potential of potassium is unchanged from the TREK2 wildtype 
(Simkin et al 2008). 
These isoforms have shown to affect the drug sensitivity of ion channels. This has been 
shown in the case of both TREK1 and TREK2. It was seen that truncated isoforms of K2P 
were 2.6 -5-fold less sensitive to the drug carvedilol. It was speculated that the change in 
sensitivity could have been exhibited because of the increase in sodium permeability of the 
channel. However, this increase in sodium conductance is only seen in TREK1 and not 
TREK2. It is therefore indicated that the N-terminal is critical region for regulation of the 
channel (Kisselbach et al 2014; Veale et al 2014).  
5.3 Aim of this chapter 
The aim is to clarify the differences in the inhibition of TREK2 by lamotrigine and sipatrigine 
and to investigate the mechanism of TREK2 is regulated by these compounds. The 
mechanism of action of sipatrigine and lamotrigine on TREK2 will be investigated by site 











5.4 Sipatrigine inhibits TREK2 channels 
TREK2 currents were measured and absence of sipatrigine (100 µM) and showed inhibition 
of 85 ± 3% (n = 10). The reversal potential showed TREK2 at -92 ± 1 mV at control and then 
a significant but minor shift to 72 ± 4 mV in the presence of sipatrigine (n = 10). The TREK2 
WT current after sipatrigine wash off was significantly higher than the baseline current before 
the application of the drug. Sipatrigine at a concentration of 100 µM showed a large over 
recovery of current after inhibition (201 ± 28%, n = 7), (see Fig 5.2). The following shows a 
representation of general TREK2 WT currents (see Fig 5.2).    
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Figure 5.2: Sipatrigine (100 µM) inhibition of WT TREK2 channels. (A) Time-course plot of 
sipatrigine effect on TREK2. Points show current in the presence and absence of sipatrigine. 
(B) Trace of current at different voltages controlled by the protocol. Each trace is an average 
of five consecutive traces in the presence and absence of sipatrigine. (C) Current-voltage 
relationship of TREK2 obtained from the ramp voltage changes in the presence and absence 
of sipatrigine. (D) Average reversal potential of TREK2 current (n = 10). The reversal 




5. 5 Lamotrigine inhibits TREK2 channels 
TREK2 currents were measured and absence of lamotrigine (100 µM) and showed inhibition 
of 14 ± 3%, n = 10. The reversal potential showed TREK2 at -87 ± 2 mV at control and then 
a negligible shift to 87 ± 2 mV in the presence of lamotrigine (n = 10). The following shows a 
representation of general TREK2 WT currents (see Fig 5.2).    
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Figure 5.3: Lamotrigine (100 µM) inhibition of WT TREK2 channels. (A) Lamotrigine time 
course effect on TREK1. Points show current in the presence and absence of lamotrigine. 
(B) Trace of current at different voltages controlled by the protocol. Each trace is an average 
of five consecutive traces in the presence and absence of lamotrigine. (C) Current-voltage 
relationship of TRE2 using ramp voltage changes in the presence and absence of 
sipatrigine. (D) Average reversal potential of TREK2 current, in control and in lamotrigine (n 








5.6 TREK2 predicted norfluoxetine interaction site is 
also predicted as a sipatrigine interaction site 
It has been identified that norfluoxetine activity is reduced when TREK2 is mutated at site 
320. This site is found at the fenestration and is believed to be an important residue for 
norfluoxetine interaction. To examine whether this site is involved in sipatrigine inhibition, the 
residue was mutated from a leucine to an alanine.     
 
Figure 5.4: TREK2 structure highlighting mutated residue (red) 
 
The mutated TREK1 was produced and electrophysiology could therefore be carried out. 
TREK2 L320A showed inhibition at 67 ± 3% (n=9) in the presence of 100µM sipatrigine. The 
recovery of current after inhibition was 98 ± 13% (n=9). The results show that sipatrigine 
inhibition was significantly decreased when the channel was mutated at the site compared to 
the WT at 85 ± 3% (n = 10) (see Fig 5.5 -C). It must also be noted that the TREK2 L320A 
has a similar degree of inhibition to that for the homologues site found on TREK1 L289A (56 
± 7%, n=9). The following shows a representation of general TREK2 L320A currents (see 
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Figure 5.5: A) TREK2 L320A is the presence and absence of sipatrigine (100µM). B) TREK2 
L320A trace of current at different voltages controlled by the protocol. Each trace is an 
average of five consecutive traces in the presence and absence of sipatrigine. C) TREK2 
WT (n = 10) sipatrigine inhibition (100 µM) compared to TREK2 L320A (n = 9). D) TREK1 
L289A (n = 9) inhibition compared to the homogenous site on TREK2 (L320A) (n = 9) in the 










5.7 TREK2 over recovery of current 
Sipatrigine was used at concentrations of 100 µM and 30 µM to study its effects on TREK2 
WT current. TREK2 WT inhibition at 30 µM was 66 ± 4% (n = 11) and inhibition at 100 µM 
was 85 ± 3% (n = 10). It was noted however that at 100 µM, there was a large over recovery 
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Figure 5.6: The recovery of current after sipatrigine inhibition on TREK1, TREK2 and TRESK 
WT. The recovery of current was measured at a concentration of 3 µM (TREK1 n = 8 and 
TRESK n = 11), 10 µM (TREK1 n = 8 and TRESK n = 10), 30 µM (TREK1 n =10, TRESK n 
= 16 and TREK2 n = 11) and 100 µM (TREK1 n = 17, TRESK n =13 and TREK2 n = 7) 
Unpaired two-tailed Welch’s t-test was used for 3 µM and 10 µM. One-way ANOVA applying 
post hoc Tukey was used at 30 µM and 100 µM.  
It was therefore hypothesized that this over recovery after sipatrigine inhibition is caused 
because sipatrigine acts as a fast inhibitor and also a slower activator on TREK2. Therefore, 
I allowed TREK2 to be exposed to sipatrigine at 100 µM for a longer period of time to see if 
there is any slow activation. 
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Figure 5.7: TREK2 in the presence of sipatrigine (100 µM) after a longer exposure time. 
The results show that the duel action of the drug is there but is only exposed after the drug is 
washed out.  
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5.8 TREK2 isoforms generated by ATI change 
sipatrigine effect 
The first isoform created was the forced long form of TREK2 which did show over recovery 
of current. The forced long form TREK2 was inhibited by 78 ± 2% (n = 11) using 100 µM 
sipatrigine. There was also over recovery of current after inhibition (149 ± 16%, n = 8) The 
following shows a representation of general TREK2 isoform currents (see Fig 5.8).    
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Figure 5.8:  A) Forced long form TREK2 in the presence of sipatrigine (100 µM) and the over 
recovery in the wash off of sipatrigine. B) Trace of current at different voltages controlled by 
the protocol. Each trace is an average of five consecutive traces in the presence and 
absence of sipatrigine. 
The intermediate forced form of TREK2 showed inhibition at 70 ± 5 (n= 7). The current did 
show recovery after inhibition however it was not at the same magnitude of the forced long 
forced. The intermediate forced form showed recovery of current at 111 ± 12 (n= 5). The 
following shows a representation of general TREK2 isoform currents (see Fig 5.9).                                       
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Figure 5.9:  A) Forced intermediate- form TREK2 in the presence of sipatrigine (100 µM) and 
the recovery of current in the wash-off of sipatrigine. B) Trace of current at different voltages 
controlled by the protocol. Each trace is an average of five consecutive traces in the 
presence and absence of sipatrigine. 
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The forced short form of TREK2 was inhibited by sipatrigine by 51 ± 11 (n = 6) and the short 
form showed recovery of 115 ± 18 (n = 5) The following shows a representation of general 
TREK2 isoform currents (see Fig 5.10).   
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Figure 5.10: A) Forced short- form of TREK2 in the presence of sipatrigine (100 µM) and the 
recovery of current in the wash off. B) Trace of current at different voltages controlled by the 
protocol. Each trace is an average of five consecutive traces in the presence and absence of 
sipatrigine. 
 
To investigate whether the over recovery of current after sipatrigine inhibition is linked to the 
N-terminal, the current was measured in the presence of sipatrigine at a concentration of 
100 µM. The results showed that at the highest measured concentration, the over recovery 
was identified when the full-length N terminal is present (49 ± 15%, n = 8). The over 
recovery of TREK WT was 101 ± 28% (n = 7) which is considered to not significantly 
different to the full-length ATI. The results of the intermediate length showed an over 
recovery of 11 ± 13% (n = 5) and the short form showed an over recovery of 15 ± 18% (n = 
5). The two smaller isoforms were significantly different to TREK WT over recovery.  






















Figure 5.11: The measured over recovery of TREK2 WT (n = 7) and TREK2 long form (n = 
8), TREK2 intermediate form (n = 5) and TREK2 short form (n = 5) after inhibition of 
sipatrigine (100 µM). One-way ANOVA applying post hoc Dunnett’s method was used.    
When characterising the current of the isoforms of TREK2 it was found that the forced short 
form expressed a significantly lower current compared to the WT. The current density of WT 
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was 68 ± 9 pA/pF (n = 19), which is significantly greater than the forced short form (14 ± 3 
pA/pF, n= 8). The current density of forced long and intermediate isoform was very similar to 
WT TREK2. The current density of the forced long form is 64 ± 13 pA/pF (n = 15) and the 
intermediate is 76 ± 10 (n = 6).   



























Figure 5.12: The current density of TREK2 WT (n = 19), TREK2 long form (n = 15), TREK2 
intermediate form (n = 6) and TREK2 short form (n = 8). The current density of TREK2 WT 
versus TREK2 ATI isoforms. One-way ANOVA applying post hoc Dunnett’s method was 
used    
 
The results further show that TREK2 WT inhibition (85 ± 3%, n = 10) was significantly 
different to the forced short ATI isoform (51 ± 11%, n = 6). The long-forced form showed 
inhibition of 78 ± 2% (n = 11) and the intermediate forced form was inhibited by 70 ± 5% (n = 
7). The two longer ATI isoforms showed no significant difference to TREK2 WT.   


















Figure 5.13: TREK2 WT (n = 10), TREK2 long form (n = 11), TREK2 intermediate form (n = 7) 
and TREK2 short form (n = 6) inhibition by sipatrigine (100 µM). One-way ANOVA applying 






5.9 25 mM K+ solution effect on TREK2 with 
sipatrigine 
The resting basal current of forced short form TREK2 is significantly lower compared to 
TREK2 WT and the other two ATI isoforms (see Fig 5.10). The current was therefore 
measured in 2.5 mM K+ solution and then perfused 25 mM K+ solution to increase the 
current. Sipatrigine (100 µM) was made in 25 mM K+ solution. 
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Figure 5.14: Current density of TREK2 WT in 2.5mM K + solution compared to the same cell 
in 25mM K +solution (n = 5). Current density of forced short form TREK2 WT in 2.5mM K + 
solution compared to the same cell in 25mM K +solution (n = 7). Paired Student t-test was 
used. 
TREK2 WT showed that when the channel was exposed to 25 mM K+ solution, there is a 
significant increase in current (48 ± 9 pA/pF, n = 5) compared to the channel under 2.5 mM 
K+ solution (30 ± 6 pA/pF, n = 5). However, the forced short form TREK2 showed no 
significant difference in between the channels current 2.5mM K+ solution (9 ± 2 pA/pF, n = 7) 
compared to the same cells under 25mM K+ solution (11 ± 2 pA/pF, n = 7). This shows the 
importance of the N terminus in channel conductance. The following shows a representation 
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Figure 5.15: A) Current change due to external potassium concentration and inhibition caused 
by sipatrigine (100 µM) in TREK2 WT. B) Current change due to external potassium 
concentration and inhibition caused by sipatrigine (100 µM) in TREK2 short form. C) Trace 
of TREK2 WT current at different voltages controlled by the protocol. Each trace is an 
average of five consecutive traces. D) TREK2 short form current using the protocol to control 
the voltage. Each trace is an average of five consecutive traces. E) Sipatrigine inhibition 
(100 µM) in 25 mM K+ external solution on TREK2 WT (n = 6) and forced short form TREK2 
(n = 7). F) There was no significant difference in sipatrigine inhibition (100 µM) in 2.5 mM K+ 
external solution versus 25mM K+ solution on the same channel, however there is a 
significant difference between the degree of sipatrigine inhibition between TREK2 WT and 
forced short form TREK2. Unpaired two-tailed Welch’s t-test was used for 2.5 mM K+ 
solution and unpaired one-tailed Welch’s t-test was used for 25 mM K+ solution. 
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Sipatrigine in 25 mM K+ external solution produced an inhibition of TREK2 WT (69 ± 9%, n = 
6). The forced short form showed a significant change in the degree of inhibition by 
sipatrigine in 25 mM K+ solution compared to WT (47 ± 5, n = 7) (see Fig 5.14 A-B). The 
increase in extracellular potassium concentration did not have the desired effect of 
increasing the current from the forced short form of TREK2, as there was no significant 
increase in current from the channel (Fig 5.13). However, the results did show no significant 
difference between sipatrigine inhibition in 2.5mM K+ solution and 25mM K+ solution (see Fig 
5.14-F).  
It was also confirmed that increasing K+ in the extracellular solution did not change the effect 
of sipatrigine of the forced short form of TREK2. There was a little to no over recovery of 
current after sipatrigine inhibition by the forced short form TREK2 (18 ± 8%, n = 5). The over 
recovery of current after inhibition by TREK2 WT was measured at 132 ± 50% (n = 5). This 
shows the importance of the N-terminus in the role of inhibition by sipatrigine and in the over 
recovery of TREK2 current (see Fig 5.15).    






















Figure 5.16: Over recovery of current seen in TREK2 WT (n = 5) and TREK2 short form (n = 
5) after exposure to sipatrigine (100 µM). (One recording was excluded as it showed no 
recovery). One-tailed Welch’s t-test was used.  



















6.1 Cen-092-C  
Cen-092-C is a newly developed Na+ inhibitor which has been investigated in a multiple 
sclerosis (MS) study in an EAE (experimental autoimmune encephalomyelitis) model. 
Blocking sodium channels is important in treating MS as sodium accumulation will lead the 
excitability of neurons. This activity will contribute to axonal injury and will exacerbate the 
neurological disability (Yang et al 2015). Cen-092-C is derived from lamotrigine and 
therefore it can only be speculated what effects the compound has on K2P channels. The 
results show that EAE symptoms were significantly decreased in the cumulative disability 
scores in mice treated with Cen-092-C compared to the untreated rats (unpublished data 
from Leach).  
When investigating neurologic disorders such as MS, the endothelial cells of small brain 
vessels have become important as the dysfunctional of the blood-brain barrier is a common 
event (Mizee et al 2014). TREK1 is known to play a significant role in regulating 
inflammatory immune response as the channel regulates immune cell trafficking across the 
blood-brain barrier like in MS. It was shown that murine lymphocytes migrate with more ease 
in TREK1-/- endothelial cells compared to the wild-type cells (Wang et al 2012). In fact, it was 
found that in EAE mice model, there was a larger demyelination area and a higher number 
of infiltrating T cells in the CNS in TREK1-/- compared to TREK1 WT. These TREK1-/-  mice 
also saw the clinical phenotype worsen in the EAE model (Bittner et al 2013).  
TRESK channels have been shown to be expressed in rat thymus and spleen. Both tissues 
contain T and B - cells which shows that these channels are likely involved in immune 
response (Han and Kang 2009). It is also seen that TRESK-like K+ channels are functionally 
expressed in human leukemic T-cells and Jurkat cells. It was found that in Jurkat cells, 
TRESK current contributes to the K+ efflux which will lead to apoptosis (Pottosin et al 2008). 
Calcineurin is a critical part of pre- T-cell receptor signaling pathway and is also involved in 
TRESK activation. A high level of calcineurin is detected in leukemic cells and are important 
regulators of inducible gene expression. When T-cells are activated, binding and 
dephosphorylation of calcineurin to the docking site on TRESK will lead to an increase in 
TRESK current. This activation could induce the transcription of new genes as calcineurin-
NFAT signaling is critical of mediating cellular activation and the immune response (Bueno 
et al 2002). Furthermore, TRESK is activated by histamine, a mediator in local immune 
response. It is known that histamine induces NFAT- mediated transcription through the H1 
histamine receptor in human umbilical endothelial cells. The H1 histamine receptor is 
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involved in decreasing the helper T cell response in the immune system. Therefore, it is 
likely that TRESK is involved in regulating T-cell function (Han and Kang 2009). 
Cen-092-C is derived from lamotrigine and has a similar structure to sipatrigine. As this new 
compound is closely related to lamotrigine, it would be interesting to find if the same degree 
of inhibition occurs on each K2P channel and how this may affect CNS disorders like MS, 
pain, depression and neuroprotection.  
6.2 Aim of the chapter 
The effect of Cen-092-C on K2P channels is unknown. Therefore, I investigated the effect of 
Cen-092-C on TREK1 and TRESK. This study will aim to see if the compound is an effective 
antagonist and understand which mechanism the drug takes on to inhibit the channels using 

















6.3 Cen-092-C inhibition of TRESK current 
Cen-092-C at a concentration of 100 µM inhibited TRESK by 42.7 ± 5%, n = 9. Results 
carried out at 30 µM showed inhibition at a degree of 31 ± 5%, n = 10. The following shows a 
representation of general TRESK WT currents (see Fig 6.1).         
A)        B) 
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Figure 6.1: A) The inhibition of TRESK WT in the presence and absence of 100 µM of Cen-
092-C. B) The inhibition of TRESK WT at two different concentrations (30 µM, n = 10 and 
100 µM, n = 9). Paired Student t-test was used.  
The results show a significantly lower inhibition rate in comparison to sipatrigine (100 µM), 
whilst there was no change in the degree of inhibition when compared to lamotrigine (100 
µM). The results also show little to no change in reversal potential. The evidence shows that 
inhibition is a direct effect of the compound as the double mutated phenylalanine showed a 
significant decrease in inhibition. This suggests that Cen-092-C may bind to the central 
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Figure 6.2: A) Inhibitory effect of Cen-092-C (n = 9), sipatrigine (n = 16) and lamotrigine (n = 
8) (each at a concentration of 100 µM) on TRESK WT. The inhibitory effect of sipatrigine on 
TRESK WT versus the inhibitory effect of lamotrigine and Cen-092-C on TRESK. One- way 
ANOVA applying post hoc Tukey test was used. B) Reversal potential of TRESK WT in the 
presence of Cen-092-C. C) Average reversal potential of TRESK WT with Cen-092-C (100 
µM) (n = 9). D) The introduction of alanines at residues F145 and F352 (n = 6) showed a 
reduction of Cen-092-C inhibition compared to WT (n = 9). The inhibitory effect of Cen-092-
C on TRESK WT versus TRESK FF. Paired Student t-test was used(C). Unpaired two-tailed 









6.4 Is Cen-092-C inhibition on TRESK state dependent? 
It has already been shown that the phosphorylation state of TRESK effects the degree of 
lamotrigine inhibition. Therefore it would be interesting to see the structurally similar Cen-
092-C acts in a similar way (se Fig 4.8). To investigate whether the state of TRESK channel 
affects the degree of inhibition of Cen-092-C, TRESK was mutated to force a 
phosphorylation state. The new compound Cen-092-C inhibited TRESK WT at a degree of 
42.8 ± 5% (n = 9). The two states showed no difference of inhibition compared to the WT 
(TRESK AA inhibition 49 ± 7%, n = 6 and TRESK EE inhibition 45 ± 4%, n = 8). 















Figure 6.3: Cen-092-C (100 µM) inhibition of TRESK WT (n = 9), TRESK AA (n = 6) and 











6.5 Cen-092-C inhibition on TREK1 
Cen-092-C selectivity was investigated by looking at another K2P channel. TRESK share 
about 20% of its sequence with TREK1 (Dobler et al 2007). It was found, however, that 
inhibition of TREK1 by Cen-092-C (30 µM) shows little to no inhibition. There were three 
recordings which showed a high degree of inhibition though these points are believed to be 
outliners as the majority of recordings showed limited effect on current in the presence of 30 
µM Cen-092-C. The inhibition by Cen-092-C at a concentration at 100 µM was 21.4 ± 4% (n 
= 9), which was significantly lower than inhibition of TRESK at the same concentration. The 
inhibitory effect of Cen-092-C on TREK1 was similar to that seen in lamotrigine inhibition at 
the largest concentration. 
A)                        B) 
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Figure 6.4: A) The degree of inhibition of Cen-092-C with a concentration of 10 µM (n = 5), 30 
µM (n = 10) and 100 µM (n = 9) on TREK1 current. B) Comparison between TRESK WT (n = 
9) and TREK1 WT (n = 9) inhibition in the presence of Cen-092-C (100 µM). C) Inhibitory 
effect of sipatrigine (n = 19), lamotrigine (n = 6), and Cen-092-C (n = 9) (each at a 
concentration of 100 µM) on TREK1 WT current. Unpaired two-tailed Welch’s t-test was 























7.1 Lamotrigine modulates TREK1, TREK2 and TRESK 
Lamotrigine has been shown to inhibit TREK1 (30 ± 6%), TREK2 (14 ± 3%) and TRESK (35 
± 5%) at a concentration of 100 µM (see Fig 7.1). This concentration has been shown to 
have analgesic effects using tail-flick test and is known to induce analgesia in neuropathic 
pain models (Saberi and Chavooshi 2009). Lamotrigine inhibits TREK1 current to a similar 
degree to TRESK current, while inhibition of TREK2 current by lamotrigine was significantly 
different to TREK1 and TRESK current inhibition. Lamotrigine has been described to have 
little or no effect on TREK1 and TREK2 current (Meadows et al 2001; Kang et al 2008).  In 
fact, lamotrigine has been used to identify TRESK channels and distinguish it from other 
channels (Liu et al 2014; Guo and Cao 2014). The previous study used 30 µM on TREK2 
channels and it was then concluded that lamotrigine had no effect on that channel and only 
TRESK is lamotrigine-sensitive (Kang et al 2008). Lamotrigine (10 µM) was found to 
produce little to no inhibition of TREK1 current expressed in HEK293 cells (Meadows et al 
2001). However, my results show that lamotrigine inhibits both TREK1 (30 ± 6%) and 
TREK2 (14 ± 3%), with TREK1 current inhibiting to a similar degree to TRESK (35 ± 5%) at 
a concentration of 100 µM. It can therefore be concluded that lamotrigine does inhibit both 
TREK1 and TREK2 to some degree. Lamotrigine has also been shown to inhibit glutamate-
induced TRESK activation. Kang et al 2008 used the inside-out patch configuration to 
demonstrate that lamotrigine inhibition is a direct action on TRESK. Lamotrigine was 
originally believed to inhibit only TRESK and so it was claimed to be regulated through a 
pathway selective for TRESK channels by the blockage of calcium influx (Kang et al 2008). 
The results here outline that lamotrigine does inhibit TRESK current (35 ± 5%), however, 
lamotrigine also inhibits TREK1 (30 ± 6%) and TREK2 (14 ± 3%) which shares only 20% of 
TRESK sequence (Dobler et al 2007) and so, lamotrigine cannot be regarded as a selective 
inhibitor of TRESK channels.   



















Figure 7.1: Lamotrigine (100 µM) inhibition of TREK1 WT (n=6), TREK2 WT (n = 10) and 
TRESK (n=8). One-way ANOVA post hoc Tukey test was used. 
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7.2 Sipatrigine is a potent inhibitor of TREK1, TREK2 
and TRESK 
The results show that TREK1 and TREK2, and to a lesser extent TRESK current, were 
effectively inhibited by the neuroprotective agent, sipatrigine. Sipatrigine had not been 
studied on TRESK previously and has now been shown to be a potent inhibitor. The rapid 
inhibition and reversible action of sipatrigine could suggest direct action on the channel by 
binding to TREK1, TREK2 and TRESK. Sipatrigine at a concentration of 3 µM inhibited 
TREK1 current by 26.8 ± 3.8% (n = 8) which is significantly different to TRESK current 
inhibition at the same concentration (11 ± 3%, n = 11). Sipatrigine (10 µM) inhibition also 
shows significant difference between TREK1 current (40 ± 5%, n = 10) and TRESK current 
(25 ± 4%, n = 11). 30 µM of sipatrigine produced TRESK current inhibition (46 ± 3%, n = 19) 
which was shown to be similar to TREK1 current inhibition of 56 ± 5% (n = 13). However, 
TRESK inhibition was significantly different to TREK2 current inhibition (66 ± 5%, n = 11). 
Sipatrigine (100 µM) has been seen to inhibit TRESK current by 73 ± 3% (n = 16) while 
TRESK current inhibition, was shown to be significantly different to both TREK1 (87 ± 2%, n 
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Figure 7.2: Sipatrigine inhibition of TREK1, TREK2 and TRESK WT at concentrations of 3 
µM, 10 µM, 30 µM and 100 µM. Unpaired two-tailed Welch’s t-test and one-way ANOVA 
post hoc Tukey test were used. 
 
Sipatrigine has also been found to inhibit both sodium and calcium channels. The 
antagonism of both sodium and calcium channels results in attenuation of glutamate release. 
The inhibitory effect on Na+ channel is believed to result in neuroprotection through the down 
regulation of action potential firing and glutamate release (Hainsworth et al 2000). The 
inhibition of presynaptic calcium channels by sipatrigine also affects the glutamate release. 
Therefore, presynaptic calcium channel antagonism is important for neuroprotection 
(McNaughton et al 1997).  Previous in vitro studies of CNS white matter ischaemia have 
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shown that complete protection was seen at a concentration of 100 µM (Garthwaite et al 
1999); a concentration which has been demonstrated in this study to show potent inhibition 
of all three channels. Therefore it must be investigated further what TREK1, TREK2 and 
TRESK inhibition, at a concentration known to be effective, means for neuroprotection and 
analgesia. 
 
7.3 Central cavity binding sites 
Voltage-gated ion channel inhibitiors have been shown bind at the central cavity which 
implies a lack of specificity at this site (Marzian et al 2013). Tetraethylammonium (TEA) is a 
selective voltage-selective K+ channel blocker. TEA has been shown to block potassium 
channel KcsA current by altering the potassium ion occupancy through binding within the ion 
conduction pathway in the selectivity filter. TEA is believed to bind to the potassium channel 
at dehydration transition sites insuring a blockade of potassium ions (Lenaeus et al 2005). 
Similarly, fatty acids are shown to bind with KcsA on the hydrophobic lining of the central 
cavity therefore blocking current (Smithers et al 2012). 4-Aminopyridine (4AP) is another 
“classic” K channel blocker, which is known to interact with the central cavity of KcsA 
channels. 4AP enters the channel from the cytoplasmic side and will promote a closed 
conformation (Armstrong and Loboda 2001). The central cavity has also been shown to be 
imperative in the binding of drugs in K2P channels. The TASK1 blocker A1899 binds on the 
selectivity filter at residues T93 and T199 on the M2 and the M4 segment of the channel. 
This region is lined with hydrophobic amino acids which can therefore provide a potential 
binding surface for small hydrophobic molecules. The hydrophobic lining also allows for 
rapid movement of K+ ions through the cavity. Alanine scanning mutagenesis abolished any 
inhibition of current which determined the importance of these residues. These threonine 
residues are conserved in K2P channels and have been indicated in binding studies of 
various K channels inhibitors (Streit 2011; Piechotta et al. 2011; Schewe et al 2016; 
Viswanath et al 2016). K2P channel activation also involves the central pore as mutations of 
threonine close the selectivity filter abolishes activation of TRAAK by AA and PIP2 (Schewe 
et al 2016). Further evidence of the importance of the central pore cavity as a binding site in 
K2P channels was found through the in-silico investigation of TREK1 antagonists. The in-
silico experiments found that L289 is an important site for binding as it made strong binding 
interactions with the aliphatic chains of quaternary ammonium blocker compound (QAs) 
(Viswanath et al 2016). Docking of norfluoxetine to TREK2 again shows strong evidence that 
binding to the equivalent residue, L320, is important in regulation of the current (Dong et al 
2015). Therefore, the docking of the potent antagonist sipatrigine at the central cavity of 
TREK2 is in line with these studies. The key residue, L289 in TREK1 and L320 in TREK2, 
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were substituted to an alanine and a significant reduction in sipatrigine inhibition was 
observed. These results support the proposition that sipatrigine binds to this residue found in 
TREK1 and TREK2.  The same mutated site in TREK1 (L289A) showed no change in the 
degree of lamotrigine inhibition. It could therefore be proposed that lamotrigine has no 
interaction with this site. This could be why lamotrigine shows a significantly lower degree of 
inhibition compared to sipatrigine, even though sipatrigine is derived from lamotrigine. It is 
therefore proposed that the two compounds act on different sites of the channel.  
The in-silico study also showed T142 and T251, found close to the selectivity filter, as 
important sites in channel inhibition (Viswanath et al 2016).  However, when these threonine 
residues were mutated to alanine, there was no significant change in the degree of inhibition 
of sipatrigine. Therefore, these sites are not involved in TREK1 sipatrigine sensitivity, even 
though these residues are important for other regulators of TREK channel activity.  
A)                                           B) 
                          
Figure 7.3: TREK1 (4TWK) illustrates sites investigated for sipatrigine and lamotrigine 
binding. The fenestration site L289 is labelled magenta. The two threonine sites at the pore 
are also highlighted. T142 is labelled in red and T251 is labelled in blue.   
 
Furthermore, a very recent study investigating K2P activation has shown that TREK1 
mutation of lysine 271 on the TM4 results in the reversal of ML335 and ML402 activation. 
The equivalent residue in TRAAK (Q258K) was also found to decrease activation by ML335 
and ML402. This mutation also showed to not change the effects of other activators such as 
arachidonic acid, BL1249 and ML67-33. To further analyse the cation-ヾ interaction with 
ML335 the aliphatic ring was put in place of the original aromatic upper ring called ML335a. 
It was found that this new compound had no effect on TREK1 which shows that K271 cation-
ヾ interaction with the C-type gate is important for ML335 and ML402 selectivity and 
essential for current activation (Lolicato et al 2017). This site could also be of interest in 




7.4 Dynamic structural changes involving 
fenestrations in K2P channels 
The structural gating changes in K2P channels have been frequently investigated in recent 
times, however there have been some conflicting evidence about the conformational 
changes. A new TRAAK model proposed activation as a tilting with a straight M4 
transmembrane helix to reveal the fenestrations. This new conformational change in 
structure causes the channel to stabilise and lead to channel activation (Lolicato et al 2014). 
This conflicts with the idea that K2P channels activation is caused by a shift from the down to 
the up state (Brohawn, Campbell and MacKinnon 2014; Dong et al 2015). Consequently, it 
was questioned if structural activation in K2P channels are two-state changes or something 
more complex. The solution to this problem is the knowledge that activation of the upper 
selectivity filter gate, can be independent from the conformation of the channel. It was found 
that when the gain-of-function (GOF) mutations near the selectivity filter (G167I and W306S) 
were introduced into TREK2 sequence, there were no change in norfluoxetine inhibition. 
This is interesting as norfluoxetine is a state dependent inhibitor whose binding sites can 
only be found in the non-conductive down state and the GOF mutation should have 
abolished this site. This would then indicate that norfluoxetine binding sites still exist and that 
structural changes did not occur with the GOF. This may explain the new TRAAK model as 
activation can be independent from conformation change (McClenaghan et al 2016). TREK1 
GOF mutations have also shown changes in the inhibitory effect of compounds. TREK1 C 
terminal GOF mutation showed a reduction in fluoxetine inhibition. This is believed to be due 
to the E306A mutation causing the channel to couple to the membrane bilayer which is 
therefore more likely to enter the open-up state resulting in the reduced fluoxetine inhibitory 
effect (Kennard et al 2005). This is similar to results seen in TREK2 GOF as the mutation in 
the middle of the TM4 helix (Y315A) shows a dramatic reduction in norfluoxetine inhibition. 
Hence when the channel enters the open-up state, norfluoxetine exhibits a reduction in 
sensitivity as a result of the changing state of the fenestration binding sites (McClenaghan et 
al 2016). The reduced effect of sipatrigine seen in TREK1 E306A could therefore illustrate 
that the binding of the C terminus to the plasma membrane, does affect the fenestration 
sites. The other fenestration site (TREK2 F316) may be interesting when investigating 
further interaction sites. All results then show that structural changes at the TM4 are 






7.5 Access to TREK through fenestrations   
Fenestrations sites are common in K+ channels and have thought to be used by drugs to 
access the central cavity of the channel. As aforementioned, fatty acids inhibit KcsA at the 
central cavity, as the tetrabutylammonium (TBA) ion will displace the blocker and bind itself 
to the central cavity. To characterise the binding of fatty acid, 11-dansylaminoundecanoic 
acid (Dauda) was used as a fluorescence probe. The rapid block of Dauda compared to the 
slower TBA inhibition suggested that TBA needed an open channel to enter the central 
cavity. Dauda, however, did not require the channel to be open for binding to occur. This 
implication lead to the idea that fatty acid can bind to the closed KcsA channel via the 
fenestrations connecting to the lipid bilayer (Smithers et al 2012). This apparent drug access 
to the central cavity through the fenestrations has also been identified in voltage-gated 
sodium channels. Small neutral or hydrophobic drugs (for example phenytoin and 
benozocaine) were found to gain access through the passages when the channel was 
closed (Payandeh et al 2011). To investigate fenestrations drug access in K2P, the 
“bottleneck radius” of the cavity was measured. In TWIK1, the fenestrations increased its 
bottleneck radius as lipid membrane molecules entered into the opening. Thus, it is believed 
that this connection could be used as a drug pathway to the pore.  
This is interesting as the TREK2 fenestration sequence, including L320 and L316, is 
conserved in TWIK1 and therefore it was concluded that K2P channels could interact with 
drugs that access via fenestrations (Jorgensen et al 2016). However, after all this evidence it 
must still be added that the intracellular gate in K2P channels remains permanently open 
(Piechotta et al 2011). This would mean that drug entrance via the fenestrations is not 
essential. Moreover, there has been evidence that direct block of the conductive pathway by 
lipid through the fenestrations does not demonstrate the full mechanism of mechanogating in 
TREK2 channel. The principal action involving membrane stretch involves ion occupancy in 
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Figure 7.4: TREK2 states which show fenestrations being formed. A) TREK2 (4BW5) shows 
the fenestration residues (magenta) in the “upstate”. B) TREK2 (4XDJ) in the “downstate” 
state which will lead to fenestration forming as the residues shift. 
 
7.6 Sipatrigine has a biphasic effect on TREK2 current 
The results showed that sipatrigine potently inhibits TREK2 with the effect also being 
reversible. The over-recovery of current followed withdrawal of sipatrigine at a concentration 
of 100 µM. TREK2 current after sipatrigine wash off was significantly higher than the 
baseline current before the application of the drug. TREK2 current significantly over 
recovered current by 101 ± 28% during washout following application of sipatrigine (100 
µM),  
There has been some evidence of dual effects of drugs on ion channels. Riluzole is a known 
activator of TREK1 and TRAAK and is used as a treatment for amyotrophic lateral sclerosis 
as it is an anticonvulsant. TRAAK shows a sustained level of activation however TREK2 
activation is transient and is followed by inhibition. This inhibition is believed to be caused by 
riluzole increasing intracellular cAMP concentration. This is followed by a protein kinase A 
(PKA)-dependent decrease in current as PKA will phosphorylate TREK2 at serine 334 and 
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352 at C terminus. This biphasic effect is not seen in TRAAK is not regulated by cAMP 
(Duprat et al 2000). Amitriptyline is a tricyclic antidepressant (TCA) which shows a dual 
effect on epithelia Na+ channel. Amitriptyline is shown to increase current at 0.1 – 50 µM 
concentrations and inhibits the current at higher concentrations (Pena et al 2002). Most 
notably however is that sipatrigine (10 µM) showed a short lived over recovery of TREK1 
current after the initial inhibition (Meadows et al 2001). Therefore, it was thought that 
sipatrigine at high concentrations could have a biphasic effect on TREK2 current. The over 
recovery of current is rapid and is therefore thought to occur because of a direct action on 
the channel. This indicates a difference in the time course of the two competing drug effects 
of TREK2. The inhibition of current counteracts the underlying activation effect of the drug. 
Fig 5.2-A shows a slight enhancement of current when sipatrigine was initially introduced 
which may again show the underling activation. The experiments which used a longer 
exposure time of sipatrigine (100 µM) showed long lasting inhibition of TREK2 current which 
will lead to enhanced over recovery of current which appears after sipatrigine was washed 
off (see Fig 5.7). It is only through the action of wash-off of sipatrigine at a high concentration 
(100 µM) that the over recovery of current is exposed. The observed over recovery of 
TREK2 current after sipatrigine withdrawal does suggest an activation effect of the drug.  
 
7.7 N-terminus is important in over-recovery of TREK2 
current following sipatrigine  
 
It is evident that sipatrigine is a potent inhibitor of TREK2 and exhibits an over-recovery of 
current after wash-off of compound at a high concentration (100 µM). Our initial studies 
established that sipatrigine had a biphasic effect on TREK2 and so the structure of the 
channel was investigated further.   
It has been shown that the N terminus plays a role in the overall sensitivity of the channels to 
various stimuli. It was demonstrated that the short form TREK1 (〉N52) showed less 
sensitivity to fluoxetine inhibition. This indicates that the N terminus of TREK1 is involved in 
regulation of the channel (Eckert et al 2011). In addition to blockers of TREK1, the short 
isoform showed to enhance activity of fenamates all while showing reduced K+ selectivity 
(Veale et al 2014). The truncated form of TREK1 similarly lost its sensitivity to the inhibitor 
carvedilol. In fact, carvedilol inhibition of full length TREK2 was significantly greater 
compared to the intermediate and short form TREK2 inhibition (Kisselbach et al 2014). This 
is similar to the results seen with sipatrigine (100 µM) and TREK2. The shorter, truncated 
form showed significantly less sensitivity to sipatrigine compared to TREK2 WT. This 
illustrates the fact that the distal half of the N terminus is necessary to promote full inhibition 
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of TREK2 by sipatrigine. The reduced inhibition seen in the short isoform of TREK1 is 
believed to be connected to the channels newly found Na+ selectivity of the channel pore. 
This cannot be said for TREK2 as this channel does not shift the Na+ conductance 
(Kisselbach et al 2014). It must be noted however that the truncation may alter the channel 
gating rather than disrupting the compound binding to the channel.  
In addition to the decrease in sipatrigine inhibition, TREK2 ATI isoforms also shows a 
change in the over- recovery of current. The results demonstrate that there is little to no over 
recovery of current in the forced short form and the intermediate form of TREK2. The over-
recovery of current seen in the full length TREK2 would suggest that the N- terminal domain 
is important for the over-recovery of current. A previous study had shown a short lived over 
recovery of TREK1 current when sipatrigine was washed off. TREK1 channel used in this 
experiment had the long form N terminus. This may indicate the importance of the N 
terminus not only in TREK2 but also TREK1 current over-recovery after wash off (Meadows 
et al 2001). Furthermore, TREK1 current will also spontaneously increase after several 
minutes the whole cell configuration i.e. run-up of channel current. To investigate this 
occurrence, the intercellular proteins which interact with TREK1 were studied. TREK1 is 
known to interact with the adaptor protein ezrin-radixin-moesin (ERM)-binding 
phosphoprotein 50 (EBP50) which is known to bind ion channels and stabilise the structure 
of proteins. EBP50 is colocalised with ezrin, a membrane-organising protein. The interaction 
of TREK1 with EBP50 is involved in the translocation and formation of actin and ezrin 
membrane protrusions. TREK1 N terminus has shown to be an important region in the 
interaction with EBP50. An inhibitor of ezrin decreased the upturn of TREK1 current and the 
surface expression of TREK1 channel. Therefore, it could be theorised that the N terminus of 
TREK1 and its interaction with ezrin is important to stabilise the channel to the membrane 
(Andharia et al 2017). Therefore truncating the N terminus could influence the effects of 
sipatrigine on TREK2 current. The over recovery of TREK2 current seen here by sipatrigine 
(100 µM) could involve the N terminus binding to the plasma membrane. A channel with a 
truncated N terminus lacks this binding and loses the over recovery effect.  
The initial studies of TREK2 ATI has shown that the N terminal controls the conductance 
phenotypes. TREK2 isoforms are expressed in a variety of different regions including the 
brain, heart, pancreas, and kidney (Staudacher et al 2011). It was shown using single 
channel electrophysiology, that the full length TREK2 produces the small and large 
conductance, while the intermediate and the short form results in large conductance (Simkin 
et al 2008). This contrasts with my results where it is the short form TREK2 which produces 
significantly smaller conductance compared to the intermediate and long form (albeit when 
measuring the whole cell current through many channels simultaneously). In fact, increasing 
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the extracellular potassium concentration could not significantly enhance the resting current. 
This is more in line with TREK1 ATI isoforms where the short isoforms express smaller 
currents.  
It was discussed that the N terminal could regulate TREK2 at the proximal part near the start 
of TM1 where there is a predicted short g-helix. In deletion experiments, if this part is 
excluded there is a large change in the conductance. It was thought that this region may 
interact with other, parts of the channel that may affect the function. It could also function in 
a similar manner to the C terminal by binding to the plasma membrane and influencing the 
channel conductance (Simkin et al 2008). All of this taken together shows insight into the 
mechanism of TREK2 and the major influence of the N terminal in current recovery. 
7.8 Influence of TRESK central cavity  
The identification of the two residues facing the cavity, F145 and F352, has been important 
in investigating channel regulation. The results here show that the current density of the 
double mutation TRESK F156A, F364A channel is significantly higher compared to wildtype 
TRESK current density. A recent study has also found that after injecting TRESK F156A, 
F364A cRNA into oocytes, the current was five time higher compared to wildtype TRESK. 
This showed that the double mutation converts the TRESK channel into a more active state 
(Lengyel et al 2017).  Mutating these sites has been shown to reduce the inhibition effect of 
TRESK blockers quine, propafenone, lidocaine and loratadine (Kim et al 2013; Bruner et al 
2014). Through a structure-activity relationship (SAR) model, these sites are also believed to 
be involved to the regulation of activators flufenamic acid (FFA) and BL-1249 (Monteillier et 
al 2016). However, the failure of activators ionomycin and cloxyquin shows that these sites 
may not be binding sites for compound activators, but rather that the TRESK channel is in a 
constitutively active state (Lengyel et al 2017). Docking studies showed that F145 and F352 
function in a similar way to TREK2 fenestrations. The bulky phenylalanine faces into the 
pore, which is similar the fenestration sites in the down state. Further evaluation of channel 
binding, found that amine linkers of FFA and BL-1249 form hydrogen bonds with backbone 
oxygen of L321 in the pore loop. Additionally, a hydrogen bond forms between BL-1249 and 
the side chain of T323. It is therefore thought that activators of TRESK stabilise the open 
state by pushing the transmembrane domains TM2, TM3 and TM4. The blockers described 
in this study showed binding to F130, F487 and F490. This binding is a result of ヾ-ヾ 
interactions and causes TM4 and TM2 domains to shift closer together. This shows that 
these sites are not be important in binding activators and that the reduction in activation is a 
result of the channel being in an activated state (Monteillier et al 2016). Benzocaine, a local 
anaesthetic, is an inhibitor of TRESK WT, however it has been found to be more potent in 
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the calcineurin activated TRESK channel. Furthermore, benzocaine efficiently inhibited 
mouse TRESK F156A, F364A current, which may show that the channel is in the active 
state (Lengyel et al 2017).  It must therefore be investigated whether the double human 
TRESK F145/F352 alanine mutation simply alters the channel pore and therefore the 
channel state. The inhibition is abolished in sipatrigine, lamotrigine and Cen-092-C when the 
double mutation is added to the TRESK channel. This change in degree of inhibition could 
be due to a direct effect of the binding sites of the compounds or that the change at the pore 
could alter the channel gating structure. However, it has been shown with benzocaine 
inhibition of the double mutation showed that the gate was functional. The benzocaine 
results could show that the TRESK channel is in a more fixed active state which halts the 
effects of compounds. Further investigation is needed to conclude if the phenylalanine is 
important in compound binding or if the new active state affects the channel in other ways.    
  
7.9 TRESK phosphorylation state influences 
lamotrigine but not sipatrigine sensitivity 
 
As previously discussed, TRESK channels have been shown to be directly regulated by 
intracellular calcium through activation of calmodulin-dependent phosphatase calcineurin 
(CaN). CaN dephosphorylates the TRESK channel which leads to enhanced current. Under 
resting conditions, TRESK is phosphorylated. It was investigated whether the inhibition of 
TRESK channels by sipatrigine, lamotrigine and Cen-092-C are dependent on the 
phosphorylation state of the channel or whether inhibition is mediated by phosphatase 
activity. It was found that sipatrigine and the structurally similar Cen-092-C are not reliant on 
the dephosphorylated pathways, as changes made in TRESK phosphorylation state caused 
no change in the degree of inhibition. However, it was found that lamotrigine showed a 
significant increase in inhibition in the permanently “dephosphorylated” form of the channel 
(S352A/ S264A). A similar result was seen in the inhibition of mouse TRESK current by 
benzocaine. Benzocaine inhibition is more sensitive when TRESK is constitutively active 
state. It was discussed here that the compound which acts this way could be used to identify 
which phosphorylation state the TRESK channel is in (Czirják and Enyedi 2006). This 
illustrates that lamotrigine distinguishes activated TRESK channel from the resting channel 






7.10 Cen-092-C inhibition on TREK and TRESK current   
Cen-09-C has been shown to reduce MS symptoms in EAE models (unpublished data from 
Leach). TREK1 and TRESK channels are thought to serve as a potential target for immune 
dysfunction. TREK1-/- resulted in higher EAE severity score. Spadin, a TREK1 inhibitor, 
significantly worsened the course of EAE in WT mice, while activation of TREK1 by riluzole 
showed to attenuate the clinical symptoms. (Bittner et al 2013). TRESK channels are highly 
expressed in human leukemic T-lymphocytes. TRESK channels have the salient feature of 
being activated by calcineurin binding at the PQIIIS -site. NFAT in T cells will induce 
calcineurin, which will bind and activate TRESK. NFAT will translocate into the nucleus and 
will initiate transcription of new genes as well as regulating T-cell immune function. 
Immunosuppressants such as cyclosporine A and FK506 are known calcineurin inhibitors 
which will inhibit TRESK current. These immunosuppressants function to suppress activation 
of NFAT by halting the formation of immunophilin proteins. This suggests that that TRESK 
could regulate the immune system through its link to T-cells. When the T-cells are activated, 
TRESK channels will become dephosphorylated by the binding of calcineurin and will 
regulate transcription and T-cell function (Han and Kang 2009).  
Cen-092-C (100 µM) inhibition of TRESK was 43 ± 5%. Lamotrigine is structurally similar to 
Cen-09-C and the degree of inhibition is also similar on TRESK at this concentration (Fig 
1.15). This inhibition is seen as a direct effect on the channel as the double mutation shows 
a significant reduction in current inhibition. Cen-092-C did not show state dependent TRESK 
inhibition, which differs from lamotrigine. Cen-092-C (30 µM) was also tested on TRESK 
which show the degree of inhibition at 31 ± 5%. TREK1 effect with Cen-092-C was also 
tested at a concentration of 30 µM and 10 µM. However, it was found that these 
concentrations showed minimal inhibition. TREK1 was shown to have a more steady degree 
of inhibition at a concentration of 100 µM (21 ± 4%). TREK1 showed comparable inhibition 
under Cen-092-C and lamotrigine at a concentration of 100 µM. These results taken 
together show that this new compound is more effective on TRESK than on TREK1. This is 
similar to results seen with lamotrigine. Cen-09-C was developed to target multiple sclerosis 
and has been shown to be a potent sodium channel blocker. However, the inhibition of 






7.11 Therapeutic implications of regulating TREK and 
TRESK channels 
7.11.1 TREK and TRESK channels are modulated by 
antidepressants 
There is significant research which suggests that TREK1 is involved in depression and 
response to antidepressants. Antidepressants such as serotonin selective reuptake inhibitor 
(SSRI), work by inhibiting the serotonin transporter (SERT) allowing for an increase of 
serotonin concentration in the system. It has also been shown that SSRIs block TREK1, 
leading to downregulation of the presynaptic serotonin 1A (5HT1A) receptors. The 
desensitization of the receptor leads to an increase in postsynaptic serotonin 1A receptors 
activity through increasing serotonin levels. Furthermore, a development in TREK1 specific 
antagonist found a new antidepressant named spadin. It was also found that spadin 
increase the release of serotonin. However, the effect of spadin as an antidepressant was 
reduced in TREK1-/- mice. This shows that the spadin effect and the increase in serotonin 
release is controlled by the TREK1 current inhibition (Mazella et al 2010). However, the 
TREK1 knockout also showed a decrease in corticosterone in stress. This effect cannot be 
linked to an increase in serotonin. This shows that the TREK1-/- anti-depressant effect is not 
solely linked to serotonin. This could lead to a multi drug target treatment for depression 
using a combination of a TREK1 antagonist with SSRIs (Heurteaux, C., et al 2006). 
Several antidepressants are known to inhibit TREK and TRESK channels including 
amitriptyline, citalopram and fluoxetine.  This is similar to results seen with lamotrigine and 
sipatrigine. Lamotrigine is already used in patients with depression linked to bipolar disorder 
and has reportedly been used in treatment for patients were there is resistance to first line 
antidepressants. Therefore, the structurally similar sipatrigine could also be a useful for 
depression treatment as it is a more potent TREK1 and TRESK antagonist. Thus, is could be 
a more effective agent for depression than lamotrigine (Tsai 2008). 
TRESK channels are inhibited by protein kinase A and activated by protein kinase C, 
however TRESK channels are not regulated by cAMP at all (Czirják et al 2004). TRESK 
channels are therefore not thought to have any connection to serotonin or depression, 
however TRESK current is known to be inhibited by antidepressants amitriptyline, bupropion 
and fluoxetine. Opposing effects can be seen in TRESK and TREK2 as the channels hold 
different action with exposed to the antidepressant bupropion. Bupropion inhibits the 
reuptake of norepinephrine and dopamine and has been found to relief for neuropathic pain. 
The compound inhibits TRESK current but has little effect on TREK2. Further studies are 
needed to account for antidepressants as analgesics and how inhibition of TREK and 
132 
 
TRESK current lead to alleviating pain. This analgesic effect could be connected to 
activation of inhibitory interneurons resulting in the reduction of pain transmission. However, 
it must be stated again that there is no known of expression of TREK2 and TRESK in 
inhibitory interneurons (Park et al 2016). In conclusion, these antidepressants have been 
shown to have analgesic effects and therefore could be important in pain relief rather than 
just depression. 
 
7.11.2 TREK1 inhibition linked to neuroprotection  
TREK1 is known to be closely related to pathophysiological conditions such as cerebral 
ischemia and has been shown to be influential in neuroprotection. The mechanism of 
neuroprotection action is thought to be through activation of K2P channels which will prevent 
enhancement of neuronal signalling (Pollema-Mays et al 2013).  This is clear when you 
consider that PUFA will induce neuronal protection linked to TREK1 activation (Heurteaux 
2007). TREK1-/- are also more sensitive to ischemia and epilepsy (Heurteaux et al 2004). It 
must also be noted, however, that TREK1 channel expression is upregulation in the DRG of 
neuropathic pain model. TREK1 was also shown to be higher colocalization with IB4+ 
compared to IB4- which shows that expression is higher in nociceptive C fibers (Han et al 
2016). TREK1 expression has also found to be enhanced after cerebral ischemia. This 
increase in TREK channels however is thought to protect against glutamate toxicity as 
glutamate clearance is decreased by TREK1 channel inhibition (Ryoo and Park 2016). It is 
also noted that excessive potassium efflux, due to cerebral ischemia or hypoxia/anoxia, will 
also deplete intracellular potassium and will promote apoptosis. Therefore, inhibition of these 
channels could prevent potassium efflux and against ischemia-induced neuronal apoptosis. 
It was found that a compound named lig4-4 would selectivity inhibit TREK1 current and was 
shown to reduce the apoptotic-effect. Therefore, in therapeutic practice, it may be necessary 
to activate TREK1 during the early stage of cerebral ischemia, but then inhibit the channel to 
prevent neuronal apoptosis (Wang et al 2018).      
 
7.11.3 Analgesic effects linked to TREK and TRESK regulation  
TREK1 channels are highly expressed in small and medium DRG sensory neurons and are 
extensively localised with capsaicin-activated non-selective ion channel named TRPV1. In 
inflammatory models, mRNA levels of TREK1 in DRG neurons increased 3-fold. TREK1 KO 
mice however, showed an increase thermal and mechanical hyperalgesia by induced 
inflammation. This suggests that TREK1 plays a role in the regulation of nociceptor 
excitation. It may be observed that depolarisation of TRPV1 nociceptors could be controlled 
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by hyperpolarisation of TREK1 (Alloui et al 2006). TREK2 channels are expressed in small 
DRG neurons and are selectivity expressed in IB4+ C fibres, which modulate excitability of 
neurons. TREK2 is important in setting the resting membrane potential as was seen in 
siRNA knockdown of DRG neuron where TREK2 depolarised the neuron by 10mV. 
Hyperpolarisation of DRG C-fiber limits the electrical excitability so knockout TREK2 will 
enhance the excitability and increase the pain (Acosta et al 2014). TRESK channel is 
expressed in all different sizes of DRG neurons which suggests a role for TRESK in the 
regulation of the resting membrane potential. TRESK dysfunction has been shown in cause 
migraine and activation of current was seen to alleviate pain (Lafrenière and Rouleau 2011). 
Blocking of TRESK channels through pharmacological means causes pain while over-
expression of TRESK relieves pain via inhibition of capsaicin mediated substance P release 
in DRG neurons (Zhou et al 2012).  
The evidence shown suggests that upregulation of K2P current may be a novel strategy for 
analgesia. The overall activation of TREK1, TREK2 and TRESK will depress neuronal 
activity and therefore suppress pain neurotransmission. This effect can be seen in non-
steroidal anti-inflammatory drug, Flufenamic Acid (FFA), which activates TREK1, TREK2 
and TRESK channels (Takahira et al 2005; Monteillier et al 2016). However, there are 
known analgesics which inhibit some K2P channels. Acetaminophen, ibuprofen and 
nabumetone will inhibit TRESK current but has no effect on TREK2. 
 A traditional analgesic aristolochic acid holds opposing result as it blocks TRESK current 
but enhances TREK2. This difference in activity between TRESK and TREK2 may be due to 
the differences in how the channel are regulated. TREK2 channels are activated by 
arachidonic acid and inhibited PKC activity. While TRESK channels are inhibited by 
arachidonic acid and activated by PKC (Park et al 2016). TRESK are expressed in DRG 
neurons are known to be co-expressed with the pain mediator lysophosphatidic acid (LPA). 
LPA signalling is known to influence neurological disorders such as neuropathic pain and 
has been shown to activate TRESK, whereas LPA transmission will lead to the inhibition of 
TREK1 currents. The activation of LPA and TRESK will have limit excitation of TRPV1 
channels as TRESK will cause hyperpolarisation. The opposite will occur with the inhibition 
of TREK1 via LPA leading TRPV1 excitation. The effect of TRESK and the co-activation by 
LPA will decrease excitability of DRG neurons. This effect was clearly seen in TRESK-/- mice 
under analgesic compounds which saw an enhancement of depolarisation. This shown to 
activation of TRESK by the inflammatory mediator LPA will reduce TRPV1 activity and 
reduce pain (Kollert et al 2015).  
Hydroxyl- g- sanshool, the active ingredient of Szechuan peppers, is another known 
traditional analgesic and has been seen to bock TRESK current. This effect however is 
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believed to be caused by desensitising the excitatory neurons which leads to a numbing 
sensation. Therefore, the two natural analgesics are predicted to be similar pathway to 
produce pain relief (Veale and Mathie 2016). It has been documented that activation of 
inhibitory interneurons could also have an analgesic effect. So, antagonism here could lead 
to enhanced activity of inhibitory neurons and lead to neuroprotection. However, there is no 
known expression of TREK2 and TRESK channels in inhibitory neurons (Park et al 2016). 
Another hypothesis, relates to the effect that sipatrigine and lamotrigine has on TREK and 
TRESK current inhibition. The antagonism of these channels leads to depolarisation and 
thus calcium channel inactivation as the channel becomes inactive at – 45 mV. As calcium 
channels stimulate exocytosis of glutamate, the blockade of TREK and TRESK current and 
resulting depolarisation will lead to the elimination of glutamate release (Meadows et al 
2001).  All this taken together shows that further studies into the mechanism of analgesia 
through TREK and TRESK channels. The expression of these K2P channels are different 
among individuals and reactions to analgesics are different as each type of pain condition is 
unique. This will lead to a novel method of how pain could be alleviated through 
pharmacological modulation.  
All this taken together brings into question the function of TREK and TRESK channels 
regarding pain. Pain killers and antidepressants with analgesic effects will inhibit TREK2 and 
TRESK currents however there is evidence will suggest that activation of these currents will 
lead to the depression of neuronal activity leading to pain relief. More evidence is needed to 
determine the specific action of K2P channels which results in analgesia. Investigating the 
distribution and expression of these channels in inhibitory neurons could be an approach in 
examining TREK and TRESK physiological role in pain.  
 
7.12 Future work 
Previous studies have shown that TREK2 is subject to alternative translation initiation (ATI) 
which will lead to differing lengths of intracellular N terminal domain and changes in 
functional properties (Veale et al 2010). The results shown here highlight the importance of 
the N terminal regarding over recovery of current after sipatrigine wash off. However, it 
should be determined if all TREK2 structures are trafficked to the plasma membrane. 
Cellular localization of TREK2 ATI isoforms should be examined under confocal microscope 
using membrane staining and GFP tagging. 
Norfluoxetine binds within intramembrane fenestrations found in the down state of TREK2 
(Dong et al 2015). Sipatrigine, but not lamotrigine, has shown a decrease in inhibition when 
one fenestration site is mutated (L289A). Furthermore, the second fenestration site (L285) 
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may be of interest in sipatrigine sensitively. Mutating this site could show further evidence of 
sipatrigine interaction at the fenestration sites.  
A recent paper has also has shown that TREK1 K271Q lacks activation by ML335 and 
ML402, showing that this site is important for stabilising the primary gate at the selective 
filter (Lolicato M et al 2017). To investigate binding sites further, a mutation of site K271 
could be used with sipatrigine, lamotrigine and Cen-092-C to see if there is any change in 
current inhibition.  
 
7.13 Conclusion 
This study suggests that the binding site for sipatrigine is within the intramembrane 
fenestration site of TREK1 and TREK2. TREK1 was found to exhibit no change in the 
degree of inhibition with the structurally similar lamotrigine when the fenestration site was 
mutated. This shows that this site is profoundly important in the inhibition of both TREK1 and 
TREK2. Furthermore, the binding of the N terminal to the plasma membrane is believed to 
be important in this over recovery of TREK2 current. This may alter the functional profile of 
TREK1 and the excitability of cells. Phosphorylation of TRESK channels resulted in a 
change in lamotrigine sensitivity. This could show that lamotrigine inhibition is state 
dependent. Cen-092-C has also been identified as a TREK1 and TRESK antagonist with a 
similar degree of inhibition to lamotrigine. This means that the change in structure had little 
change in TREK1 and TRESK inhibition, however there was no sensitivity to TRESK 
dephosphorylation state. These results clearly demonstrate that sipatrigine sensitivity is 
regulated at the central cavity TREK1 and TREK2. It also could illustrate how state 
dependent inhibition of TRESK channels by lamotrigine may contribute to a possible off-
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